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Abstract 
Chemical carcinogenesis involves metabolic activation of carcinogens to 
electrophilic species which can react with important cellular biomolecules including 
DNA to form covalent adducts. Covalent carcinogen-DNA adducts which are not 
removed by DNA repair mechanisms can induce transforming mutations, ultimately 
leading to cancer. Hence, carcinogen-DNA adducts are deemed the ultimate biomarkers 
of carcinogen exposure, metabolic activation, and possibly of cancer risk. 
1,3-Butadiene (BD) is a recognized human and animal carcinogen present in 
cigarette smoke, automobile exhaust, wood fires, and also in some occupational settings 
such as BD monomer and polymer plants. BD is metabolically activated by CYP2E1 to 
form three electrophilic epoxides: 3,4-epoxy-1-butene (EB), 3,4-epoxy-1,2-butanediol 
(EBD), and 1,2,3,4-diepoxybutane (DEB). EB, EBD, and DEB can modify DNA bases to 
form covalent DNA adducts such as N-7-(1-hydroxy-3-buten-2-yl) guanine (EB-GII), 
N7-(2, 3, 4-trihydroxybut-1-yl)-guanine (N7-THBG) and 1,4-bis-(guan-7-yl)-2,3-
butanediol (bis-N7G-BD). Although BD-DNA adducts had been successfully detected 
and quantified in tissues of laboratory animals exposed to relatively high concentrations 
of BD ( ≥ 6.25 ppm), they had not been previously quantified in humans, preventing their 
use as biomarkers of BD exposure, metabolic activation, and cancer risk. The main 
purpose of this research was to develop ultra-sensitive bioanalytical methodologies based 
on mass spectrometry to enable the detection and quantitation of BD-DNA adducts in 
animals treated with sup-ppm levels of BD and in exposed human populations. 
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In Chapter 2 of the thesis, a novel nanoHPLC-nanoESI
+
-MS/MS method was 
developed for sensitive, accurate, and precise quantitation of BD-induced guanine-
guanine cross-links (1,4-bis-(guan-7-yl)-2,3,-butanediol, bis-N7G-BD) in tissues of 
laboratory mice treated with low - sub-ppm concentrations of BD (0.5-1.5 ppm) which 
approximate human occupational exposure to BD (1 ppm). Bis-N7G-BD concentrations 
increased in a concentration-dependent manner in mouse liver DNA as a function of BD 
exposure. In Chapter 3 of this Thesis, we investigated DNA repair mechanisms 
responsible for bis-N7G-BD repair using isogenic Chinese hamster lung fibroblasts 
proficient or deficient in nucleotide excision repair (NER) and Fanconi Anemia (FA) 
repair pathways. We found that while both pathways contributed to bis-N7G-BD 
removal, FA pathway was most effective at alleviating the toxicity and replication 
blockage imposed by bis-N7G-BD cross-links. 
To enable BD-DNA adduct detection in humans, we developed an isotope 
dilution capillary HPLC-ESI
+
-HRMS/MS methodology for the most abundant BD-DNA 
adducts identified in vivo: N7-(2,3,4-trihydroxybut-1-yl)-guanine (N7-THBG) (Chapter 
4). This method was successfully applied to quantify N7-THBG adducts in blood 
leukocyte DNA of smokers, nonsmokers, and occupationally exposed workers. In 
addition, we have developed an isotope dilution nanoLC/ESI
+
-HRMS
3
 methodology for 
the quantitation of BD-induced N-7-(1-hydroxy-3-buten-2-yl) guanine (EB-GII) adducts 
in human blood leukocyte DNA and human urine (Chapters 5 and 6). This method was 
applied to quantify EB-GII adducts in blood and urine of BD-exposed populations such 
as smokers, nonsmokers, and occupationally exposed workers.  
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Overall, during the course of the studies described in this Thesis, we have 
developed a range of novel mass spectrometry-based quantitative methods which have 
excellent sensitivity, accuracy, and precision, and can be used for future human BD 
exposure biomonitoring studies. Furthermore, these methodologies are now being 
employed in epidemiological studies to identify any ethnic/racial differences in BD 
bioactivation and to help understand the origins of ethnic/racial differences in lung cancer 
risk in smokers.  
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1 I. LITERATURE REVIEW 
1.1 Carcinogen induced DNA adducts as biomarkers of exposure and cancer risk 
1.1.1 Role of DNA adducts in chemical carcinogenesis 
 
Humans are exposed to multiple chemical carcinogens from various exogenous 
sources such as air (1), water (2), and food (3), as well as endogenous reactive oxygen 
species (ROS) (4) and lipid peroxidation products (5). These reactive species can either 
directly or indirectly react with essential cellular biomolecules such as proteins, DNA, 
RNA, and lipids, producing undesirable biological effects such as cellular toxicity and 
genetic mutations (6).   
Directly acting DNA modifying agents include reactive alkylating agents, reactive 
oxygen species, aldehydes and α, β-unsaturated carbonyl compounds (6;7). In contrast, 
carcinogenic molecules known as pre-carcinogens require some form of metabolic 
activation to be converted to the ultimate reactive electrophilic metabolites, which modify 
cellular biomolecules (8). Electrophilic carcinogen metabolites can undergo 
detoxification to nontoxic metabolites which are excreted in blood and urine (9).  
If not detoxified, activated carcinogen metabolites can react with DNA 
nucleobases (A, T, G, and C) to form covalent adducts  (10). Depending on their 
chemical structure, DNA adducts have variable stability and persistence in DNA (11). 
They may or may not be recognized by specialized DNA repair mechanisms such as base 
excision repair (BER), nucleotide repair (NER), and homologous recombination repair 
(HRR) that restore DNA to its original state  (12). Unrepaired DNA adducts can interfere 
with DNA replication (13;14), causing toxicity and inducing irreversible genetic changes 
(mutations). Non-viable mutations can lead to apoptosis / programmed cell death (15). 
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Viable mutations occurring within tumor suppressor genes (16) and protooncogenes (17) 
such as Kras and p53 can lead to an uncontrolled cell growth and the initiation of cancer 
(10) (Scheme 1.1). Because of their direct role in the development of cancer, DNA 
adducts represent a biologically relevant dose of the carcinogen exposure and can be used 
as mechanism-based biomarkers of carcinogen exposure and metabolic activation (18). 
Some examples of DNA adducts induced by known carcinogens include 
alflatoxin B1 induced 8,9-dihydro-8-(N7-guanyl)-9-hydroxy aflatoxin B1(AFB1-N7-
Gua) (19), tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) induced 7-[4-(3-pyridyl)-4-oxobut-1-yl]-2'-deoxyguanosine (7-pobdG) and O
2
-[4-
(3-pyridyl)-4-oxobut-1-yl]-2'-deoxycytosine (O
2
-pobdC) (20), polycyclic aromatic 
hydrocarbon  benzo[a]pyrene induced (+/-)-cis/trans-N
2
- benzo[a]pyrene dihydrodiol  
epoxide-2'-deoxyguanosine (N
2
-BPDE-dG) (21), heterocyclic amine 2-amino-1-methyl-
6-phenylimidazo[4,5-b]pyridine (PhIP) induced N-(2'-deoxyguanosin-8-yl)-PhIP (dG-
C8–PhIP) (22), acrolein induced α/γ-hydroxypropano-2'-deoxyguanosine (HOP-dG) (23) 
and aristocholic acid (AA) induced 7-(deoxyadenosin-N
6
-yl)aristolactam and  7-(deoxy-
guanosin-N
2
-yl)aristolactam adducts (Figure 1.1). Many common anticancer drugs act by 
forming toxic DNA adducts which are responsible for the pharmacological activity of 
these drugs. Some examples include cisplatin-induced N7-guanine-N7-guanine 
intrastrand cross-links (cis-Pt(NH3)2d(pGpG)) or Pt-(GG)) (24), temozolomide-induced 
O
6
 and N7-methyl guanine adducts (25), and cyclophosphamide-induced interstrand 
DNA-DNA cross-links (G-NOR-G) (26) (Figure 1.1). 
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Scheme 1.1. Role of DNA adducts in chemical carcinogenesis (27). 
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DNA adducts can also be formed by endogenously generated reactive oxygen 
species (ROS) such as superoxide, hydrogen peroxide, and hydroxyl radical (28). ROS 
can oxidatively damage DNA nucleobases to form 8-oxo-2'-deoxyguanosine (8‐oxo‐dG), 
8-oxo-2'-deoxyadenosine  (8‐oxo‐dA), ring opened 4,6‐diamino‐5‐formamidopyrimidine 
(FapyAdenine) adducts, and 2,6‐diamino‐4‐ hydroxy‐ 5‐formamidopyrimidine 
(FapyGuanine) adducts (29) (Figure 1.1). 4‐hydroxynonenal (HNE) formed as result of 
endogenous lipid peroxidation induces etheno-DNA adducts such as 
N
2‐3‐ethenodeoxyguanosine (30).  Endogenously formed estrogen metabolites, 
particularly catechol estrogens, form bulky DNA adducts such as 4-hydroxyestradiol-
1(α,β)-N7-guanine (4‐OHE2-N7-G) and 4- hydroxyestradiol-1(α,β)-N3-adenine (4-
OHE2-N3-Ade)  (4;31;32) (Figure 1.1).  
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Figure 1.1 Examples of DNA adducts formed by chemical carcinogens, drugs and 
endogenous electrophiles. 
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DNA adducts as biomarkers of carcinogen exposure, metabolic activation, and 
cancer risk. 
Human exposure to carcinogens can be quantified using carcinogen specific 
biomarkers. As mentioned above, many chemical carcinogens require metabolic 
activation to DNA-reactive species, which can be detoxified via hydrolysis and 
conjugation steps. Therefore, the health outcomes of chemical exposures are defined in 
part by the balance of carcinogen bioactivation and detoxification (33). Useful 
biomarkers of carcinogen exposure include urinary metabolites, DNA, and protein 
adducts. While urinary metabolites and protein adducts mostly reflect the extent of 
carcinogen exposure and bioactivation to reactive species, DNA adducts can be 
considered biomarkers of risk because of their central role in the carcinogenic process  
(18) (34).  
Among various enzymes responsible for carcinogen bioactivation, cytochrome 
P450 monooxygenases are the most important, based on their ability to perform complex 
oxidation and reduction reactions on a wide range of substrates. Electrophilic metabolites 
generated by P450-mediated reactions can undergo detoxification via hydrolysis or 
conjugation reactions with endogenous nucleophiles such as glutathione (35). Both 
bioactivation and detoxification pathways are important to consider, as cancer risk is 
defined by a balance between the two pathways (Scheme 1.2).  
For example, benzo[a]pyrene (B[a]P) is a carcinogenic polyaromatic hydrocarbon 
(PAH) present in tobacco smoke, automobile exhaust, and cooked foods. B[a]P is known 
to be metabolically activated by cytochrome (CYP) P450 enzymes 1A1 and 1B1 to 
B[a]P-9,10-oxide and B[a]P-7,8-oxide, which are hydrolyzed by epoxide hydrolase to the 
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corresponding diols. Further oxidation of the B[a]P-7,8-diol by CYP450s produces 
carcinogenic diolepoxide metabolite, B[a]P-7,8-diol,9,10-epoxide, which reacts with 
guanine and adenine bases of DNA to form DNA adducts capable of inducing mutations 
and cancer (36). Detoxification pathways of B[a]P include glucuronidation of B[a]P-
9,10-diol and  B[a]P-7,8-diol and glutathione conjugation of 7, 8-diol 9, 10 –epoxides of 
B[a]P, followed by mercapturic acid formation and urinary excretion (37;38). 
Quantification of urinary metabolites of benzo[a]pyrene gives an estimate of carcinogen 
exposure, while the quantification of B[a]P-DNA adducts exclusively measures the 
extent of metabolic activation and carcinogenic risk posed by B[a]P (Scheme 1.2 ).  
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Scheme 1.2  Partial metabolic bioactivation (in red) and detoxification products of B[a]P 
(Green). UDPGT: uridine diphosphate glucuronyltransferase, GST: Glutathione S-
transferase. 
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Typical biomarkers of carcinogen exposure include inactivated metabolites which 
no longer possess DNA-reactive functional groups (such as B[a]P tetrols in the previous 
example (Scheme 1.2)). Although these metabolites provide a measure of carcinogen 
exposure and metabolism, they do not quantify the extent of DNA damage induced by the 
carcinogen  (39). In contrast, DNA adducts represent carcinogen bioactivation markers 
because nucleobase adducts are ultimately responsible for causing mutations and cancer. 
Hence, carcinogen-induced DNA adducts are considered the ultimate biomarkers for 
estimating the extent of pharmacologically relevant carcinogen exposure, bioactivation, 
and potentially of cancer risk.  
DNA adducts are commonly used as biomarkers to estimate the pharmacological 
activity of some important anticancer drugs. For example N,N-bis[2-(N7-guaninyl) ethyl] 
amine (G-NOR-G) DNA-DNA cross-links were quantified in blood leukocyte DNA of 
cancer patients treated with nitrogen mustard prodrug cyclophosphamide (CPA) for the 
treatment of lymphoma, leukemia, and solid tumors (40). CPA-induced cytotoxic G-
NOR-G cross-links (Figure 1.1) represent a measure of CPA metabolic activation to 
DNA-reactive species. Hence, G-NOR-G crosslinks are useful for biomonitoring the 
pharmacological activity of CPA in individual patients (40). Other examples of 
biomarkers useful for biomonitoring the potency of drugs include DNA-DNA crosslinks 
induced by cisplatin (41) and N7-Me-dG adducts induced by temozolomide (Figure 1.1) 
(42). On the other hand, DNA adducts were also used as biomarkers to monitor the extent 
of undesirable bioactivation  (43). For example, DNA adducts formed by reactive 
metabolites of tamoxifen are believed to be responsible for its ability to induce 
endometrial cancer (44).  
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DNA adducts can also used as biomarkers of exposure and metabolic activation of 
environmental carcinogens. For example, 7-(deoxyadenosin-N6-yl) aristolactam I (dA-
AL-I) and 7-(deoxyguanosin-N2-yl) aristolactam I (dG-AL-I) DNA adducts were used as 
biomarkers of exposure to aristolochic acids, which are implicated in Chinese herbs 
nephropathy and Balkan endemic nephropathy (45)(Figure 1.1). Urinary aflatoxin-N7-
guanine adducts, which is formed by aflatoxin B1, a food contaminant and a liver 
carcinogen, were used as biomarkers of exposure and metabolic activation in aflatoxin 
exposure cohort studies in China (46;47)(Figure 1.1). Acrolein and crotonaldehyde- 
derived 1,N
2
-propanodeoxyguanosine DNA adducts were used as biomarkers of 
smoking-mediated DNA damage in human oral tissue (48). Hence, carcinogen induced 
DNA adducts are of significant biological interest and can be used as biomarkers of 
exposure, metabolic activation, and cancer risk.  Increased levels of DNA adducts in 
target tissues have been correlated to the carcinogenicity of carcinogens such as aflatoxin 
B1, dimethylnitrosamine, ethylene oxide, and 4-aminobiphenyl in exposed animals 
(49;50). 
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1.2 Mass spectrometry based quantitation of DNA adducts 
1.2.1 Mass spectrometry methods for DNA adducts analysis in humans 
Among various methodologies available for DNA adduct analysis, mass 
spectrometry has a number of advantages such as excellent sensitivity, selectivity and 
robustness when compared to traditional 
32
P-postlabeling and high performance liquid 
chromatography–ultraviolet visible light absorbance detection (HPLC-UV-vis) methods 
(51). In particular, isotope dilution mass spectrometric methods are generally considered 
the best approach for absolute quantitation of DNA adducts (51). In this approach, 
naturally occurring isotopes of carbon, nitrogen or hydrogen within the adduct structure 
are replaced by stable isotopes such as 
13
C, 
15
N, 
2
H, respectively to generate stable 
isotope analogues of the adducts which have distinct molecular mass, but similar 
physicochemical properties as compared to the analyte of interest. A known amount of 
this isotopomer is added to samples at the beginning of sample preparation to be used as 
an internal standard to account for any analyte losses during the DNA adduct enrichment 
and to allow for absolute quantitation. Based on the known amounts of the internal 
standard added, the amount of DNA adduct is quantified by using the ratio of areas under 
the HPLC-MS/MS peaks corresponding to analyte and its internal standard (Scheme 1.3). 
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Scheme 1.3 General scheme for the mass spectrometry (MS) based analysis of DNA 
adducts. 
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1.2.1.1 DNA adduct enrichment and sample preparation procedures   
Carcinogen-DNA adducts can be quantified in DNA extracted from various 
biological sources/matrices. These include DNA extracted from target tissues such as 
liver, lung, and kidney. Surrogate matrices from accessible tissues include DNA from 
white blood cells in blood (23;52;53), saliva/buccal cells  (54;55), exfoliated cells from 
human breast milk (56), and exfoliated urothelial cells from human urine (57). 
Carcinogen-induced DNA adducts can also be quantified in human urine as free bases 
(58;59) after they are released from DNA following active repair or spontaneous 
hydrolysis. DNA adducts can be enriched using sample enrichment strategies. 
Hydrolytically labile DNA adducts such as N7-guanine and N3-adenine adducts can be 
released from the DNA backbone by neutral thermal hydrolysis by heating at 70-90 °C 
(60). N7-guanine or N3-adenine alkylation generates a positive charge, which 
destabilizes the N-glycosidic bond of the modified nucleoside, leading to spontaneous 
depurination of adducts from the DNA, and this process can be accelerated by heating 
(Scheme 1.4). Some DNA adducts can also be released by selective enzymatic treatment 
with formamidopyrimidine [fapy]-DNA glycosylase (Fpg) which releases 8-oxodG (61) 
and N7-substituted (62) and unsubstituted FAPY bases (63). Nonselective DNA adduct 
release strategies include mild acid hydrolysis to liberate all purine nucleobases form 
DNA backbone  (64) and enzymatic hydrolysis of DNA to individual 2'-
deoxynucleosides. Specific enzymes used for enzymatic hydrolysis of DNA to 
deoxynucleotides include deoxyribonucleases (DNAse I and II), phosphodiesterases 
(PDE I and II), and nuclease P1, which cleave either at the 3' end or 5' end of DNA to 
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generate 3' or 5' phosphates. The use of alkaline phosphatase removes the phosphate 
groups, generating 2'-deoxynucleosides  (65-67)(Scheme 1.4). 
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Scheme 1.4 (A) Neutral thermal hydrolysis to release N7-guanine and N3-adenine 
adducts from DNA. (B) Mild acidic hydrolysis to release nucleobases in DNA. (C) 
Enzymatic hydrolysis of DNA to 2'-deoxynucleosides.  
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The liberated nucleoside or nucleobase adducts can be enriched using specialized 
sample preparation techniques such as ultrafiltration, solid phase extraction (SPE), liquid-
liquid extraction (LLE), immunoaffinity purification, or offline HPLC fractionation. 
These enrichments are performed to remove interfering unmodified nucleobases, 
nucleosides, proteins, and salts which are present in large excess. Interfering compounds 
can increase ion background and lead to signal suppression during mass spectrometry 
analysis (68). During ultra-filtration, the samples are loaded onto filters with specific 
molecular weight cut off (10000, 30000 Da) and then subjected to centrifugation to 
remove high molecular weight constituents such as proteins and unhydrolyzed DNA (51). 
For some DNA adducts, liquid-liquid extraction can be used for enrichment. Liquid-
liquid extraction using mixture of organic solvents such as ethyl acetate and hexanes has 
been used for the enrichment of hydrophobic DNA adducts such as aristolactam-DNA 
adducts (67).  
Solid phase extraction (SPE) is the most popular method for DNA sample 
enrichment because of its versatility. DNA adducts can be retained on the SPE stationary 
phases based on their hydrophobicity or ionizability. Various SPE catridges packed with 
stationary phases such as reverse phase C18, phenyl, cation and anion exchange phases 
are commercially available. Cation exchange and anion exchange SPE methods can be 
employed for the enrichment of DNA adducts that are ionized at specific pH. The pKa 
values of adducts must be considered. As a rule of thumb, a weak acid is fully ionized 
(negatively charged) at a pH valve 2 units above the pKa and unionized at 2 units below 
pKa. In contrast, a weak base is fully ionized (positively charged) at a pH value 2 units 
below the pKa and uncharged at pH 2 units above pKa. Since nucleobase adducts are 
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generally weak bases due to the presence of nitrogen containing heterocycles in their 
structures, they can be protonated and retained on cation exchange SPE cartridges under 
acidic conditions. Following retention, any interfering compounds can be removed by 
washing with buffer of weak solvents, while adducts of interest are retained. Finally, the 
analyte and its internal standard are released from the cation exchange resin by increasing 
the pH to favor uncharged form of the adduct. Mixed mode SPE cartridges which possess 
both reverse phase and ion exchange capabilities can also be used. 
  Off-line HPLC can be efficiently employed for the enrichment of DNA adducts. 
HPLC fractions containing the analyte are collected, concentrated, and reconstituted for 
liquid chromatography-mass spectrometry (LC-MS) analysis. HPLC cleanup methods 
provide a more efficient separation of DNA adducts from interfering compounds than 
SPE and can be more cost efficient. Fraction collection is performed using retention time 
markers (e.g. 2'-deoxythymidine and 2'-deoxycytidine) to accurately determine the 
elution times. Since the analytes are typically present in low picogram amounts, their 
chromatographic peaks are not visible by UV absorption. Retention time markers can be 
used to adjust the fraction collection times because of the influence of sample matrix on 
HPLC retention times. Offline HPLC fraction collection have been previously used for 
the enrichment of a range of DNA adducts such as 1,4-bis-(guan-7-yl)-2,3-butanediol 
(bis-N7G-BD) (69) and N-7-(1-hydroxy-3-buten-2-yl) guanine (EB-GII) (70) adducts in 
our laboratory.   
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1.2.1.2 Quantitative mass spectrometric methods for DNA adducts  
 Mass spectrometry is the preferred method for the quantification of DNA adducts 
in biological matrices as it offers structural information, accurate detection, and absolute 
quantitation of the analytes. A number of mass spectrometry-based methods are reported 
in literature for the quantitation of nucleoside adducts. The majority of the recent reports 
employ liquid chromatography (LC)-mass spectrometry, although GC-MS can be useful 
for some applications.  
Liquid Chromatography -Mass Spectrometry 
  High performance liquid chromatography (HPLC) is the preferred method of 
choice for sample introduction into the mass spectrometers for quantitative analysis of 
DNA adducts (34). Mass spectrometers determine the mass to the charge ratios (m/z) of 
the analyte following sample ionization. HPLC provides an efficient way to separate 
DNA adducts from interfering compounds in the biological matrices before introduction 
into the mass spectrometer for sample ionization and m/z measurements. DNA adducts 
are typically present in very low concentrations (1-3 adducts/10
8
 nucleotides or 5-10 
pg/100 µg DNA), and HPLC provides a way to reduce MS signal suppression caused by 
interfering matrix components. A variety of HPLC stationary phases are commercially 
available, including reverse phase C12, C18, C8, polyphenyl, and others. For extremely 
polar DNA adducts that are not retained on reverse phase HPLC packing, hydrophilic 
interaction liquid chromatography (HILIC) may be a viable option. HILIC is variant of 
normal phase liquid chromatography which uses hydrophilic stationary phases with 
reversed-phase type eluents and thus has the ability to retain polar DNA adducts. Flow 
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rates typically used in LC-MS analysis include normal analytical flow (0.1-0.2 mL/min), 
capillary flow (5-15 µL/min), and nanoflow (100-400 nL/min). As described below, 
better sensitivity is attained using lower flow rates due to the higher efficiency of 
ionization (51). 
 The first critical step in mass spectrometry based analysis of DNA adducts is 
analyte ionization. One of the most common methods of ionization for LC-MS analysis is 
electrospray ionization (ESI) (Figure 1.2) (71). ESI can be conducted in the positive or 
negative ion modes to generate positive and negative ions, depending on voltage polarity. 
DNA adducts such as N
2
-(1-carboxyethyl)-2'-deoxyguanosine (CEdG), 8-nitroguanine, 
N
6
-(1-carboxyethyl)-2'-deoxyadenosine (72), and cisplatin-DNA adducts (73) are 
quantified in negative mode because of their propensity to lose a proton and to  become 
negatively charged. However, the majority of nucleobase adducts are readily protonated 
under mildly acidic buffer conditions, hence enabling their detection in the positive ion 
mode. Aqueous and organic mobile phases containing volatile acids such as 0.05% acetic 
acid, 0.1% formic acid, 0.01% trifluoroacetic acid, or buffers containing 5-10 mM 
ammonium acetate are typically used in HPLC of structurally modified nucleosides and 
nucleobases to aid in the separation and ionization of the analyte. An alternative 
ionization method for the analysis of DNA adducts is atmospheric pressure chemical 
ionization (APCI), typically used with higher HPLC flow rates (0.2-1.0 mL/min)  (51). 
Tandem mass spectrometry analysis (LC-MS/MS or SRM analysis) 
 Tandem mass spectrometry (MS/MS) in the selected reaction monitoring mode 
(SRM) is by far the most efficient method used for the accurate quantitation of DNA 
adducts. Tandem mass spectrometry experiments are most commonly conducted on triple 
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quadrupole mass analyzers.  Triple quadrupole MS consists of three quadrupole mass 
analyzers made up of four parallel metal rods with alternating radio frequency voltages 
and can filter specific ions based on the m/z ratio. Triple quadrupole MS is used for 
quantitation by monitoring the gas phase fragmentation of the parent protonated molecule 
to its fragment ions and this mode is called selected reaction monitoring (SRM) or 
multiple reactions monitoring (MRM). As shown in Scheme 1.5 A and B, the sample is 
introduced by HPLC and ionized by ESI, and the resulting ions move through the triple 
quadrupole mass spectrometer. For example, consider the case of guanine and 
15
N5 
labeled guanine spiked as internal standard in the sample. Following ionization in the ESI 
source, quadrupole 1 (Q1) is used for initial mass selection of m/z 152 [(M+H)
+
] for 
guanine and m/z 157 [(M+5+H)
+
] for its internal standard. Q2 is used for fragmentation 
of the ions selected in Q1 using high energy collisions with an inert gas such as argon or 
nitrogen (collision-induced dissociation). After fragmentation, Q3 is used for mass 
analysis of specific product ions. In the case of guanine and 
15
N5 guanine, fragment ions 
corresponding to cleavage of the exocyclic amino group can be employed: m/z 135.1 
[(M+H-NH2)
+
] for guanine and m/z 139.1 [(M+5+H-NH2)
+
] for 
15
N5 internal standard. 
The selected fragment ions are finally detected by the mass detector to produce the MS 
signal. The MS signal for selected reaction monitoring of m/z 152  135 and m/z 157 
139.1 is transformed into the corresponding peaks for analyte and the internal standard. 
The analyte amounts can be accurately determined using the ratios of areas under the 
peaks and the known amount of internal standard added before starting the sample 
preparation (Scheme 1.5 A, B). Apart from SRM/MRM modes, triple quadrupole MS can 
also be used for single ion monitoring (SIM) mode for selecting and monitoring only 
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ionized analyte ions, or in the precursor ion or neutral loss mode to detect a range of 
structurally related adducts. Triple quadrupole MS are ideally suited for trace analysis of 
DNA adducts due to their high duty cycle in SIM and SRM modes, relatively good 
resolution power (1000-3000), their low cost, and the ease of operation. Resolution 
power (R) of a mass spectrometer is defined as its ability to distinguish between two ions 
with close m/z ratios and it calculated as the ratio of nominal mass (M) to the mass 
difference between two ions (∆M) (R = M/∆M). Typically limits of quantitation for DNA 
adducts measured using triple quadrupole LC-MS based SRM analysis are in the range of 
1-4 adducts per 10
7
 to 10
8
 nucleotides (74;75). 
 
Ion trap mass spectrometric analysis (LC-MS
n
) 
Linear ion trap (LTQ) MS instruments are designed to store ions within specified 
mass range. Generally, LC-ion trap (IT) MS/MS operated in the “collision activated 
dissociation” (CID) mode can be used for analysis of DNA adducts. For example, N-
(deoxyguanosin-8-yl) (dG-C8) DNA adducts formed by alkylation of guanine by 
aromatic amines such as 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-
amino-9H-pyrido[2,3-b]indole (AαC), 2-amino-3,8-dimethylmidazo[4,5-f]quinoxaline 
(MeIQx) and 4-aminobiphenyl (4-ABP) were successfully identified in human salivary 
DNA using Linear Quadrupole Ion Trap/Multistage Tandem Mass Spectrometry (55). 
Another advantage of ion trap MS includes the multi stage fragmentation (MS
n
) of ions. 
MS/MS fragment ions can be selected and further fragmented to generate MS
3
 ions, 
which can to provide rich structural information for the analyte. This can theoretically be 
continued to yield even smaller fragments (MS
n
) (Scheme 1.6 A, B). Monitoring the 
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fragmentations of the analyte ions in the MS
3
 mode can provide increased signal to noise 
ratios due to an increased selectivity. Liquid chromatography-stable isotope dilution mass 
spectrometry on linear ion trap mass spectrometer (LC- ITMS) has been used 
successfully for detection and quantitation of aristolactam-DNA adducts in human 
biomonitoring studies (45).  
Major differences between ion trap MS and triple quadrupole MS include type of 
fragmentation of ions in gas phase. Triple quadrupoles are only capable of fragmentation 
of ions until MS
2
 stage to generate fragments while ion trap MS can perform sequential 
fragmentation reactions from a single precursor ion, generating up to approximately 
10cycles of fragments or theoretically MS
n
 fragmentation. Hence ion traps can perform 
multi-stage tandem mass spectrometry experiments (MS
n
) as compared to triple 
quadrupoles, which can provide additional rich structural information of the molecule  
(55). In iontrap MS, fragmentation is achieved by Collision Induced Dissociation (CID) 
which can be acquired by ejection of all ions other than the ion with required  m/z ratio of 
interest, and then fragmenting the selected ions with inert gases such as helium or argon 
followed by mass analysis of the resulting fragment ions. In triple quadrupole MS, SRM 
based fragmentation is achieved in the second quadrupole collision cell (Q2) using inert 
gas such as nitrogen after precursor mass selection in first quadrupole (Q1) mass analyzer 
and final MS
2
 fragment mass analysis in third quadrupole (Q3).  In case on adducted 
DNA nucleosides the major MS/MS fragmentation is the neutral loss of the sugar moiety, 
which provides little structural information; in contrast, MS
3 
and MS
4
 fragmentation 
experiments using ion trap MS can reveal rich structural details for the modified base 
allowing for its identification. Use of ion traps in trace quantitative analysis of DNA 
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adducts is limited as compared to triple quadrupole MS due to their relatively low duty 
cycle and nonlinear response to MS fragmentation. But modern LTQ ion traps have 
improved sensitivity, specificity, and S/N ratios for DNA adduct analysis which can be  
achieved by monitoring specific MS
3
 transitions (45).  
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Scheme 1.5 A. Schematic representation of a triple quadrupole mass spectrometer (A) 
operated in the selected reaction monitoring mode to detect guanine and its 
15
N5-labeled 
analog (B). 
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Scheme 1.6 A. Schematic of a HPLC-ion trap MS/MS system (A) and MS
3
 dissociation 
of N7-methyl guanine and its 
15
N-labeled internal standard (B). 
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1.2.2 Ultra-sensitive advanced mass spectrometry based methods 
Human biomonitoring of trace levels of DNA adducts requires higher sensitivity 
and selectivity for accurate quantitation. For example, 1,N
2
-propano-2'-deoxyguanosine 
DNA adducts derived from environmental carcinogens such as acrolein (AdG) and 
crotonaldehyde (CdG) are present in very low amounts in the range of 78 ± 23, 6.2 ± 3.8 
adducts per 10
8
 nucleotides (5-50 fmol) in human blood leukocyte DNA and 108 ± 2.6, 
26 ± 3.1 adducts per 10
8
 nucleotides in human placental DNA (76). The amounts of 
ethylated thymidine DNA adducts such as O(2)-ethyl dT, N(3)-ethyl dT, and O(4)-ethyl 
dT in smokers were found to be 44.8 ± 52.0, 41.1 ± 43.8, 48.3 ± 53.9 per 10
8 
normal 
nucleotides respectively (77).  
 1.2.2.1 Capillary and nanospray LC-MS analysis of DNA adducts  
Electrospray ionization (ESI) is the most common form of ionization method used 
for the analysis of DNA adducts as it is conducive to liquid chromatography. Flow rate 
and ion transmission into the mass spectrometer play a major role in the sensitivity of the 
method (78). Capillary LC-MS methods which employ columns with internal diameters 
of 0.3-0.5 mm and flow rates typically in the range of 5-10 µL/min are used for the 
quantitation of DNA adducts. Also, with the advent of nanoLC-MS systems, which 
operate at very low flow rates (100-400 nL/min) and use nano columns with diameters of 
50-100 µm in combination with nanoESI source, it is possible to develop highly sensitive 
methods for DNA adduct analysis. Smith RD et al. reported that use of low flow rates in 
the range of 200 nL/min improves ESI sensitivity. Nanoflow rates lead to efficient ion 
spray, better ionization and highly efficient ion transfers as the ions can be introduced 
directly into the MS ion transfer tube of the mass spectrometer, thereby increasing the 
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overall ion current (78). Nanospray emitters are commercially available with different 
configurations such as metal coated tip for application of voltage at the front end of the 
tip and emitters with frit at the front end which can be packed in house with desired 
stationary phases etc.  
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Figure 1.2 Electrospray ionization using capillary LC flow (A) and nanoLC flow rates 
(B).  
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1.2.2.2 Accurate mass quantitation of DNA adducts 
 Accurate mass quantitation is the determination of mass of the molecule such that 
its elemental composition of the molecule can be determined unambiguously. For 
example, consider the protonated guanine molecular ion ([Gua +H]
+
). Mass 
spectrometers such as triple quadrupoles and ion traps determine the mass of guanine as 
m/z 152.05, for which there are numerous possible elemental compositions. But, accurate 
mass spectrometers are capable of measuring the exact mass of protonated guanine as m/z 
152.05669 with mass error less than 5 ppm, for which there is only one plausible 
elemental composition. Mass error is defined as the difference between the experimental 
mass (Mexp) and the theoretical value (Mtheo), calculated from elemental composition. It is 
generally reported in relative terms as ppm calculated using (Mexp-Mtheo)/ Mtheo. Accurate 
mass measurement instruments are also capable of distinguishing two close masses which 
is defined as mass resolution factor (R), calculated as nominal mass (M)/ mass difference 
(∆M). ∆M can be calculated using full width at half maximum (FWHM) measurements. 
FWHM is a measure of width of a single peak measured at 50% peak apex (79). 
 One of the popular accurate mass measurement (high resolution) mass 
spectrometers uses orbitrap mass analyzers. Orbitrap mass analyzers are basically ion 
traps developed by Marakov A et al.  (80). Orbitrap mass analyzers are made up of outer 
barrel-like and coaxial inner spindle-like electrodes that traps ions, move in an orbital 
motion following ion injection and, finally the ion current frequency signal is Fourier 
transformed (FT) into a mass spectrum. It works on the principle that the angular 
frequency of the orbital motion of ions is related to the mass to the charge ratio by the 
equation ω=√(k/(m/z)), where k=force constant. Most of the modern mass spectrometers 
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are hybrid/ tandem instruments assembled with linear ion traps or quadrupole with 
orbitrap mass analyzers or linear ion traps and quadrupoles with orbitrap mass analyzers. 
For example the orbitrap Velos (Thermo scientific, Waltham, MA, USA) instrument has 
linear ion trap (LTQ) mass analyzer upfront of the orbitrap mass analyzer. Hence, there is 
an option for detection of ions in low resolution mode using ion trap or high resolution 
(HRMS) mode using orbitrap mass analyzer after efficient ion transmission into the 
instrument.  
Orbitrap HR-MS
n
 scanning analysis of DNA adducts  
 Instruments such as orbitrap Velos can be efficiently used for the analysis of 
DNA adducts in trace amounts by using ion trap MS
n
 fragmentation followed by 
detection of the final product ions in high resolution mode using the orbitrap mass 
analyzer (Figure 1.3). Analyzing the ions in high resolution mode significantly improves 
the signal to noise ratio as compared to conventional triple quadrupole based tandem MS 
(SRM or MS/MS) analysis. HRMS detection also increases the confidence in the analysis 
of DNA adducts because of non-interference of other masses and absence of artifacts or 
co elution problems. For example use of orbitrap HRMS analysis was reported by Zhang 
NR et al. for the identification and quantitation of small molecules in biomatrices with 
comparable assay precision, accuracy, linearity and better sensitivity as compared to 
triple quadrupole SRM based analysis (81). Nanospray LC with nanoESI ionization can 
be used in combination with HRMS detection to increase the sensitivity of analysis of 
DNA adducts. For example, nanoLC-ESI in combination with orbitrap HRMS analysis 
was used for the quantitation of N7-ethylguanine using isotope dilution with 
15
N5-N7-
ethyl guanine internal standard in blood leukocyte DNA of smokers. In this method the 
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protonated adduct of m/z 180 (M+H)
+
 was fragmented in the LTQ ion trap and the MS
2
 
(MS/MS) fragment of protonated guanine with m/z 152.05669 (Gua+H)
+
 was detected 
using HRMS detection by orbitrap mass analyzer. Similar transition of m/z 185 (
15
N5-
M+H)
+
 m/z 157.04187(15N5-Gua+H)
+
 was used for the internal standard. In orbitrap 
Velos, MS fragmentation of ions can be achieved either by CID in LTQ ion trap or by 
high collision dissociation (HCD), also known as C-trap assisted dissociation (82). 
Hence, with the help of hybrid instruments such as orbitrap Velos, MS
n 
fragmentation can 
be performed either in LTQ ion trap or in HCD collision cell, and the ions can be 
detected using ion trap nominal mass or orbitrap mass analyzer (HRMS) (Figure 1.3).  
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Figure 1.3 Schematic of a hybrid/Linear ion trap-Orbitrap Velos HRMS instrument 
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1.3 1,3-Butadiene (BD) an human and animal carcinogen: An Overview 
1.3.1 Sources of exposure, metabolism and toxicity of BD 
1,3-Butadiene (BD) is a volatile and colorless gas used in polymer industries for 
the production of rubber (83). BD is a classified as a carcinogen based on studies in 
laboratory rodents, which developed tumors in multiple organs after exposure to BD 
(84;85). Studies in humans occupationally exposed to BD in the butadiene-monomer 
industry and polymer rubber industries showed increased risk of leukemia (86-88). The 
general human population is exposed to sub ppm (1-10 ppb) concentrations of BD in 
urban air from automobile exhaust (89), mainstream (20-75 μg), and sidestream (205-360 
μg) cigarette smoke, wood burning and forest fires (90;91). 
Metabolism and toxicity of 1,3-butadiene (BD) 
BD is known to be metabolically activated by cytochrome P450 monoxygenases 
CYP 2E1 and CYP 2A6 to 3,4-epoxy-1-butene (EB) (92). EB is further oxidized by CYP 
P450 2E1, 3A4 to form the diepoxide 1, 2, 3, 4-diepoxybutane (DEB) (92;93). DEB is 
reported to undergo hydrolysis by epoxide hydrolase (EH) to another mono epoxide 3,4-
epoxy-1,2-butanediol (EBD). EB can also undergo hydrolysis by epoxide hydrolase (EH) 
to form EB-diol which can further undergo metabolic activation by CYP 2E1 to form 3,4-
epoxy-1,2-butanediol (EBD) (Scheme 1.7) (94;95).  
 BD toxicity is mainly attributed to its three reactive epoxides EB, EBD and DEB 
which all can react with nucleophilic biomolecules such as DNA and proteins to form 
covalent adducts. Among the three BD epoxides, EBD is the most abundant epoxide 
formed in vitro and in vivo followed by EB and DEB. Though DEB is the least abundant 
epoxide, it is the most mutagenic and genotoxic epoxide probably because of its 
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Scheme 1.7 Metabolism of BD to DNA reactive epoxides. 
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bifunctional crosslinking nature (96). The mutagenic ability of various sterioisomers of 
DEB (RR, SS and meso) is also different with S,S-DEB being the most mutagenic epoxide 
(97). In vitro studies in human lymphoblastoid TK6 cells have shown that DEB is 
mutagenic at concentration levels less than 5 μM. In comparison, EB and EBD were 
mutagenic at higher concentration levels of 100–800 μM (98). DEB induced A→T 
transversions and partial deletions in hprt gene of TK6 lymphoblasts exposed to 4 μM of 
DEB for 24h, while EB required at least 100 fold higher concentrations (400 μM, 24h) to 
induce GC→AT point mutations and AT→TA transversions (98). In vivo studies in 
B6C3F1 laci transgenic mice exposed to higher concentrations of BD (62.5 – 1250 ppm, 
6 h/day, 5 days/week for 4 weeks) reported that BD induced AT→GC or AT→TA point 
mutations in spleen and bone marrow (96). A significant increase in frequency of exon 
deletions in hprt gene (99) and increased AT→TA transversions and frameshift 
mutations were observed in workers exposed to BD (100). However, other research 
studies found no statistically significant differences in hprt gene mutation frequencies 
between exposed and control workers (101;102). 
1.3.2 Biomarkers of BD exposure and metabolic activation 
BD is metabolized to its reactive epoxides which can react with biomolecules 
such as DNA and proteins. Alternatively, BD reactive epoxides can potentially be 
detoxified by glutathione conjugation followed by conversion to mercapturic acids which 
are finally excreted in urine. To assess the extent of toxicity by BD, biomarkers of 
bioactivation and detoxification pathways can be used.  
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1.3.1.1 BD-DNA adducts 
BD reactive epoxides are electrophilic and therefore can react with nucleophilic 
groups on DNA bases guanine, adenine, thymidine and cytosine to form covalent DNA 
adducts. For example, the most abundant BD epoxide 3,4-epoxy-1,2-butanediol (EBD) is 
known to react with DNA bases such as guanine and adenine to form N7-(2’,3’,4’-
trihydroxybut-1’-yl)guanine (N7-THBG) (meso and racemic), N6-(2’,3’,4’-
trihydroxybut-1’-yl)adenine (N6-THB-Ade), and N3-(2’,3’,4’-trihydroxybut-1’-
yl)adenine (N3-THB-Ade) (75;103;104) (Scheme 1.8). 3,4-Epoxy-1-butene (EB) is also 
reported to form DNA adducts N7-(2-hydroxy-3-buten-1-yl)guanine (EB-GI), N7-(1-
hydroxy-3-buten-2-yl)guanine (EB-GII), N1-(2-hydroxy-3-buten-1-yl)adenine (EB-Ade 
I) and N1-(1-hydroxy-3-buten-2-yl)adenine (EB-Ade II) (75;103;104)(Scheme 1.8). 1, 2, 
3, 4-Diepoxy butane (DEB), the most mutagenic of the BD epoxides is a bis electrophile 
and can sequentially react with two DNA bases to form inter-strand and intra-strand 
DNA-DNA crosslinks such as 1,4-bis-(guan-7-yl)-2,3-butanediol (bis-N7G-BD), 1-
(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD), 1-(guan-7-yl)-4-(aden-3-yl)-
2,3-butanediol (N7G-N3A-BD), 1-(guan-7-yl)-4-(aden-7-yl)-2,3-butanediol (N7G-N7A-
BD) and 1-(guan-7-yl)-4-(aden-N6-yl)-2,3-butanediol (N7G-N6A-BD) cross-links  
(105;106)(Scheme 1.8). DEB is also known to react with two different sites on the same 
nucleobase to form exocyclic DNA adducts such as 1,N6-(2-hydroxy-3-
hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (1,N6-γ-HMHP-dA) and 1,N6-(1-
hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (1,N6-α-HMHP-dA) 
(107)(Scheme 1.8). BD DNA adducts are regarded as the ultimate biomarkers of BD 
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induced carcinogenesis and cancer risk, as they are directly responsible for DNA damage 
and mutations leading to cancer.  
In the literature, there is an increased interest to develop BD induced DNA 
adducts as biomarkers to estimate the extent of bioactivation, biologically effective dose 
and cancer risk of BD. Rodents such as rats and mice exposed to BD by inhalation were 
used as models to identify DNA adducts that can potentially be used as biomarkers to 
quantify BD exposure and metabolic activation. Initially, 
32
P-post labeling and HPLC 
methodologies were used to quantify several DNA adducts induced by BD and its 
metabolites. Koivisto et al. used 
32
P-post labeling methodologies to identify N7-gunaine 
and N6-adenine adducts of 3,4-epoxy-1-butene, N7-guanine adducts of EBD and DEB in 
liver, lung and testis of mice and rats exposed to BD (108-111). N1-THB-Ade adducts of 
EBD were quantified in human blood leukocyte DNA and were present in higher 
concentrations in BD-exposed workers as compared to unexposed workers or controls 
(112). With the advent of isotope dilution mass spectrometry and LC-ESI-MS/MS (SRM) 
analysis, 3,4-epoxy-1-butene specific EB-GI, EB-GII and EBD specific N7-THBG were 
quantified in liver tissues of mice and rats exposed to 1250 ppm BD for 10 days (104). 
Koc et al. observed a clear dose-response relationship between EB-GI, II and N7-THBG 
and BD concentrations in liver, lung and kidney tissues of mice and rats (75). 
Ultra sensitive HPLC-ESI
+
-MS/MS methods for quantification of DEB-specific 
DNA adducts in vivo were developed in our laboratory. Goggin et al. found significantly 
increased levels of guanine-guanine crosslink (bis-N7G-BD) adducts in the liver (3.2 ± 
0.4 adducts per 10
6
 dG) and lung (1.8 ± 0.5 adducts per 10
6
 dG) tissues of C57BL/6 mice 
exposed to 625 ppm BD for 7h/day for 5 days (74). 
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Scheme 1.8  DNA adducts formed by various BD epoxides (EB, DEB, EBD)  
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BD induced Guanine-adenine crosslinks (N7G-N1A-BD) were also quantified in 
liver DNA of B6C3F1 mice exposed to 625 ppm BD for 2 weeks (113). Bis-N7G-BD and 
N7G-N1A-BD adducts increased linearly with BD concentrations in tissues of laboratory 
mice exposed to BD by inhalation (0-625 ppm) (114). In contrast, the same adduct levels 
in tissues of rats reached a plateau at 62.5 ppm, indicating saturation in metabolism in 
rats (114). Goggin et al. developed a highly sensitive column switching HPLC-ESI
+
-
MS/MS method, for the quantitation of 1,N
6
-HMHP-dA exocyclic adducts (0.44 ± 0.08 
adducts per 10
8
 nucleotides) induced by DEB in liver DNA of B6C3F1 mice exposed to 
625 ppm BD. Persistence, repair and tissue distribution of BD induced guanine-guanine 
crosslinks (bis-N7G-BD), guanine-adenine crosslinks (N7G-N1A-BD) and exocyclic 
(1,N
6
-HMHP-dA) adducts were also investigated in B6C3F1mice and F344 rats. When 
compared to bis-N7G-BD adducts, N7G-N1A-BD and 1,N
6
-HMHP-dA were found to be 
persistent with a half life greater than 30 days in various tissues such as liver, lung and 
kidney (115).  
So far, BD-DNA adducts have been detected and quantified in laboratory animals 
exposed to BD in a dose dependent manner, but they have not been successfully 
quantified in humans to evaluate BD exposure. Humans are exposed to very low amounts 
of BD (occupational BD exposure: 2-4 ppm), leading to formation of very low levels of 
BD-DNA adducts and, hence bioanalytical quantitation of BD-DNA adducts in humans is 
a challenge.  
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1.3.2.2 BD-protein adducts 
BD electrophilic epoxides are known to react with N-terminal valine of 
hemoglobin to form hemoglobin protein adducts (116). EB is known to react with N-
terminal valine in globin to form N-(2-hydroxy-3-butenyl)–valine (HB-Val) adducts 
(Scheme 1.9) (117). Similarly, EBD and DEB are also known to react with N-terminal 
valine of hemoglobin to form N-(2,3,4-trihydroxybutyl)–valine (THB-Val) and N,N-(2,3-
dihydroxy-1,4-butadiyl)-valine (pyr-Val) protein adducts, respectively (Scheme 1.9) 
(118). Unlike DNA adducts, protein adducts do not represent actual risk of mutations and 
cancer. However, BD hemoglobin adducts are known to be relatively more abundant than 
DNA adducts as they accumulate over lifetime of red blood cells and hence can be 
relatively easily quantified (119). BD induced hemoglobin adducts were quantified as 
biomarkers of exposure in humans occupationally exposed to BD in rubber production 
industries. All three N-terminal valine adducts were quantified in hemoglobin isolated 
from blood erythrocytes of laboratory animals and humans. HB-Val and THB-Val 
adducts were quantified by a methodology which involves modified Edman protein 
degradation, followed by derivatization to pentafluorophenyl thiohydantoins and stable 
isotope dilution GC-MS/MS analysis (117;120). As pyr-Val does not have a free amine 
for thiohydantoin derivatization, it was quantified as a 7- or 11-mer peptide, generated by 
proteolytic trypsin digestion of blood hemoglobin, followed by HPLC or immunoaffinity 
enrichment and stable isotope dilution LC-MS/MS analysis (116;121). HB-Val adduct 
levels increased linearly with BD exposure (0-1000 ppm) in Wister rats exposed to BD 
for 6 h/day for 2 weeks (122).  
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Scheme 1.9: N-terminal valine hemoglobin adducts of BD-derived epoxides. 
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A similar linear dose response relationship was also observed for THB-Val. THB-
Val hemoglobin adducts were also quantified in workers occupationally exposed to BD in 
the polymer industry (1 ppm) and the mean THB-Val concentrations in these workers 
were reported to be 1-3 pmol HB-Val/g of hemoglobin (123). DEB specific pyr-Val 
adducts were also detected and quantified in mice and rats treated with DEB (124). BD 
induced hemoglobin adducts have been used to evaluate the species differences in 
metabolic activation in mice, rats and humans. HB-Val and THB-Val adducts were at 
least 2-8 times higher in mice than rats after exposure to BD (1,000 ppm at 6 h/day, 5 
days/week for 13 weeks), indicating interspecies differences in BD metabolism. 
Statistically significant differences in THB-Val amounts were observed between 
occupationally exposed Chinese workers (88 ± 59 pmol/g Hb) and unexposed workers 
(39 ± 13 pmol/g Hb) (P <0.001) (119). In another study HB-Val and THB-Val adduct 
levels were compared between male workers in administration (BD, 0.010 ppm), 
monomer production (BD, 0.29 ppm) and polymer production (BD, 0.811 ppm) in a BD 
and styrene-butadiene rubber production facility in the Czech Republic and it was 
reported that the hemoglobin adduct levels correlated with BD exposure (125;126). In 
human male versus females comparison study, THB-Val adduct levels were found to be 
significantly higher in males as compared to females. In contrast, female rats or mice 
were reported to have higher levels of THB-Val as compared to males exposed to the 
same dose of BD (127). No significant differences in THB-Val levels were observed 
between control workers and workers occupationally exposed to very low concentrations 
of BD (0.014 ppm) in a BD plant in Italy (128;129). 
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Pyr-Val adducts represent a biomarker for the most genotoxic BD epoxide, DEB. 
pyr-Val was quantified in B6C3F1 mice and F344 rats exposed to 3, 62.5, 1250 ppm BD 
(6 h/day for 2 weeks) and its levels were compared with HB-Val and THB-Val adducts. 
THB-Val was the major adduct in both species, which indicated that EBD is the most 
abundant BD-epoxide in both the species. The concentrations of Pyr-Val were found to 
be higher in mice than rats because of the efficient formation of DEB in mice as 
compared to rats (130). Recently, a highly sensitive nanoLC-ESI
+
-MS/MS method was 
developed and validated for the quantification of pyr-Val in mice and rats exposed to sub 
ppm concentrations of BD in the range of 0, 0.5, 1, 1.5 ppm (131). The concentrations of 
pyr-Val adducts in control, monomer, and polymer production workers were found to be 
0.11 ± 0.07, 0.16 ± 0.12, and 0.29 ± 0.20 pmol/g globin, respectively (132). 
1.3.2.3 Urinary mercapturic acid biomarkers of BD exposure 
Detoxification pathways of BD involve reaction of electrophilc BD epoxides with 
endogenous nucleophilic molecules such as glutathione (GSH). Glutathione adducts are 
known to be biotransformed to polar mercapturic acids which are finally excreted in urine 
(Scheme 1.10). Four mercapturic acids of BD were reported in literature as biomarkers of 
BD exposure. EB, HMVK (formed after oxidation of 1-butene-3,4-diol (EB-diol) by 
alcohol dehydrogenase (ADH)), EBD, DEB can be conjugated with glutathione and 
excreted in urine as the corresponding mercapturic acids 2-(N-acetyl-L-cystein-S-yl)-1-
hydroxybut-3-ene/1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-3-ene (MHBMA), N-acetyl-
S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA), 4-(N-acetyl-L-cystein-S-yl)-1,2,3-
trihydroxybutane (THBMA) and bis-butanediol-mercapturic acid (bis-BDMA) 
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respectively (Scheme 1.10) (133-135). One advantage of analysis of urinary biomarkers 
is that the urine collection is non-invasive and human urine sample is readily available as 
compared to blood samples. Urinary BD metabolites can be used as a measure of BD 
detoxification, which can further be used as an indicator of BD induced carcinogenesis.  
MHBMA and DHMA were quantified in various animal species including 
Sprague-Dawley rats, B6C3F1 mice, syrian hamsters, and cynomolgus monkeys exposed 
to 8000 ppm for 2h of radioactive 
14
C-BD. MHBMA and DHBMA concentrations were 
highest in mouse, followed by the hamster and the rat, and are lowest in the monkey, 
indicating that the monoepoxide availability is inversely related to the hepatic activity of 
epoxide hydrolase enzyme. The concentration epoxide hydrolase is highest in monkeys as 
compared to the other three species (136). 
  Among the two metabolites quantified in human urine of workers exposed to BD, 
DHBMA was found to be significantly more abundant than MHBMA since the majority 
of EB is hydrolyzed by epoxide hydrolase (137). Another study in rats and mice exposed 
to 200 ppm radioactive 
14
C-BD for 6 h confirmed the formation of another minor BD 
mercapturic acid 4-(N-acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane (THBMA) and its 
regio-isomer 3-(N-acetyl-L-cystein-S-yl)-1,2,4-trihydroxybutane  (138). Boogaard et al. 
found the evidence for the formation of bis-glutathione conjugate of DEB, which can 
ultimately be converted via mercapturic acid pathway to bis-BDMA and excreted in urine 
(139). 
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Scheme 1.10  Formation of BD- mercapturic acids and their excretion in urine.  
 
Mercapturic Acid (MA) Pathway: 
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Recently bis-BDMA was quantified in the urine of rats exposed to BD by 
inhalation (0, 62.5 and 200 ppm) in dose dependent manner (135). MHBMA (2 ng/mL) 
and DHBMA (524 ng/mL) were quantified in the urine of workers in the rubber industry 
from the Netherlands and Czech Republic using a sensitive GC-MS/MS method (LOD: 
0.1 ng/ml) (140). The median values of MHBMA and DHBMA were highest in polymer 
workers as compared to monomer workers and the least in controls. Metabolic ratio 
calculated as DHBMA/(MHBMA+DHBMA) is used as a measure of hydrolysis of BD 
epoxides by epoxide hydrolase. The metabolic ratio in humans was determined to be 0.98 
as compared to 0.5 and 0.3 in rats and mice, respectively. Hence humans were reported to 
be more efficient at hydrolysis of BD epoxides than rats and mice (120). 
Albertini et al. found positive correlations between MHBMA, DHBMA levels and 
BD induced hemoglobin adducts. No significant associations were found between either 
of the urinary metabolites and polymorphisms in CYP2E1, EH and ADH, hprt gene 
mutations and cytogenetic end points (126). MHBMA levels decreased significantly 
(>80%) 3 days after smokers quit smoking and >95% after 56 days post smoking 
cessation indicating strong correlation between MHBMA and cigarette smoking. 
However, DHBMA levels remained constant after smoking cessation (141). Our 
laboratory also developed a sensitive isotope dilution MS method for the quantitation of 
THBMA and bis-BDMA in human urine after BD exposure (134;135). Several other 
isotope dilution mass spectrometric methods using triple quadrupole MS were developed 
for the quantitation of MHBMA, DHBMA in smokers, nonsmokers, control and 
occupationally exposed workers (129;133;142-146) and humans exposed to BD in the 
environment (147), and automobile exhaust (148). 
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1.3.3 Species and gender differences in BD metabolism 
Animal models to study the effects of BD exposure uncovered species differences 
in BD carcinogenesis and metabolism. Mice developed tumors even at 6.25 ppm BD 
exposure, while rats developed only a small number of tumors even at 150-200 fold 
higher BD exposures (84;85). In another study, female mice developed lung tumors at 10 
fold lower concentrations of BD than male mice (91). In vivo concentrations of EB and 
DEB in blood were at least 5 fold higher in mice as compared to rats showing species 
differences in BD metabolism (149;150). Female rats were also found to have 4.75-fold 
higher blood concentrations of DEB as compared to male rats exposed when exposed to 
62.5 ppm BD for 6h by inhalation (150). Similarly, female mice had greater DEB 
concentrations in several tissues such as blood, femur, lung and fat tissue as compared to 
male mice receiving the same BD exposure (150). These results clearly confirm the 
presence of species differences in BD metabolism. In vitro studies that determined 
catalytic Vmax/Km values for the epoxidation of EB to DEB in mice, rat and human liver 
microsomes revealed that the rates of conversion in mice were 3.5 fold faster than rats, 
and 3-60 fold greater than humans (151)  (152). Furthermore, the catalytic activity of the 
enzymes responsible for hydrolysis of DEB and detoxification of EB to EB-diol were 
higher is humans followed by rats and least in mice explaining the higher concentrations 
of BD epoxides in mice (93;94).There is also evidence that rat CYP P450 2E1 
monooxygenase, the major enzyme responsible for BD metabolism to EB and DEB is 
inactivated by phosphorylation of ser residues by PKA/cAMP (153)or by covalent 
binding of BD metabolites, especially EB to Tyr and His residues within its active site 
(154) and hence leading to decreased bioactivation of BD. 
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The rates of detoxification by GST of BD epoxides are higher in rats as compared 
to mice (93). BD metabolic detoxification ratio [DHBMA/(DHBMA +MHBMA)] is an 
indicator of EB metabolism by epoxide hydrolase (EH) or GST. The ratio was observed 
to be 0.20, 0.52 and 0.98 in mice, rats and humans, respectively (137). No statistically 
significant differences were observed in MHBMA and DHBMA concentrations per unit 
of BD exposure between occupationally exposed female and male workers. Furthermore, 
the DHBMA/(DHBMA +MHBMA) ratio was similar for males and females, reflecting 
the same relative utilization of the hydrolytic (DHBMA) and the conjugation (MHBMA) 
detoxification pathways in both genders  (155).  
BD-hemoglobin adducts HB-Val and pyr-Val levels were also 4-10 fold higher in 
B6C3F1 mice as compared to F344 rats exposed to BD. THB-Val adduct was present in 
higher amounts as compared to HB-Val and pyr-Val adducts, and the ratio of THB-val to 
total BD-hemoglobin adduct formation in rats and mice was found to be 2-6 and the 
corresponding ratio in humans was >500 (116;118). THB-Val adduct levels were 
significantly higher in male workers than female workers (in both control and exposed 
groups) which in contrast to the gender differences observed in mice and rats (127). At 
low occupationally relevant exposure of 1 ppm BD in mice, rats and humans, HB-Val 
and pyr-Val adducts were the highest in mice indicating a highly efficient metabolic 
activation in this species. The percentage of THB-Val to the total BD-hemoglobin 
adducts was highest in humans (99.6%) indicating the highly efficient hydrolysis of BD 
epoxides by epoxide hydrolase to EBD (116).  
 
 49 
 
Concentrations of DEB are highest in mice as compared to rats and humans as 
indicated by the higher DEB specific pyr-Val adduct levels in mice  (132). Even DEB 
specific DNA crosslinks bis-N7G-BD adduct levels were also higher in mice as 
compared to rats exposed to the same concentration of BD (114). Gender differences 
were also observed in mice, where females have significantly higher levels of DEB 
specific bis-N7G-BD, N7G-N6A-BD adducts as compared to males. However, these 
differences were not observed in rats. EBD specific N7-TBHG adducts were also 
significantly higher in liver, lung and kidney tissues of mice as compared to rats exposed 
to same dose of BD (625 ppm) (75). Hence, significant inter-species and gender 
differences were observed in metabolism of BD. Among the rodent species examined, 
mice were known to form higher levels of DEB, followed by rats and humans exposed to 
BD which is consistent with the greater carcinogenicity of BD in mice as compared to 
rats and humans. Gender differences in BD hemoglobin adduct formation were observed 
at relatively high exposure of BD but not at low BD exposures in laboratory rodents 
(131). These species and gender differences in BD metabolism make BD risk assessment 
challenging and complex. 
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1.3.4 BD exposure in cigarette smoke and lung cancer risk in various ethnic groups 
Lung cancer accounts for 14% of all cancer deaths worldwide and 27% of all 
cancer deaths in the US (156). Cigarette smoking is one of the major risk factors for lung 
cancer development, accounting for approximately 87% of lung cancer deaths and 30% 
of all other cancer deaths (157;158). Other environmental exposure risk factors for lung 
cancer include radon, secondhand smoke, asbestos, chromium, cadmium, arsenic, 
ionizing radiation, air pollutants, and diesel exhaust (157). Cigarette smoke is a complex 
mix of known carcinogens such as polycyclic aromatic hydrocarbons (PAHs), 
heterocyclic compounds, aromatic amines, heterocyclic aromatic amines, N-nitrosamines, 
phenolic compounds, volatile hydrocarbons, nitrohydrocarbons, metals, inorganic 
compounds, and other small molecule aldehydes such as acetaldehyde, formaldehyde and 
volatile organic compounds such as benzene, 1,3-butadiene and isoprene. Among various 
carcinogens in cigarette smoke, 1,3-butadiene has one of the highest cancer risk index per 
cigarette per day (159). BD is generated as a gas in mainstream smoke either from 
incomplete combustion or thermal cracking process of complex molecules such as 
carbohydrates, amino acids, phytosterols, paraffins, and many other tobacco components 
in tobacco  (160;161).  
Ethnic differences in lung cancer risk due to smoking 
Smoking related lung cancer risk and incidence was found to be different among 
various ethnic groups in the United States. In a study of 740 lung cancer patients and 
1616 controls, the age adjusted lung cancer incidence rates in males were found to be in 
the order of Hawaiian > Caucasian > Chinese > Japanese > Filipino (162). In the same 
study lung cancer incidence rates in females were Hawaiian > Caucasian > Chinese > 
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Filipino > Japanese (162). From this study, it was hypothesized that the differences in 
lung cancer risk among various ethnic groups might be due to differences in diet and 
metabolic differences in activation and detoxification of carcinogens present in cigarette 
smoke due to genetic polymorphisms  (162). Hinds et al. also conducted a multi-ethnic 
cohort study involving 375 lung cancer subjects and 2404 controls in Japanese, Chinese 
and Hawaiian women from Hawaii and found the lung cancer risk among the ethnic 
groups to be Hawaiian > Japanese > Chinese women (163). An independent study was 
conducted to identify ethnic differences in lung cancer risk among African American and 
European Americans smokers including 5588 lung cancer cases and 3692 controls (164). 
It was concluded that African Americans have 2-4 times higher risk of lung cancer than 
European American smokers in the 40-54 age group (164). Stellman et al. found that the 
lung cancer risk was at least 10 times higher in Americans than Japanese Americans  
(165). In another study conducted by Stellman et al. in European American and African 
American smokers, no statistically significant differences in lung cancer risk were 
identified (166).  
 In a large multi ethnic cohort study by Haiman and co workers involving 180,000 
smokers (≤ 10 cigarettes/day) belonging to African-American, Japanese-American, 
Latino, Native Hawaiian, European American ethnicity, the relative risk of lung cancer 
was found to be 1.00, 0.25, 0.21, 0.88 and 0.45, respectively. But, at a higher smoking 
level (>30 cigarettes/day), the relative risks were 1.00, 0.75, 0.79, 0.95 and 0.82, 
respectively (167). This study hypothesized that the ethnic differences might be due to 
differences in metabolism of tobacco carcinogens  (167). Five year (2006-2010) lung 
cancer incidence rate statistics from National Cancer Institute among different ethnic 
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groups were African American > European American > American Indian > Asian > 
Hispanic in males. In females, the corresponding lung cancer incidence rates were 
European American > African American > American Indian > Asian > Hispanic (158). 
 
1.4 Carcinogen induced small molecule DNA adducts repair mechanisms 
 DNA damage is an important step in mutagenesis and the development of cancer. 
DNA damage induced by exogenous and endogenous carcinogens is known to be 
repaired by cellular DNA repair mechanisms such as base excision, nucleotide excision 
and homologous recombination repair pathways. 
 For example, O6-methylguanine DNA methyltransferase (MGMT, DNA 
alkyltransferase) cleaves both methyl and ethyl adducts from methyl/ethyl guanine 
adducts. MGMT reaction is noncatalytic but is rather stoichiometric consuming one 
molecule of MGMT for each adduct removed (168). DNA polymerases such as pol-δ 
contain proofreading activities and are involved in the repair of DNA adducts (169). pol-
δ is known to halt the process of DNA replication when it encounters bulky DNA adducts 
such as 1,N6-ethenoadenine and works backward to excise nucleotides with the adduct 
from the growing DNA chain and, then starts the forward replication process. Point 
mutations of a conserved active site residue in pol-δ significantly elevates the frequency 
of insertion errors of pol-δ (169). Another type of repair called mismatch excision repair 
(MMR) is capable of correcting errors of DNA replication not detected by the 
proofreading activities of replicative DNA polymerases. MMR enzymes excise an 
incorrect nucleotide from the daughter DNA and repair the strand using watson and crick 
base pairing of parent DNA strand as the correct template (170). 
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1.4.1 Base Excision Repair and Nucleotide Excision Repair of DNA adducts 
Base excision repair (BER) of DNA adducts involves several enzymes depending 
on the nature of DNA adduct. DNA adduct base modifications primarily repaired by BER 
enzymes include 7,8-dihydro-8-oxoguanine (8-oxoG) (171), uracil in DNA due to 
cytosine deamination (172), ring opened N7 substituted and unsubstituted guanine and 
adenine bases also called formamidopyrimidine (Fapy) adducts (173), and psoralen 
induced DNA adducts by UV radiation (174). BER enzymes are typically DNA 
glycosylases and cleave the N-glycosidic bond between the nucleotide base and ribose 
resulting in an apurinic or apyrimidinic (AP) site. 8-Oxoguanine DNA glycosylase I 
(Ogg1) is known to remove 7,8-dihydro-8-oxoguanine (8-oxoG) (175). Mutations or 
polymorphisms in the human OGG1 gene are associated with the risk of lung and 
colorectal cancer (176;177). Uracil DNA glycosylase, another BER enzyme, excises the 
uracil in the DNA that is the product of unnecessary cytosine deamination, thereby 
preventing the subsequent C→T point mutations (172). BER enzyme N-methylpurine 
DNA glycosylase (MPG) is able to remove a variety of adducted purine bases (178), and 
the enzyme formamidopyrimidine [fapy]-DNA glycosylase (fpg) is known to remove 
various fapy adducts such as fapy-guanine, methy-fapy-guanine, fapy-adenine, aflatoxin 
B1-fapy-guanine (179) . AP sites generated by the action of BER enzymes are known to 
be repaired by the action of AP-endonuclease 1 (APE1) and DNA polymerase β (Polβ). 
Other proteins such as X-ray repair cross-complementing group 1 (XRCC1), a scaffold 
protein and DNA ligase III (LIG3) are also involved in ligation of the correct base and 
this process is known as short patch BER pathway (180;181). Long-patch BER replaces a 
strand of nucleotides with a minimum length of 2 nucleotides and up to 12 nucleotides 
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next to the AP site and this process involves scaffolding protein proliferation cell nuclear 
antigen (PCNA), DNA polymerases such as Polδ and Polε, flap endonuclease-1 (FEN1) 
and DNA ligase I (LIG1) (182). 
Nucleotide excision repair (NER) is another common DNA repair pathway 
capable of removing bulky base modifications from DNA. NER involves cleavage at two 
phosphodiester bonds, 3′ and 5′ of the site of damage, followed by excision from single-
stranded fragment  (183;184). The excised oligonucleotide is replaced by DNA repair, 
synthesis, and ligation. NER deficiency in humans results in xeroderma pigmentosum 
(XP), a genetic disorder characterized by photosensitivity to UV light, leading to 
increased incidence of skin cancer (185). XP patients are impaired in the removal of 
radiation products and DNA adducts induced by the UV component of sunlight  (185). 
Somatic cell lines created from these patients have also been reported to have decreased 
efficiency in NER of bulky DNA adducts resulting from genotoxic chemicals (184). In 
vitro studies in cellular extracts showed that the range of base lesions detected by 
mammalian NER extends to nonbulky adducts, and even abasic sites (186). 
Several biological experiments demonstrated that mammalian NER process 
involves over 20 proteins including XPA, XPC, replication protein A (RPA), XPB and 
XPD DNA helicases, ERCC1-XPF and XPG, Polδ, Polε, PCNA etc. with defined roles in 
detection, removal and repair of DNA adducts (187). Detailed molecular mechanisms by 
which several NER proteins distinguish a large number of chemically unrelated DNA 
lesions as substrates for NER are unknown. However, NER is believed to be involved in 
repair of DNA lesions when the system recognizes conformational changes imposed on 
DNA. Even within NER, Global genomic NER (GGR) repairs damage throughout the 
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genome, while another specific NER pathway called Transcription Coupled Repair 
(TCR) is known to repair genes during active RNA polymerase transcription (188). 
Recombination and fanconi anemia (FA) repair pathways of DNA adducts 
 Many bifunctional crosslinking agents such cisplatin and nitrogen mustards form 
interstrand crosslinks in DNA which in turn lead to the formation of DNA double strand 
breaks during replication to initiate various repair pathways such as recombination and 
FA repair pathways (189).  
Recombination repair can happen either by homologous recombination (HR) or 
nonhomologous end-joining (NHEJ). The HR pathway requires the presence of an 
identical or partially identical sequence linked to the damaged DNA region via the use of 
a repair template. The nucleotide sequences are exchanged between two similar or 
identical molecules of DNA to initiate the recombination (190). Non-homologous end 
joining occurs when no homologous template is available and the break ends are directly 
ligated. NHEJ generates single-stranded overhangs on the ends of double-strand breaks 
and when completely repaired, the overhangs are removed without loss of genetic 
information (191). Imprecise repair can cause loss of nucleotides which can further lead 
to translocations and frame shift mutations. In NHEJ, either the Ku heterodimeric 
proteins or other multiple enzymes (Ku independent pathway) are involved in the 
rejoining process, including DNA ligase IV, XRCC4, and DNA-dependent protein kinase 
(DNA-PK) (192). 
 Fanconi anemia (FA) repair pathway is associated with the repair of interstrand 
DNA crosslinks formed by bifunctional crosslinking agents (193). FA pathway is known 
to work in coordination with three other DNA repair pathways such as homologous 
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recombination, nucleotide excision repair, and mutagenic translesion bypass DNA 
synthesis in response to the DNA modification produced by carcinogens (194). Fanconi 
Anemia (FA) is a rare autosomal recessive or X-linked genetic disease condition and 
patients with FA are hyper-sensitive to bifunctional DNA damaging agents such as 
mitomycin C (MMC) or diepoxybutane (DEB) that create DNA interstrand crosslinks 
(ICLs) (195). FA pathway is activated not only by bifunctional DNA damaging 
chemicals, but also by other agents, such as ultraviolet radiation (UV), ionizing radiation 
(IR) or spontaneously during replication (196;197). FA pathway is a complex process 
involving unique nuclear protein complex consisting of at least 13 complementation 
groups FANCA to N, leading to formation of DNA repair structures either upstream or 
downstream of the pathway (193). 
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1.5 Development of novel DNA adducts as biomarkers 
Mass spectrometry is used as a tool for the identification of novel DNA adducts as 
biomarkers of exposure, metabolic activation and cancer risk in DNA adductomics (198). 
Previously, MS analysis of DNA adducts was a bottom-up approach where 
predetermined and structurally known DNA adducts were quantified in both in vitro and 
in vivo studies. DNA adductomics approach is a top down generalized procedure to 
characterize overall DNA damage induced by carcinogens by identifying structurally 
known or unknown DNA adducts 
In MS based DNA adductomics approach, MS based fragmentation of a common 
structural feature of nucleosides, a deoxyribose sugar moiety bonded to the nucleobase 
through a N-glycosidic bond is performed. MS based fragmentation reactions for the 
neutral loss of 2′ deoxyribose sugar (dR = 116 amu) ([M-B-dR+H]+ [M-B+H]+ - dR, M 
= modification, B = nucleobase) are monitored using different MS scanning modes 
(Scheme 1.11) (199). 
Scanning modes to determine loss of dR ( 116 amu) 
Constant neutral loss (CNL) scanning for the neutral loss of 116 amu has been 
performed on a triple quadrupole MS for determination of polycyclic aromatic 
hydrocarbon DNA adducts (200). In this type of scanning, quadrupole 1 (Q1) and Q3 
scan were offset from each other by the neutral loss of dR (m/z = 116 amu). Collision cell 
(q2) filled with inert gas such as argon or nitrogen is used to induce fragmentation. 
Finally, only ions that fragment with the specific neutral loss of dR (m/z = 116 amu) will 
pass through Q1, q2, and Q3 and be recorded as an MS signal (Scheme 1.11). A variant 
of the above CNL scan method known as the pseudo-CNL approach was used to assess 
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and comprehensively detect DNA adducts in human lung, esophagus (201) and food 
derived modified nucleosides (202). In this approach, instead of CNL scanning, the 
system is set to monitor a number of sequential selected reaction monitoring (SRM) 
transitions, all involving a loss of 116 amu. Although time consuming, the pseudo-CNL 
approach is proposed to have better sensitivity over the normal CNL approach because 
triple quadrupole instruments are good at performing multiple SRMs rather than scanning 
over a wide mass range. 
 Another advanced MS-based DNA adductomics method involved usage of data-
dependent (DD) scanning approach to monitor the CNL of dR (116 amu) using newer 
MS instruments such as linear ion trap quadrupole (LTQ) and orbitrap velos, for high 
resolution accurate mass analysis. DD scanning is optimized software dependent 
scanning performed in real time and provides increased DNA adduct coverage by 
preventing the repeated fragmentation of the most abundant ions using dynamic 
exclusion of already fragmented ions. In addition, a predetermined reject mass list can be 
included to exclude interfering high abundant background ions from fragmentation (199). 
Examples of the use of this approach include DD analysis in MS
2
 mode (203) or in MS
3
 
mode for fragmentation (204-206). In DD-MS
3
 mode, adducts that have a neutral loss of 
m/z 116 can be further fragmented via MS
3
 mode to obtain structural information from 
MS
3
 fragments (Scheme 1.11). Recently Balbo et al. used DD-MS
3 
scanning to monitor 
the accurate neutral loss of dR (m/z 116.0474) using the Orbitrap Velos HRMS 
instrument. This method has advantages over previous methods as the high resolution 
accurate mass measurement significantly decreases the nonspecific fragmentation. 
Furthermore, more than 10 adducts were identified in liver DNA of mice exposed to the 
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tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
(205). Hence, with advancing MS instructions, it is possible to adopt top down DNA 
adductomics based approaches to identify novel DNA adducts as biomarkers. 
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Scheme 1.11 MS/MS fragmentation based neutral loss of deoxyribose sugar from 
adducted DNA nucleosides (dR = 116 amu) (A), triple quadrupole based scanning of the 
neutral loss of sugar from nucleosides (B), Data dependent constant neutral loss based 
scanning of sugar (C).  
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1.6 Summary and thesis goals 
BD is a carcinogen known for its widespread human exposure in polymer and 
monomer rubber industries and environmental exposure due to automobile exhaust, 
cigarette smoke, and wood burning due to forest fires. The metabolically activated BD-
epoxides EB, EBD and DEB are responsible for BD carcinogenicity (Scheme 1.7). BD 
electrophilic metabolites are known to react with DNA to form various DNA adducts 
which can cause mutations that are ultimately responsible for the carcinogenicity of BD 
(Scheme 1.8). Though there are various biomarkers of BD exposure such as protein 
adducts and mercapturic acids, DNA adducts are known as ultimate biomarkers as they 
represent biologically relevant dose of exposure, and are a direct measure of metabolic 
activation and cancer risk. Though BD induced DNA adducts are quantified in animals 
exposed to relatively high concentrations of BD ( > 6.25 ppm), they have not been 
quantified in humans exposed to sub ppm concentrations of BD (< 1-3 ppm BD). Hence 
the initial goals of this thesis work were to develop highly sensitive isotope MS methods 
for the absolute quantification of DEB specific bis-N7G-BD in animal model exposed to 
low sub ppm (0.5 – 1.5 ppm) concentrations of BD.  
We have developed sensitive accurate mass spectrometric methods using 
advanced capillary and nanospray LC-MS techniques for the quantitation of BD DNA 
adducts such as N7-THBG and EB-guanine. N7-THBG and EB-guanine adducts were 
quantified in human blood leukocyte DNA of smokers, nonsmokers, occupationally 
exposed individuals and control administrative workers. As blood leukocyte DNA is 
limited and the levels of BD-DNA adducts are very low in blood (1-3 adducts/10
8
 to 10
9
 
nucleotides), we worked on the development of a novel high resolution accurate MS 
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method for the quantitation of the BD-DNA adducts in urine. Differences in smoking 
related lung cancer risk in various ethnic/racial differences has been hypothesized to be 
because of the differences in genetic polymorphisms of the genes involved in the 
metabolic activation and deactivation of carcinogens. Though cigarette smoke contains 
more than 70 different carcinogens, BD is one of the most potent and abundant 
carcinogens present in mainstream and sidestream cigarette smoke. We tested this 
hypothesis by quantification of BD-DNA adducts in urine of European American and 
African American smokers to evaluate the ethnic/racial differences in metabolism of BD .  
Additional studies were performed on isogenic repair deficient cell lines from 
Chinese hamster lung fibroblasts to understand the repair of DNA–DNA crosslinks 
induced by DEB. We also investigated the formation of novel ring opened 
formamidopyrimidine (Fapy) BD-DNA adducts.  
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2 II. NANO HPLC-NANO ESI
+
-MS/MS QUANTITATION OF BIS-N7-GUANINE 
DNA-DNA CROSS-LINKS IN TISSUES OF B6C3F1 MICE EXPOSED TO SUB-
PPM LEVELS OF 1,3-BUTADIENE 
Reprinted with permission from: Dewakar Sangaraju , Melissa Goggin, Vernon Walker , 
James Swenberg, Natalia Tretyakova. Anal Chem. 2012, 84(3), 1732-9. © 2012 
American Chemical Society 
2.1 Introduction 
1,3-Butadiene (BD) is an important industrial chemical commonly used in rubber 
and plastic manufacturing (83) and an environmental pollutant present in automobile 
exhaust (207) and in cigarette smoke (208). BD is classified as human carcinogen based 
on epidemiological studies in occupationally exposed workers that revealed an increased 
incidence of leukemia (86;87;91;209). Furthermore, inhalation experiments with 
laboratory animals have shown that BD is a multi-site carcinogen, inducing lung, liver, 
heart stomach and other solid tumors in mice (84) and thyroid, pancreas, uterus, testes 
and other tissue tumors in rats (85). BD requires metabolic activation to DNA-reactive 
epoxides 3,4-epoxy-1-butene (EB), 1, 2, 3, 4-diepoxybutane (DEB), and 1,2-dihydroxy-
3,4-epoxybutane (EBD) (95;210). Among these, DEB is the most genotoxic, inducing 
large numbers of base substitutions, sister chromatid exchanges, and chromosomal 
aberrations in vitro and in vivo (95;98;211). Large interspecies differences in 
carcinogenicity of BD in mouse and rat animal models (84;85) have been attributed to 
more efficient metabolic activation of BD to DEB in the mouse (212-214). Because of its 
key role in carcinogenicity of BD, there is a need for sensitive biomarkers of DEB 
formation in vivo. 
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Georgieva et al. have developed DEB-specific biomarkers based on N-terminal 
valine hemoglobin adducts (Hb) adducts, namely N,N[2,3-dihydroxy-1,4-butyl]valine 
(pyr-Val)  (127;131). Pyr-Val adducts have been detected in blood of B6C3F1 mice and 
F344 rats exposed to BD as low as 0.5 ppm BD (131). More recently, Pyr-Val adducts 
were observed in blood of occupationally exposed workers at concentrations of 0.08 to 
0.86 pmol/g globin (116). Hb-based biomarkers are valuable because these adducts are 
not repaired and therefore are representative of cumulative exposure over time(the 
lifetime of red blood cells is ∼120 days in humans, 45 days in mice, and 63 days in rats). 
However, Hb based biomarkers may not represent a biologically relevant dose of DEB 
since protein adducts do not lead to mutations, and DNA rather than cellular proteins is 
the ultimate biological target of genotoxic carcinogens such as DEB.  
Our laboratory previously identified several DEB-specific DNA adducts including 
DNA-DNA cross-links, 1,4-bis-(guan-7-yl)-2,3-butanediol (bis-N7G-BD) (Scheme 2.1) 
and 1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD), and an exocyclic DEB-
dA adduct, 1,N
6
-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2’-deoxyadenosine 
(65;74;107;113;215;215). DEB-specific bifunctional DNA adducts have been quantified 
in tissues of laboratory rats and mice that were exposed to 6.25-625 ppm of BD by 
inhalation (114). Among DEB-DNA adducts, bis-N7G-BD were present at the highest 
concentration (3.95 ± 0.89 adducts/10
7 
nucleosides (nts) in livers of mice exposed to 625 
ppm BD), followed by N7G-N1A-BD (0.27 ± 0.07 adducts/10
7
 nts), 1,N
6
-HMHP-dA 
(0.044 ± 0.008 adducts/10
7
 nts) (65;114).  
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Scheme 2.1 Metabolism of 1,3-butadiene to DEB and its reactions with DNA to form 
bis-N7G-BD crosslinks. 
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While our previously capillary HPLC-ESI
+
-MS/MS methods were adequate for 
detection of bis-N7G-BD in tissues of laboratory animals exposed to 6.25 ppm BD and 
higher, (114) greater sensitivity is required in order to detect DEB-DNA adducts 
following typical human exposures (1 ppm and lower). In the present work, we have 
developed and validated a nanoHPLC-nanoESI
+
-MS/MS method for the quantitation of 
bis-N7G-BD in vivo. The sensitivity and accuracy of the new method are as follows: 
LOD: 0.5 fmol/ 100 µg DNA, LOQ: 1.0 fmol/ 100 µg DNA, and accuracy: 97.1 ± 6.3 % 
(n = 5). To our knowledge, this is the first quantitative analysis of DEB-specific DNA 
adducts following exposure to occupationally relevant BD concentrations (OSHA limit = 
1 ppm)  (216). Our results indicate that bis-N7G-BD formation is more efficient at low 
BD exposure levels (< 1.5 ppm), probably because a greater fraction of BD is 
metabolized to DEB. These results will be useful for human risk assessment from 
exposure to BD. 
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2.2 Materials and Methods 
Note: DEB is a known carcinogen and must be handled with adequate safety 
precautions. Phenol and chloroform are toxic chemicals that should be handled in a well-
ventilated fume hood with appropriate personal protective equipment. 
LC-MS grade water, methanol and acetonitrile were obtained from Fisher Scientific 
(Pittsburgh, PA). All other chemicals and solvents were obtained from Sigma-Aldrich 
(Millwaukee, WI, St. Louis, MO) with the exception of bis-N7G-BD and [
15
N10]-bis-
N7G-BD, which were prepared in our laboratory as described elsewhere (74;105;215).  
Animals and treatment  
BD inhalation exposure experiments were performed at the Lovelace Respiratory 
Research Institute (Albuquerque, NM) as previously reported (114). Briefly, B6C3F1 
female mice (5 per group) were exposed to 0, 0.5, 1.0, or 1.5 ppm BD by inhalation for 2 
weeks (6 h/day, 5 days/week). Animals were euthanized by CO2 and cardiac puncture at 
the end of the exposure period. Liver tissues were collected, flash frozen, and shipped to 
the University of Minnesota on dry ice, where they were stored at -80 ºC. 
Cell culture  
V79 chinese hamster lung fibroblasts were obtained from the Coriell institute 
(Camden, NJ, USA). Cells were grown to confluence on 15 cm dishes in Ham's F-12 
modified essential Eagle's media supplemented with 9% fetal bovine serum. The cell 
culture was maintained in a humidified environment containing 5% carbon dioxide and 
95% air at 37°C. Cells were subjected to serial passage at a dilution of 1:10 following 
brief exposure to porcine pancreatic trypsin and mechanical agitation. All experiments 
were performed on cells at low passage number. 
 68 
 
DNA isolation  
DNA was isolated from mouse liver tissue using NucleoBond AXG500 anion 
exchange cartridges (Macherey-Nagel) according to the manufacturer’s instructions. 
DNA employed for method validation was isolated from CHL-V79 cells by standard 
phenol-chloroform extraction. DNA concentrations were estimated using UV 
spectrophotometry. DNA purity was assessed from A260/A280 absorbance ratio, which was 
typically between 1.7 and 1.8. DNA amounts were determined by quantitation of dG in 
enzymatic hydrolysates as described below. 
dG quantitation  
DNA aliquots (~10 µg) were enzymatically digested with phosphodiesterase I 
(6.0 mU/μg DNA), phosphodiesterase II (8.0 mU/μg DNA), DNase (3.0 U/μg DNA), and 
alkaline phosphatase (6.69 U/μg DNA) in 10 mM Tris-HCl/15 mM MgCl2 (pH 7.2) at 37 
°C overnight. HPLC-UV analysis of dG was conducted by HPLC-UV using a Zorbax 
SB-C8 column (4.6 x 150 mm, 5 μm, from Agilent Technologies, Palo Alto, CA) eluted 
with a gradient of 150 mM ammonium acetate (A) and acetonitrile (B) described 
previously (217).  
Neutral thermal hydrolysis and isolation of bis-N7G-BD adducts  
DNA samples (100 µg) were spiked with 50 fmol of S,S;R,R 
15
N10- bis-N7G-BD 
(racemic 
15
N10- bis-N7G-BD, internal standard for mass spectrometry) and incubated at 
70 ºC for 1 hour to release bis-N7G-BD from the DNA backbone as a free base 
conjugate. Partially depurinated DNA was removed by ultrafiltration with Nanosep 10K 
filters (Pall Life Sciences, Ann Arbor, MI). The filtrates containing bis-N7G-BD and its 
internal standard were purified by offline HPLC. A Zorbax Eclipse XDB-C18 (4.6 x 150 
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mm, 5 µm, from Agilent Technologies, Palo Alto, CA) column was eluted at 1 mL/min 
with a gradient of 0.4% formic acid in Milli-Q water (A) and HPLC grade acetonitrile 
(B). Solvent composition was maintained at 0% B for 5 min and then increased to 3% B 
in 10 min and further to 40% B in 5 min. The solvent composition was returned to 0% B 
in 5 min and maintained at 0% B for 15 min. 2’-deoxythymidine (dT) and 2’-
deoxyadenosine (dA) (12.0 nmol each) were added as retention time markers, eluting at 
13.7 and 18.8 min, respectively. HPLC fractions containing bis-N7G-BD (14 – 18 min, 
about 1.25 mL) were collected, dried under vacuum, and dissolved in water (25 µL) for 
nanoHPLC-nanoESI
+
-MS/MS analysis. 
NanoLC-nanoESI
+
-MS/MS analysis of bis-N7G-BD  
A Waters nanoAcquity UPLC system (Waters Corp., Millford, MA) interfaced to 
a Thermo-Finnigan TSQ Quantum UltraAM mass spectrometer (Thermo Fisher 
Scientific Corp., Waltham, MA) was used in all analyses. HPLC solvents were 0.01% 
acetic acid in LC-MS grade water (A) and LC-MS grade methanol: acetonitrile (1:1) (B). 
Samples (8 µL) were loaded on a trapping column (Symmetry C18 nanoAcquity, 0.18 x 
20 mm, Waters Corp., Millford, MA) for 1 min at 0% B at a flow rate of 10 µL/min. The 
chromatographic separation was achieved with a nano-HPLC column (75µm x 200 mm) 
manually packed with Zorbax SB-C18, 5 µm chromatographic packing (Agilent Tech. 
Santa Clara, CA). The column was eluted at a flow rate of 0.4 µL/min. Solvent gradient 
started at 0% B for 1 min and was increased to 10% B in 2 min, further to 50% B in 8 
min, and finally to 80% B in 5 min. Solvent composition returned to 0 %B for 14 min 
equilibration at a flow rate of 0.4 µL/min. Under these conditions, bis-N7G-BD eluted as 
a sharp peak at ~15 min. 
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The triple quadrupole mass spectrometer was fitted with a nanospray source from 
Thermo Fisher Scientific Corp. (Waltham, MA). The instrument was operated in the 
positive ion mode ESI mode with Ar as a collision gas (1.4 mTorr). The mass 
spectrometer was tuned upon infusion of authentic bis-N7G-BD solution to achieve 
maximum sensitivity. Quantitative analyses were conducted in the selected reaction 
monitoring (SRM) mode by following the MS/MS transitions corresponding to the 
neutral loss of guanine from protonated molecules of the analyte (m/z 389.1 [M + H]
+
 → 
m/z 238.1 [M + H - Gua]
+
), and the formation of protonated guanine (m/z 389.1 [M + H]
+
 
→ m/z 152.1 [Gua + H]+). Typical instrument settings included a spray voltage of 2.0 kV, 
capillary temperature at 300 °C, and collision energy at 32 and 22 V for the first and the 
second SRM transition, respectively. The corresponding transitions for the 
15
N10-
isotopically-labeled internal standard were m/z 399.1 [
15
N10-M + H]
+
 → m/z 243.1 [M + 
H - [
15
N5]Gua]
+
 and m/z 157.1 [
15
N5-Gua + H]
+
. The Q1 peak width was 0.4 amu, while 
the peak width for Q2 was 0.7 amu. The scan width was 0.4 amu, and the scan time was 
0.5 s. NanoHPLC-nanoESI
+
-MS/MS quantitation was based on the areas of the peaks in 
the extracted ion chromatograms corresponding to the analyte and the internal standard. 
Method standard curves were constructed by analyzing solutions containing a 
fixed amount of 
15
N10-bis-N7G-BD (50 fmol) and increasing amounts of bis-N7G-BD 
(0.5, 1.0, 5.0, 10.0, 15.0, 25.0, and 50.0 fmol) in water (in triplicate), followed by 
regression analysis of the actual and observed amounts of bis-N7G-BD (Figure 2.1). 
Solvent blanks were periodically injected to monitor for potential analyte carry-over. 
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Figure 2.1: NanoHPLC-nanoESI
+
-MS/MS method standard curve. 
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Method validation  
DNA isolated from CHL V-79 cells (100 µg, in triplicate) was spiked with 0, 1, 5, 
10, 15, 25 or 50 fmol of bis-N7G-BD and 50 fmol 
15
N10-bis-N7G-BD internal standard. 
Following heating at 70 ºC for 1 hour (neutral thermal hydrolysis), samples were filtered 
through Nanosep-10K ultra- centrifugation devices to remove partially depurinated DNA. 
Bis-N7G-BD and its internal standard were purified by off-line HPLC as described above 
and subjected to nanoHPLC-nanoESI
+
-MS/MS analysis by usual methods. Regression 
analysis was conducted to compare the measured and the spiked amounts of bis-N7G-
BD. 
Determination of LOD/LOQ, precession, and accuracy.  
DNA extracted from CHL V-79 cells (100 μg) was spiked with 1, 0.75, 0.5, or 0.1 
fmol of bis-N7G-BD and 50.0 fmol of 
15
N10-bis-N7G-BD. Samples were subjected to 
thermal hydrolysis, ultrafiltration, purified by offline HPLC, and analyzed by 
nanoHPLC-nanoESI
+
-MS/MS as described above. Method limit of quantification (LOQ) 
was estimated as the amount of analyte which gave a signal-to-noise ratio (S/N) greater 
than 10 and % CV < 15%. Limit of detection (LOD) was determined as the amount of 
analyte that produced a signal-to-noise ratio > 3. 
To evaluate the interday and intraday accuracy and precision of the new method, 
bis-N7G-BD (2.0 fmol) and 
15
N10-bis-N7G-BD (50.0 fmol) were spiked into blank DNA 
from CHL cells (100 µg). Samples were processed as described above and analyzed three 
times per day on three consecutive days. Method accuracy was calculated from the 
equation (Am/Aa × 100%), where Am is the measured amount of bis-N7G-BD and Aa is 
the actual amount added. 
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Analysis of bis-N7G-BD in mouse liver samples:  
DNA was extracted from livers of B6C3F1 mice exposed to either 0, 0.5, 1.0 or 
1.5 ppm BD by inhalation (2 weeks at 6 h/day, 5 days/week) using methodology 
described above. DNA aliquots (100 µg in 200 µL water) were subjected to neutral 
thermal hydrolysis (70 °C for 1 hr), followed by Nanosep10K ultra filtration and offline 
HPLC as described above. Our previous experiments confirmed that these conditions 
efficiently release bis-N7G-BD adducts form the DNA backbone (74;105). Bis-N7G-BD 
adducts were quantified using the newly validated nanoHPLC-nanoESI
+
-MS/MS method. 
Adduct numbers were expressed as number of adducts per 10
9
 nucleotides. DNA 
amounts were determined by HPLC-UV analysis of dG in DNA hydrolysates as 
described above.  
Method Reproducibility  
DNA was extracted from six 100 mg aliquots of liver from F344 rat treated with 
62.5 ppm BD by inhalation and analyzed by the standard methodology. An additional 
two aliquots were extracted by the Qiagen DNA extraction kit and analyzed for 
comparison. A good agreement was observed between these separate analyses (CV 
9.4%). 
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2.3 Results  
2.3.1 Experimental Approach  
The goal of the present study was to develop ultra-sensitive methodologies to 
quantify bis-N7G-BD adducts in tissues of mice exposed to low ppm and sub-ppm levels 
of BD. In our approach (Scheme 2.2), genomic DNA extracted from tissue is spiked with 
[
15
N10]-bis-N7G-BD internal standard, and bis-N7G-BD lesions are released from the 
DNA backbone by neutral thermal hydrolysis. Our previous results indicate that heating 
at 70 °C for 1 h results in a quantitative release of bis-N7G-BD cross-links  (74;114). 
Following the removal of partially depurinated DNA via ultrafiltration, bis-N7G-BD and 
its internal standard are isolated from the bulk of the sample matrix using offline HPLC. 
HPLC fractions containing analyte are then dried, reconstituted in buffer, and subjected 
to nanoHPLC-nanoESI
+
-MS/MS analysis on a triple quadrupole mass spectrometer. Our 
new method employs a flow rate of 0.4 µL/min and nanoESI MS/MS detection as 
compared to the earlier capillary HPLC-ESI-MS/MS method that uses a flow rate of 10 
µL/min (114).  
2.3.2 NanoHPLC-nanoESI
+
-MS/MS method development and validation.  
MS/MS fragmentation pattern of bis-N7GBD in a triple quadrupole mass 
spectrometer is characterized by predominant product ion peaks at m/z 238.1 
corresponding to neutral loss of guanine base from protonated molecules of the adduct 
[M + H - Gua]
+
 (74;215). Another abundant fragment of m/z 152.1 corresponds to the 
protonated guanine [Gua + H]
+
 (Figure 2.2).  
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Scheme 2.2. Bis-N7G-BD Analytical Procedure 
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Figure 2.2 NanoLC-nanoESI
+
-MS/MS analysis of a mixture of pure bis-N7G-BD (1.0 
fmol) and 
15
N10-bis-N7G-BD (10 fmol). 
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The corresponding fragments for the corresponding 
15
N10 isotopically labeled 
internal standard are m/z 243.1 [M + H - [
15
N5]Gua]
+
 and m/z 157.1 [
15
N5-Gua + H]
+
.The 
quantitative method for bis-N7G-BD is based on selected reaction monitoring of the 
MS/MS transitions m/z 389.1 [M + H]
+
 → m/z 238.1 [M + H - Gua]+ and m/z 389.1 [M + 
H]
+
 → m/z 152.1 [Gua + H]+. The corresponding transitions for the 15N10-isotopically-
labeled internal standard are m/z 399.1 [
15
N10-M + H]
+
 → m/z 243.1 [M + H - 
[
15
N5]Gua]
+
 and m/z 157.1 [
15
N5-Gua + H]. A sum of the two transitions is used for 
quantitation to improve sensitivity. 
To optimize analyte separation from interfering components of the biological 
matrix, the new method employs an offline HPLC sample cleanup. dT and dA were 
spiked in each sample as retention time markers eluting at 13.7 and 18.8 min, 
respectively, while the retention time of bis-N7G-BD and its internal standard is ∼16 
min. HPLC fractions containing bis-N7G-BD and 
15
N10-bis-N7G-BD (14−18 min, about 
1.25 mL) were collected and concentrated for nanoLC-nanoESI+-MS/MS analysis. 
We have chosen nanospray LC-MS method over conventional capillary flow LC-
MS because of its greater sensitivity. When HPLC flow rate is reduced to < 1 μL/min, 
droplet formation in the electrospray source occurs more readily, requiring only the 
applied voltage (typically 2000V) to generate a spray (218). The efficiency of 
electrospray ionization is greatly improved under nanoflow conditions, because a smaller 
amount of mobile phase passes through the emitter, producing fine aerosol droplets. 
Consequently, the stability of ion spray, and therefore MS signal, is improved, thus 
leading to improved detection sensitivity (219;220). As an additional benefit, nanoHPLC 
methods consume very small amounts of solvents as compared to conventional capillary 
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flow LC MS methods. Several laboratories have previously reported the use of nanospray 
for sensitive quantitation of DNA adducts (76;221-224).  
Several HPLC stationary phases were evaluated during nanoHPLC method 
development, including Symmetry C18 (Waters Corp., Millford, MA), Luna C18 
(Phenomenex, Torrance, CA), HILIC-NH2 (Phenomenex, Torrance, CA), Synergi Polar 
RP and Hydro RP (Phenomenex, Torrance, CA). The best analyte retention and peak 
shape were obtained with Zorbax SB-C18 stationary phase (Agilent Technologies, Santa 
Clara, CA). We found that the best sensitivity was achieved with a gradient of 0.01% 
aqueous acetic acid (solvent A) and acetonitrile:methanol (1:1, solvent B). All solvents 
were LC-MS grade. Using a linear gradient between 10% and 100% B, bis-N7G-BD 
adducts eluted at 14.5 min and were resolved from the impurities present in DNA 
hydrolysates (Figure 2.3) 
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Figure 2.3: NanoLC-nanoESI
+
-MS/MS analysis of bis-N7G-BD in liver DNA from a 
mouse exposed to 1.0 ppm BD for 2 weeks. 
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2.3.3 Method Validation  
The limit of detection of the new method was estimated as 50 amol bis-N7G-BD 
on column, a significant increase in sensitivity as compared to our previous capillary 
HPLC-ESI
+
-MS/MS method (114).To validate the new methodology, aliquots of DNA 
from Chinese hamster lung fibroblasts (100 µg) was spiked with known amounts of bis-
N7G-BD and corresponding 
15
N10-labelled internal standard, followed by sample 
processing and nanoHPLC-nanoESI
+
-MS/MS analysis as described above. An excellent 
correlation was observed between the expected and observed concentrations of bis-N7G-
BD, with an R
2
 value of 0.999 (Figure 2.4). We found that the method’s lower limit of 
quantitation (S/N ratio of 10 or better) was 1.0 fmol bis-N7G-BD in 0.1 mg DNA (3 bis-
N7G-BD adducts per 10
9
 nts), and the LOD value was 0.5 fmol/0.1 mg DNA. The LOD 
value for pure standard of bis-N7G-BD was 0.1 fmol. Method accuracy (n = 5) and 
precision (n = 3) were determined for replicates of bis-N7G-BD (2.0 fmol ) spiked into 
0.1 mg of DNA. Accuracy was determined to be 97.1 ± 6.3 % (n = 5) and the interday 
and intraday precision were less than 8 % RSD (n = 3) (Table 2.1). 
2.3.4 Analysis of bis-N7G-BD in mouse liver DNA 
 The newly validated quantitative nanoHPLC-nanoESI
+
-MS/MS method was employed 
to analyze the formation of bis-N7G-BD adducts in liver DNA of B6C3F1 mice that were 
exposed to 0.5 – 1.5 ppm BD by inhalation for 2 weeks. Representative extracted ion 
chromatogram from nanoHPLC-nanoESI
+
-MS/MS analysis of bis-N7G-BD in liver DNA 
samples from a mouse exposed to 1.0 ppm BD is shown in Figure 2.3. 
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Figure 2.4: NanoHPLC-nanoESI
+
-MS/MS method validation curve  
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Table 2-1. Accuracy and precision of nanoHPLC-nanoESI
+
-MS/MS analysis for bis-
N7G-BD (2 fmol) in DNA (0.1 mg). 
Day  Parameter value 
Day 1 Mean 1.9 
 RSD (%) 5.4 
 Accuracy (%) 93.5 
 N 3 
Day 2 Mean 2.1 
 RSD (%) 6.7 
 Accuracy (%) 106.0 
 N 3 
Day 3 Mean 2.2 
 RSD (%) 0.9 
 Accuracy (%) 108.1 
 N 3 
Interday Mean 2.1 
 RSD (%) 7.9 
 Accuracy (%) 102.6 
 N 9 
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We found that DNA extracted from tissues of mice treated with 0.5 ppm BD for 2 
weeks contained 5.7 ± 3.3 bis-N7G-BD adducts per 10
9 
normal nucleotides (N = 3), while 
animals exposed to 1.0 ppm BD contained 9.2 ± 1.5 bis-N7G-BD adducts per 10
9 
ntds (N 
= 4) and those exposed to 1.5 ppm BD contained 18.6 ± 6.9 bis-N7G-BD adducts per 10
9 
normal nucleotides (N = 4). DNA of control animals (N = 5) did not contain detectable 
amounts of bis-N7G-BD (N = 5) (Figure 2.5). 
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Figure 2.5: Bis-N7G-BD adduct levels in mice treated with 0, 0.5, 1.0 and 1.5 ppm 1,3- 
butadiene 
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2.4 Discussion 
A potent human and animal carcinogen, BD is metabolically activated to DEB, 
which reacts with DNA to form DNA-DNA cross links, e.g. 1,4-bis-(guan-7-yl)-2,3-
butanediol (bis-N7G-BD) (65;74;113;215). If not repaired, the interstrand bis-N7G-BD 
adducts can block DNA replication and lead to genotoxicity, while the corresponding 
intrastrand lesions are likely to be mutagenic (105). It is important to have specific 
biomarkers of DEB formation in vivo because of its central role in BD-mediated adverse 
health effects. In particular, DEB is 100−200-fold more mutagenic than other epoxide 
metabolites of BD (95) and is thought to be responsible for most of the genotoxic effects 
of BD at low exposure concentrations(<62.5 ppm BD) (211).  
Bis-N7G-BD lesions have been previously identified and quantified in laboratory 
animals exposed to relatively high concentrations of BD 6.25-625 ppm (114). However, 
DEB-specific DNA adducts have not been previously analyzed in animals subjected to 
BD exposures approaching the human Occupational Safety and Health Administration 
(OSHA) time weighted average levels (1 ppm) (216). Ambient BD concentrations in 
monomer and polymer work places range from 0.3 to 3 ppm. New and improved 
bioanalytical methods were required in order to quantify bis-N7G-BD adducts in tissues 
following low ppm and subppm exposures.  
In the present study, an ultra sensitive nanoHPLC-nanoESI
+
-MS/MS was 
developed for quantitation of bis-N7G-BD in liver DNA of mice exposed to sub-ppm 
levels of BD. Capillary flow HPLC-ESI-MS based methods typically employed for DNA 
adduct analysis are limited in their sensitivity due to the presence of relatively large 
amounts of solvent, which reduces the efficiency of ion formation in the ESI source. In 
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contrast, nanospray analysis is characterized by more efficient ionization and improved 
sensitivity (218;225). Therefore, we adopted a nanospray LC-MS/MS methodology for 
quantitative analysis of bis-N7G-BD in vivo. Our new analytical method is more sensitive 
than our previous capillary HPLC-ESI-MS/MS methodology (LOQ, 1.0 fmol) because of 
an improved sample clean up by offline HPLC and the inherent advantages of nanospray 
HPLC-ESI-MS/MS.  
NanoHPLC-nanospray MS/MS methodology has been recently employed for the 
detection of 7-ethylguanine adducts in leukocyte DNA isolated from smokers and non 
smokers (223). Solid phase extraction was employed for sample cleanup following DNA 
hydrolysis, and MS analyses were conducted with an Orbitrap LTQ Velos mass 
spectrometer using an accurate mass mode (223). The LOD and LOQ values of the 
method were reported as 0.1 fmol on column and 8 fmol per 180µg DNA, respectively 
(223). Zarbl et al. employed nanoHPLC-nanospray MS to detect and quantitate DNA 
adducts in bronchial epithelial cells treated with 10
−5−10−8 M concentrations of 1-methyl-
6-phenylimidazo[4,5-b]pyridine (PhIP), a potent food carcinogen present in overcooked 
meat (224). 
In another recent study, Chen et al. employed nanoHPLC-nanospray MS/MS 
technique to analyze 1,N
2
-propano-2′-deoxy-guanosine adducts derived from acrolein 
(AdG) and crotonaldehyde (CdG) in various human DNA samples from saliva, human 
placenta and blood leukocytes (76;221;222). Three lipid peroxidation-related etheno 
adducts:1,N
6
-etheno-2′-deoxyadenosine (εdAdo), 3,N4-etheno-2′-deoxycytidine (εdCyt), 
and 1,N
2
-etheno-2′-deoxyguanosine (1,N2-εdGuo) were also analyzed by nanoHPLC-
nanospray MS/MS (222). The limits of quantification per 5 µg of DNA were reported as 
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0.31 fmol, 1.5 fmol, 0.36 fmol, 2.0 fmol, and 1.7 fmol for AdG and CdG, εdAdo, εdCyd, 
and 1,N
2
-εdGuo, respectively (221).  
Our nanoHPLC-nanospray MS/MS methodology for bis-N7G-BD in tissue DNA 
described herein is comparable or better than previously reported methods in sensitivity 
(LOD: 0.5 fmol and LOQ: 1.0 fmol in 100µg DNA), accuracy, and precision (Table 2.1). 
With this methodology, it is possible to detect 3 adducts per 10
9
 nucleotides. Since DNA-
DNA cross-links are less abundant in DNA than DNA monoadducts such as 7-
ethylguanine, an offline HPLC sample cleanup was required to provide a higher degree of 
separation than can be afforded by solid phase extraction. While such a cleanup step 
increases the overall analysis time, minimal operator involvement is required with the use 
of an automated HPLC system incorporating an autosampler and a fraction collector.  
Using the validated nanoHPLC-nanospray MS/MS method, bis-N7G-BD adduct 
amounts were determined in livers of B6C3F1 mice following a 2 week exposure to 0.5, 
1.0, or 1.5 ppm BD (6 h/day, 5 days/week, see Figure 2.5). No bis-N7G-BD was detected 
in liver DNA of control mice (n = 5) which have not been exposed to BD. A comparison 
of the numbers of bis-N7G-BD adducts/10
7
 nucleotides/ppm of BD under low ppm 
exposure conditions determined in the present study to our earlier data for animals 
exposed to higher BD concentrations (6.25−625 ppm) (114) shows that there is a higher 
ratio of bis-N7G-BD adduct numbers per ppm of BD at low levels of BD exposure as 
compared to BD exposures greater than 62.5 ppm (Figure 2.6). Table 2.2 provides a 
comparison of bis-N7G-BD adduct levels per unit dose of BD to pyr-Val adducts 
(picomoles per gram of globin) per ppm of BD exposure in female mice.  
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Table 2-2 Bis-N7G-BD adduct concentrations in mouse liver DNA per unit dose of BD. 
Concentrations of pyr-Val adducts (picomoles per gram of globin) in the same animals 
are shown for comparison. 
BD exposure 
(ppm) 
Bis-N7G-BD adducts per 
10
7
 nucleotides/ppm BD 
Pyr-Val adducts, picomoles 
per gram of globin/ppm of 
BD
c
 
0 ND
a
 ND
a
 
0.5 0.170 21.0 
1.0 0.142 20.0 
1.5 0.144 26.0 
6.25
 b
 0.051
b
 12.0 
62.5
 b
 0.013
 b
 6.7 
200
 b
 0.009
 b
 3.7 
625
 b
 0.006
 b
 2.5 
a 
ND, not detected, 
b
From literature reference number (114), 
c 
Pyr-val adducts from (131). 
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Figure 2.6 Dose-dependent formation of bis-N7G-BD in liver DNA of female 
B6C3F1mice exposed to BD by inhalation (6.25 and 62.5 ppm values are taken from 
literature(114)) 
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Taken together, our results indicate that bis-N7G-BD adduct formation is more efficient 
at low concentrations of BD (≤6.25 ppm) as compared to higher exposure concentrations 
(≥62.5 ppm), probably a result of an increased bioactivation of BD to DEB under low 
exposure conditions. These results are relevant because typical occupational or 
environmental exposure of humans to BD is 2 ppm or less. 
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3 III. CELLULAR REPAIR OF DNA-DNA CROSSLINKS INDUCED BY 1,2,3,4-
DIEPOXYBUTANE 
3.1 Introduction 
 DNA-DNA interstrand cross-links (ICLs) are among the most toxic types of DNA 
damage known because of their ability to block DNA strand separation, interfering with 
DNA replication and transcription (226;227). The anticancer activity of many clinically 
useful drugs including platinum compounds, mitomycin C, psoralens, and antitumor 
nitrogen mustards is attributed to ICL formation and toxicity in rapidly proliferating 
tumor cells (228-231). However, ICLs can also be induced by endogenous lipid 
peroxidation products such as α, β-unsaturated aldehydes (232;233) and carcinogen 
metabolites such as 1,2,3,4-diepoxybutane (DEB), the ultimate carcinogenic species of 
industrial and environmental chemical 1,3-butadiene (95;95). DEB sequentially alkylates 
two nucleophilic sites within DNA to form interstrand and intrastrand 4-bis-(guan-7-yl)-
2,3-butanediol cross-links (bis-N7G-BD). Previous studies conducted in our laboratory 
have revealed that the cross-linking specificity of DEB is dependent on its 
stereochemistry: while SS and RR DEB preferentially form interstrand lesions, the meso 
isomer generates equal numbers of intrastrand and interstrand lesions (Scheme 3.1) 
(105;215;234). Both intrastrand and interstrand lesions are hydrolytically labile, with 
average half-lives of 3.5-4 days under physiological conditions (115).  
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Scheme 3.1 Metabolic activation of BD to its three reactive epoxides and formation of 
bis-N7G-BD DEB-DNA crosslinks. 
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Cellular repair of ICLs such as bis-N7G-BD is complicated because they inhibit 
local duplex melting at the site of adduct (235). Furthermore, both DNA strands at the 
site of cross-link are damaged, potentially compromising their use as templates for 
accurate repair synthesis. The mechanism of ICL repair is strongly dependent on the 
specific stage of the cell cycle. For cells in G0/G1 phase of the cell cycle, helix distorting 
ICLs may be removed by nucleotide excision repair (NER) of one of the strands and 
translesion synthesis past the “flipped out” ICL (236). Details regarding mechanisms of 
ICL repair in G0/G1 remain largely to be discovered, however. Fanconi Anemia (FA) 
repair pathway appears to play a central role in ICL removal for cells in the S phase of 
the cell cycle (227). FA repair pathway involves at least 16 different genes. It has been 
reported that replication forks stalled ahead of an ICL are recognized by FANCM, 
triggering the recruitment of the FA core complex (FANC A to F) to the site of damage. 
Following monoubiquitination of FANCD2-FANCI complex, the replication fork is 
stabilized, and the nascent strand is extended via the homologous recombination (HR) 
mechanism. Double incisions on each side of the cross-link are made by nucleases such 
as FANC1 and EME1/MUS81, and the unhooked intermediate is bypassed via translesion 
synthesis that may involve Pol ν, and  (227). FA pathway acts in coordination with 
other DNA repair pathways such as recombination repair (227;237), nucleotide excision 
repair (NER) (238), and mismatch repair (239;240). ICL repair deficiency in FA patients 
leads to an increased cancer risk because of genomic instability (241), increased cell 
death, (242) and genetic damage in tumor suppressor genes such as p53 (243).  
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Incomplete ICL repair leads to the formation of DNA double strand breaks 
(DSBs) (226;244). DSBs are serious types of DNA damage that have the potential to 
cause deletions and chromosomal aberrations, if not repaired by recombination repair 
pathways such as homologous recombination (HR) (245) or nonhomologous DNA end 
joining (NHEJ) (246), which are mediated by nucleotide excision repair proteins 
ERCC1–XPF (247;248). Since ICL formation is thought to be responsible for the 
efficacy of bifunctional alkylating agents used as anticancer drugs (249), complete 
understanding of the mechanisms of ICL repair is important for efforts to improve their 
efficacy and to combat tumor resistance. 
In the present work, we examined the kinetics of formation and repair of DEB 
induced bis-N7G-BD crosslinks and DNA double strand breaks in isogenic Chinese 
hamster lung fibroblasts proficient or deficient in NER and FA recombination repair 
pathways in an effort to identify specific repair pathways involved.  
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3.2 Materials and methods 
Note: DEB is a known carcinogen and, should be handled with adequate safety 
precautions in a well ventilated fume hood strictly following its material safety data 
sheet. 
Materials  
LC-MS grade acetonitrile, methanol, and water were obtained from Fisher 
Scientific (Pittsburgh, PA). All other chemicals and solvents were obtained from Sigma-
Aldrich (Millwaukee, WI, St. Louis, MO). bis-N7G-BD and 
15
N10-bis-N7G-BD internal 
standard was prepared in our laboratory as described previously (74;105;215) and their 
concentration was determined by UV spectrophotometry (ε252 = 15700, pH 1). 
Cell Culture  
Cell lines: V79 Chinese hamster lung fibroblasts (wild type, Catalog ID: 
GM16136), V-H4 (Catalog ID: GM16142) Chinese hamster lung mutant cell line derived 
from V79 wild type cells possess phenotype similar to that of cells derived from Fanconi 
anemia individuals were produced by ethylnitrosourea-induced mutagenesis of V79 cells  
(250-252). Arwert, F. et al. (1991) Cytogenetics and Cell Genetics studies established 
that V-H4 cells are homologous to the human Fanconi anemia complementation group A 
(253). V-H1 (Catalog ID: GM16141) cells are derived from V79 by ethylnitrosourea-
induced mutagenesis and are UV hypersensitive with reduced excision repair of 
photoproducts and belongs to complementation group 2 of UV-sensitive rodent mutants. 
V-H1 is mutated in the ERCC2 gene which codes for XPD protein involved in the 
helicase activity for unwinding DNA during NER (254). All of the above cell lines were 
obtained from the Coriell Institute (Camden, NJ, USA). Cells were grown to 80-90% 
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confluence on tissue culture dishes in Ham’s F-12 modified essential Eagle’s media (Life 
Technologies, Grand Island, NY, USA) supplemented with 9% fetal bovine serum. Cells 
were then cultured in a humidified atmosphere of 5% carbon dioxide, 95% air, at 37 °C.  
Cytotoxicity Assays  
The cytotoxic effects of DEB were examined by direct counting and clonogenic 
assays. For direct-counting assays, cells (V79, V-H1 and VH-4) were seeded into 6 cm 
dishes at a density of 0.5 x 10
6 
cells/dish. The following day, the cells were exposed to 
various concentrations of DEB for three hrs in serum free media. Following DEB 
treatment, the media was replaced with drug-free normal growth media. Twenty-four 
hours later, cells were harvested and counted using a haemocytometer. Trypan blue 
exclusion confirmed that > 99% of recovered cells were viable. The percent cell death 
was calculated by dividing the number of recovered cells obtained from drug-treated 
cultures by the corresponding number of cells recovered from control cultures not 
exposed to DEB. Experiments were performed in triplicate, and the results represent the 
average +/- the standard error of the mean (SEM) from three or more independent sets of 
experiments. For clonogenic assays, V79, V-H1 and V-H4 cells were plated in triplicate 
in 6 cm dishes at a density of 500 cells/dish. The following day, the cells were exposed to 
various concentrations of DEB for 3 hrs in serum free media. Following this incubation 
period the media was replaced with drug-free normal growth media. After 7 days the 
colonies were fixed and stained with 1% crystal violet in 95% ethanol. Colonies (>50 
cells) were counted manually. The surviving fraction was calculated as follows: number 
of colonies in drug treatment/number of colonies in non-drug treatment. Results depict 
mean value +/- SEM, N = 3. 
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Concentration dependence for bis-N7G-BD adduct formation: 
V79 cells (6-8 million, in duplicate) were treated with 0, 10, 15, 25, 50 and 100 
µM DEB in media in duplicate for 3 hrs. DEB-containing media was removed, and the 
cells were washed with phosphate buffered saline (PBS). Cells were harvested with PBS, 
pelleted, and stored at - 20 °C until DNA extraction and adduct analysis. 
Time dependent adduct formation and repair studies of bis-N7G-BD adducts in cell 
lines  
V79, V-H4, and V-H1 cells (6-8 million, in duplicate) were treated with 15 µM 
DEB for 0, 1, 2 and 3 hrs. Following treatment, DEB-containing media was replaced with 
fresh media, and the cells were allowed to recover for 2, 24 or 48 hrs to allow for adduct 
removal. To quantify the remaining bis-N7G-BD adducts, cells were harvested with 5 mL 
of PBS, pelleted, and stored at -20 °C until DNA extraction and adduct analysis as 
described below. 
Inhibitor treatment 
V79 cells in culture (6-8 million, in duplicate) were pre-treated with 20 nM UCN-
01 (7-hydroxystaurosporin, NER inhibitor) (255) for 2 hrs. Following treatment with the 
inhibitor, cells were exposed to 15 µM DEB for 0, 1, 2, or 3 hrs. DEB-containing media 
supplemented with UCN-01, was replaced with fresh media containing 20 nM UCN-01, 
and the cells were allowed to recover for 2, 24, or 48 hrs post DEB treatment. Following 
repair incubation, the cells were harvested, pelleted, and stored at -20 °C until DNA 
extraction and adduct analysis as described below. 
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NanoLC-ESI
+
-MS/MS analysis of bis-N7G-BD adducts in DEB-treated cells 
DNA extraction from cells was performed using standard phenol-chloroform 
extraction as described previously (217). DNA concentrations were determined by UV 
spectrophotometry (Thermo Scientific, Waltham, MA, USA) based on the UV 
absorbance at 260 nm. DNA purity was assessed from A260/A280 absorbance ratios, which 
were typically between 1.8 and 1.9, indicating minimal protein contamination. 
 DNA (50-150 µg) was re-suspended in water (200 µL) and spiked with 
15
N5-bis-
N7G-BD (50 fmol, internal standard for mass spectrometry). Samples were subjected to 
neutral thermal hydrolysis (70 °C for 1 h) to release bis-N7G-BD adducts from the DNA 
backbone as a free base conjugate. Following ultrafiltration to remove partially 
depurinated DNA, the solutions were subjected to offline HPLC cleanup as described 
previously (69). HPLC fractions corresponding to bis-N7G-BD and its internal standard 
were dried under reduced pressure, reconstituted in water (25 µL), and subjected to 
nanoLC-ESI
+
-MS/MS analysis as described previously (69). Selected reaction 
monitoring (SRM) transitions used for quantitation were m/z 389.1 [M + H]
+
 →m/z 238.1 
[M + H − Gua]+ , m/z 152.1 [Gua + H]+ for bis-N7G-BD and m/z 399.1 [15N10-M + H]
+
 
 m/z 243.1 [M + H − [15N5]Gua]
+
, m/z 157.1 [
15
N5-Gua + H]
+
 for 
15
N5-bis-N7G-BD 
internal standard. Quantitation was conducted using nanoLC-ESI
+
-MS/MS areas 
corresponding to the analyte and the internal standard using standard curves constructed 
with authentic standards. 
Native Comet Assay  
Chromosomal DNA strand breaks were estimated by performing comet assays 
under neutral conditions using the a CometAssay kit (Trevigen, Gaithersburg, MD) (256). 
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V79, V-H4 and VH-1 cells were incubated in the presence or absence of 15 µM DEB in 
serum free media for 3 hrs at 37 °C. Culture media was removed, and the cells incubated 
at 37 °C in drug-free growth media for times indicated (0, 3 and 24 hrs). Cells were 
harvested and suspended in PBS at a density of approximately 1 x 10
6
 cells/mL. Briefly, 
10 µL of cell suspension was mixed with 90 µL of 0.5% low melting temperature agarose 
(GIBCOBRL, Grand Island, NY) in PBS and layered on top of microscope slides pre-
coated with 1% normal agarose. Slides were placed flat at 4 °C in the dark for 15 min. 
Cells were lysed overnight at 4 °C in the dark in lysis buffer (Tris-EDTA buffer, sodium 
chloride, sodium lauryl sulfate, 1% Triton-X 100) overnight at 4 °C in the dark. After 
electrophoresis in TRIS Borate EDTA buffer [10.8% (w/v) TRIS base, 5.5% (w/v) boric 
acid, and 0.93% (w/v) EDTA] for 30 minutes at 1V/cm, slides were washed in DNA 
precipitation solution (7.5 M ammonium acetate in 95% ethanol) for 30 minutes at room 
temperature. Slides were immersed in 70% ethanol for 30 minutes at room temperature. 
Slides were dried at 37 °C for 15 min then stained with 100 µL of diluted SYBR Green 
(1:10,000 in TE Buffer) for 30 min in the dark. Comets were imaged using a Zeiss 
Axioplan 2 upright microscope. At least 50 cells were randomly selected from each 
treatment and blindly scored into five categories (0-4) (257) based upon the intensity of 
the comet tail relative to the head. 
γH2AX immunocytochemistry for visualization of double strand breaks 
The immunocytochemistry assay was performed as described before with some 
modifications (258). For all cell lines, 1 x 10
5
 cells were seeded in 3.5 cm dishes that 
contained sterilized glass cover slips (22 x 22 mm, No.1 Thickness, ThermoScientific) 
and incubated over night at 37 °C in normal growth media. On the following day, 
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individual dishes were treated with 15 μM DEB in serum free medium for 3 hrs at 37 °C. 
Drug-containing media was replaced with normal growth media and the cells maintained 
at 37 °C for recovery at various times (0, 3 and 24 hrs). Following removal of the media, 
ice cold 50% methanol: 50% acetone was added, and the cells were incubated for 8 min 
at 4 °C. Cells were then washed with ice-cold PBS three times and permeabilized with 
0.1% Triton X-100 in PBS for 5 min at room temperature. Cells were incubated in 
blocking buffer (0.1% Triton X-100, 0.2% skimmed dry milk in PBS) at 4 °C overnight 
in a humidified chamber. The following day samples were incubated with rabbit 
polyclonal antibody specific for phosphorylated H2AX (γH2AX, Bethyl Scientific, 
Montgomery, TX) at 1:10,000 dilution in blocking buffer for 1h at room temperature. 
After washing 3 times with 0.1% Triton X-100 in PBS, cells were then incubated with 
Alexa Fluor 633 conjugated goat anti-rabbit secondary antibody (Invitrogen, Grand 
Island, NY) at a dilution of 1:2000 in blocking buffer for 1h at 4 °C in the dark. Cells 
were washed with PBS and counterstained with 4’,6-diamidino-2-phenylindole 
dihydrochloride dihydrate, DAPI (Sigma) at 1:10,000 dilutions in PBS for 3 min. Stained 
cells were washed with ice-cold PBS three times and the slides mounted with 
Fluoromount-G (SouthernBiotech, Birmingham, AL), using a #1 glass cover slips and the 
edges were sealed with clear nail polish.  
Images were visualized with an Olympus FluoView FV1000 BX2 Upright 
confocal microscope (60x oil immersion objective), equipped with 633 nm HeNe 
excitation laser. Foci were counted in at least 50 cells per time point and results from 
three independent experiments averaged. Cells were scored into two categories, i.e. ≤10 
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and >10. The γH2AX foci were scored manually on coded samples in a blind manner. 
Data are expressed as the mean percentage of γH2AX-positive cells (± SEM). 
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3.3 Results  
3.3.1 Experimental Overview 
To gain insight into the dynamics of drug-induced ICL formation and removal in 
cultured mammalian cells we simultaneously pursued a number of distinct strategies: 1. 
Quantitation of ICL formation and removal in drug-treated cells, 2. Measurement of 
drug-induced acute cell death and irreversible cell cycle arrest, and 3. Determination of 
drug-induced DNA double-strand break formation and rejoining. We focused on the 
bifunctional alkylating agent 1,2,3,4-diepoxybutane (DEB) and performed this analysis 
on wild-type Chinese hamster clones (V79) and two isogenic clones derived from these 
cells that are deficient in the hamster homologs of the human FANCA gene (V-H4) (253) 
or ERCC2/XPD gene (V-H1) (254). V-H4 cells were selected because they are 
hypersensitive to cell death induced by a variety of cross-linking agents, including DEB. 
Importantly, human-derived clones with inactivating mutations in the FANCA gene also 
display hypersensitivity to death induced by these agents. While NER has not been 
implicated directly in ICL repair in mammalian cells, and clones deficient in this repair 
pathway are generally not recognized to be hypersensitive to DNA crosslinking agents, 
we chose to include the NER-deficient V-H1 cell line in our analysis because this DNA 
repair pathway plays an essential role in ICL in prokaryotes and lower eukaryotes. 
3.3.2 Cytotoxicity assays 
In order to compare the sensitivity of wild type and repair deficient cells to DEB 
exposure, cells were treated with increasing concentrations of DEB for three hours in 
serum-free growth media, and cellular drug sensitivity was analyzed using a clonogenic 
(colony forming) assay (259).  
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The results presented in Figure 3.1A show that DEB exposure exerted a 
substantially greater inhibitory effect on colony formation in V-H4 cells as compared to 
the parental V79 cell line. For example, while exposure to 25 µM DEB for three hours 
reduced colony formation by 50% (IC50) in V-79 cells, a similar magnitude effect was 
observed in V-H4 cells following exposure to 1.4 µM DEB, indicative of a ~18-fold 
enhanced DEB sensitivity of the latter cell line (Figure 3.1A). This result confirms an 
earlier report by Zdzienicka et al. that the V-H4 clone was hypersensitive to cell death 
induced by bis-electrophiles, and is consistent with the drug-sensitivity phenotype 
associated with V-H4 cells harboring loss of function mutations in the human homolog of 
the FANCA gene (251). In contrast, the NER-deficient V-H1 clone exhibited a modest 
~1.3-fold increased sensitivity to DEB than the parental V79 clone, with an IC50 value in 
the clonogenic assay of 19 µM (Figure 3.1A). This latter result is consistent with 
previous observation of De Silva et al that Chinese hamster-derived clones defective in 
the XPD gene are only slightly more sensitive to nitrogen mustard-induced cell death 
(260;261).  
 While drug-induced reductions in colony forming ability are generally interpreted 
to indicate cell death, this assay also reflects drug-induced loss of replicative potential in 
cells that otherwise remain viable following drug exposure (259). Indeed, it has been 
known for decades that a substantial population of cells exposed to bis-electrophiles such 
as mitomycin C or DEB remain viable, yet permanently exit the cell cycle (262;263). 
This phenomenon has been exploited to create non-dividing so-called ‘feeder’ cells used 
to support the cultivation of specialized cell lineages, including embryonic stem cells 
(264). It thus seemed likely that the reductions in colony formation associated with 
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exposure to DEB and the formation of ICLs (Figure 3.1A) over-estimated the direct 
cytotoxic effect of DEB exposure on V79, V-H1 and V-H4 cells. We therefore repeated 
the drug exposure experiments depicted in Figure 3.1A and analyzed cellular sensitivity 
to DEB by direct cell counting of trypan blue-excluding cells 24 hours post-drug 
treatment (Figure 3.1B). The results from this experiment revealed that all three cell lines 
examined were substantially less sensitive to DEB-induced cell death than might have 
been anticipated based on the results of the clonogenic assay (Figure 3.1B). LC50 values 
from direct cell counts were estimated as 165 µM (V79, based on extrapolation), 65 µM 
(V-H1), and 30 µM (V-H4). Comparison of the respective IC50 (clonogenic assay) and 
LC50 (direct cell count assay) values indicates that the DEB sensitivity of V-H4 cells in 
the clonogenic assay was approximately 20-fold greater than that measured in the direct 
cell counting method. In contrast, when a similar comparison is made in V79 and V-H1 
clones, one observes a substantially lower ~3-7-fold increased DEB sensitivity in the 
clonogenic assay, relative to direct cell count assay.  
These results indicate that the FANCA-deficient V-H4 clones are substantially 
more sensitive to acute DEB-induced cell death, and are also significantly more sensitive 
to DEB-induced loss of proliferative capacity than are wild-type cells. While V-H1 
clones display an intermediate sensitivity to acute DEB-induced cell death, they display 
only a very mostly enhanced sensitivity to DEB-induced loss of proliferative capacity, 
relative to wild-type cells. Taken together, these results support the interpretation that 
both the FA pathway and the NER pathway are involved in the repair of DEB-induced 
DNA damage.  
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Figure 3.1 Effect of exposure to DEB on colony formation and survival of V79 (circles), 
V-H1 (squares) and V-H4 (diamonds) cells. The influence of exposure to various 
concentrations of DEB for three hours on colony forming activity was determined using 
the clonogenic assay (A) and direct cell counting of trypan blue-excluding cells (B) as 
described in the methods section. Results represent average +/- S.D. N= 3 or more. 
 
 
 106 
 
3.3.3 Bis-N7G-BD Adduct Formation and Removal 
As discussed above, DEB induces a variety of DNA lesions including DNA 
monoadducts, DNA-protein cross-links, and both intrastrand and interstrand DNA-DNA 
cross-links. DNA monoadducts are the most abundant DEB-induced DNA lesions, 
representing about 90% of the total number of covalent chromosomal modifications. 
DNA-DNA and DNA-protein crosslinks are thought to represent 5 and 1-2% of the total 
adducts, respectively (104;114;265;266)
,
 (115;267).  
Interstrand DNA-DNA crosslinks (ICLs) are considered the most lethal and 
genotoxic among DEB-mediated DNA lesions and are believed to be largely responsible 
for its adverse health effects (226;227;231). DEB-induced ICLs predominately involve 
the N-7 residues on guanines in the opposite strands of 5’-GNC-3’ trinucleotides, and 
their structures have been established as 1,4-bis-(guan-7-yl)-2,3-butanediol (bis-N7G-
BD) (215). These lesions can be quantitatively released from the DNA backbone as 
nucleobase conjugates upon heating because N7-guanine alkylation creates a positive 
charge on N-7 and destabilizes the glycosidic bond (t ½ = 84-96 h under physiological 
conditions) (115).  
We employed a sensitive and specific mass spectrometry-based methodology 
developed in our laboratory to quantitatively assay the time-dependent formation and 
removal of bis-N7G-BD from the chromatin of wild-type and mutant Chinese hamster 
lung fibroblasts V-79, V-H1, and V-H4 (69;74). Preliminary studies in V-79 cells treated 
with increasing concentrations of DEB (0, 10, 15, 25 and 100 µM) have shown that bis-
N7G-BD formation was concentration-dependent, with adduct numbers ranging between 
0.5 and 3 adducts per 10
6
 nucleotides depending on exposure concentration (Figure 3.2).  
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Figure 3.2 Concentration-dependent formation of bis-N7G-BD adducts in wild type V79 
cells treated with increasing amounts of DEB (10-100 µM). 
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In order to compare the kinetics of bis-N7G-BD cross-link repair in control and 
repair deficient cells, wild-type V79 and mutant Chinese hamster fibroblasts were 
exposed to DEB for 3 hours, and the cells were allowed to recover in carcinogen free 
media for 1- 48 hrs. At various time points, cells were harvested, and the amounts of bis-
N7G-BD in chromosomal DNA were determined by nanoLC-ESI
+
-MS/MS (Figure 3.3) 
(69). While this approach does not allow us to distinguish amongst interstrand versus 
intrastrand bis-N7G-BD crosslinks, our previous studies have shown that SS,RR DEB 
almost exclusively forms interstrand ICLs (105;215).  
We found that bis-N7G-BD adduct numbers in fibroblasts exposed to 15 µM DEB for 0-
3 hrs increased nearly linearly during the exposure period (Figure 3.3A). At the end of 
the three hour exposure period, adduct numbers were 0.40 ± 0.01(V79), 0.76 ± 0.07 (V-
H1), and 0.62 ± 0.01 bis-N7G-BD adducts/10
7
 nucleotides (V-H4), respectively. The rate 
of crosslink formation (calculated from the slope of linear regression curves obtained 
using the data from Figure 3.3B) was the lowest in the V79 cells, corresponding to 
approximately ~ 80 GG crosslinks formed per cell per hr (based on an estimated Chinese 
hamster genome size of 2.8 gigabases). By comparison, the rate of cross-link formation in 
V-H1 and V-H4 clones were ~140 and ~110 crosslinks/cell/hr, respectively. Given that 
these latter clones are isogenic to V79, it is unlikely that the differences in rates of 
crosslink formation reflect altered drug pharmacokinetics. Instead, these differences in 
levels of bis-N7G-BD adducts present in these cells reflect diminished rates of lesion 
removal from the V-H1 and V-H4 clones, relative to the wild-type V79 clone. Thus, the 
data depicted in Figure 3.3B most likely reflect the functioning of a robust and fast-acting 
DNA ICL repair pathway that is functional in wild-type cells but is impaired to 
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Figure 3.3 Time course of bis-N7G-BD adduct accumulation in V79, V-H1, and V-H4 
cells. Cells were exposed to 15 µMolar DEB for three hours and subsequently drug was 
removed and replaced with fresh growth media. At the indicated times chromosomal 
DNA was isolated and bis-N7G-BD adduct levels determined as described in the methods 
section. A; Full time course, B; expanded view of the first three hours of DEB exposure. 
 
 
 
 
 
 
 
 
 
 110 
 
different extents in the V-H1 and V-H4 clones. Interestingly, the defect in this pathway(s) 
is substantially more pronounced in the V-H1 cells, compared to V-H4, despite the 
observation that V-H1 cells are substantially less sensitive to the cytotoxic and growth-
arresting effects of DEB than are V-H4 cells (Figure 3.1). 
Following carcinogen removal at the 3 hr time point, adduct numbers initially 
dropped off at a significant rate, but then decreased gradually, with substantial numbers 
of apparently stable crosslinks remaining up to 48 hours post-DEB exposure. This slow 
decrease at the later time points likely reflects spontaneous depurination of bis-N7G-BD 
from the DNA backbone. Our previous studies in calf thymus DNA have estimated the 
half-life of bis-N7G-BD under physiological conditions in the absence of repair as 84-96 
h (115). Overall although repair deficient cells (V-H1 and V-H4) exhibited slower 
removal of bis-N7G-BD cross-links (Figure 3.3), the rates of adduct removal did not 
correlate with DEB toxicity in these three clones (Figure 3.1), suggesting that ICL 
numbers per se are not predictive of cellular toxicity and that other DNA lesions or 
processes play a role in the mechanisms of bis-N7G-BD-mediated cell death. 
Pharmacological inhibition of NER was employed to further evaluate the 
contribution of this pathway to bis-N7G-BD removal. Similar to the kinetics observed in 
VH-1 cells, V79 cells pretreated with NER inhibitor UCN-01 demonstrated a rapid 
increase in adduct formation (0.52 +/- 0.04 adducts/10
7
 nucleotides after 3 hour 
treatment), following with a slower rate of adduct removal (0.43 +/- 0.03 adducts/10
7
 
nucleotides at 48 hour post exposure) (Figure 3.4 A, B). While the 2 hr pre-treatment of 
V79 cells with the NER inhibitor UCN-01 did not fully recapitulate the ICL removal 
deficit observed in V-H1 cells, it is conceivable that a longer period of preincubation may  
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Figure 3.4 Time course of bis-N7G-BD adduct accumulation in V79 (circles), V-H1 
(squares) and V79+20 nM UCN-01 (diamonds) cells. Cells were pretreated with 20nM 
UCN-01 for 2h and the NER inhibitor is present during and after treatment with DEB. 
Cells were exposed to 15 µM DEB for three hours and subsequently drug was removed 
and replaced with fresh growth media with 20nM UCN-01. At the indicated times 
chromosomal DNA was isolated and bis-N7G-BD adduct levels determined as described 
in the methods section A; Full time course, B; expanded view of the first three hours of 
DEB exposure. 
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have enhanced the effect of inhibitor on ICL removal. In any event, the data in Figure 3.4 
confirm the existence of a rapid-acting NER-dependent ICL removal pathway in Chinese 
hamster fibroblast clones.  
3.3.4 Formation and Repair of DEB-induced DNA Double Strand Breaks  
To gain further insight into the mechanism(s) underlying differential ICL removal 
kinetics observed in DEB-treated V79, V-H1 and V-H4 clones (Figure 3.3, 3.4) we 
performed a series of experiments to examine chromosomal DNA double-strand break 
formation and rejoining in drug-treated cells. First we performed single cell gel 
electrophoresis experiments. It is generally accepted in the literature that an increased 
amount of DNA in the so-called comet tails detected following neutral electrophoresis 
reflects elevated levels of chromosomal DNA double strand breaks (257). We therefore 
performed comet assays on V-79, V-H1, and V-H4 clones prior to drug addition (T0), at 
the conclusion of the three hour DEB exposure (T3), and at three (R3) and 24 (R24) 
hours post-drug removal. The results depicted in Figure 3.5 show that immediately 
following exposure to DEB, V79 cells display a very small increase in comet tail DNA-
indicating the presence of slightly elevated levels of chromosomal DNA double-strand 
breaks. This increase in comet tail DNA appears to peak at or shortly after the end of the 
three-hour DEB treatment and diminishes to nearly undetectable levels by 24 hours post-
drug treatment. We speculate that the basal levels of strand breaks observed in cells prior 
to DEB treatment reflect normal chromosomal breaks formed by cells in S-phase. As is 
addressed in the discussion, very low levels of tail DNA detected 24 hours post-DEB 
exposure may reflects a cell population that is largely arrested in G1 phase of the cell 
cycle. 
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Figure 3.5 Formation and repair of DEB-induced DNA double strand breaks in V79, V-
H1, and V-H4 cells. Single cell electrophoresis (Comet assays) was performed on cells 
prior to and following exposure to 15 µMolar DEB as described in the methods section. 
The data represent the percent of cellular DNA present in the ‘comet tail’ plus the SEM, 
N=3 or more. T0; pre-drug exposure, T3; following three hours of DEB exposure, R3; 
three hours post-drug exposure, R24; 24 hours post-drug exposure. 
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In contrast, drug-treated V-H4 cells displayed dramatically elevated levels of 
comet tail DNA that peaked at the time corresponding to DEB removal (Figure 3.5). 
While comet tail DNA levels rapidly declined, they were still substantially elevated 24 
hours post DEB treatment. The comet tail analysis of DEB-treated V-H1 cells broadly 
resembled that observed for V79 cells, with perhaps a slightly enhanced, and somewhat 
delayed time course. However, in contrast to the V-H4 cells, the kinetics of chromosomal 
DNA double-strand break formation and rejoining in V-H1 cells did not appear to be 
substantially different from that seen in V79 cells (Figure 3.5). These results are 
consistent with the interpretation that chromosomal DNA double-strand breaks 
accumulate in V-H4 clones immediately following DEB exposure at levels that are 
substantially higher than those observed in either V-H1 or wild-type V79 clones. Since 
DEB does not directly induce DNA strand breaks, these differences in chromosomal 
double strand breaks reflect differences in the cellular DNA damage response to ICLs in 
these three clones. 
To further explore the relationship between ICL removal kinetics and 
chromosome double strand break formation, we examined the kinetics of phospho-H2AX 
foci formation in V79, V-H1 and V-H4 cell lines during and after three hour treatment 
with 15 µM DEB (Figure 3.6A). Immunocytochemistry was performed using an antibody 
specific for phosphorylated histone H2AX (commonly referred to as γH2AX), and the 
percentage of cells within randomly-selected microscope fields that contained ten or 
more foci was determined as described in the Materials and Methods section. In these 
experiments foci containing phosphorylated H2AX are depicted as pink puncta within a 
nucleus visualized in blue due to counterstaining with the dye DAPI. This analysis was 
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performed prior to drug exposure (T0) and at one (T1), two (T2), and three (T3) hours 
after exposure to DEB, as well as at three (R3) 24 (R24) and 48 (R48) hours post-DEB 
exposure. Examination of the dynamics of focus formation in V79 cells reveals that 
γH2AX foci form rapidly in DEB-treated cells, and equally rapidly disappear (Figure 
3.6B). The peak of focus formation is centered around the second and third hour of DEB 
treatment, and by 24 hours post-drug treatment foci levels have returned to basal levels. 
In contrast, while foci rapidly form in DEB-treated V-H4 cells, their levels continue to 
increase even after drug is removed, peaking at a time point three hours post-drug 
exposure. Inspection of the data in Figure 3.6 B reveals that even at 24 and 48 hours post-
drug removal, V-H4 cells still harbor elevated levels of γH2AX foci. Again, as was 
observed using the comet assay, double strand break formation in V-H1 cells, as assessed 
by γH2AX focus formation, was somewhat delayed, and displayed a much more 
broadened peak compared to wild-type cells. The data in Figure 3.6 B indicate that 
γH2AX foci levels in V-H1 clones remain at peak levels a full day post-drug removal. 
Interestingly, despite harboring substantially elevated levels of γH2AX foci at 24 hours 
post-drug removal, by the end of the following day, foci levels in these clones had 
returned to basal levels. Intriguingly, direct cell counting experiments performed on V79, 
V-H1 and V-H4 cells 24, 48 and 72 hours post-DEB exposure revealed that at these latter 
time points the V79 and V-H1 cells were increasing in numbers whereas the V-H4 cells 
were continuing to die (data not shown). 
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Figure 3.6 (A) Images of phosphorylated histone H2AX-containing foci in V79, V-H1 
and V-H4 cells prior to and following exposure to 15 µM DEB. At the indicated times 
immunocytochemistry was performed using a mouse monoclonal antibody specific for 
phospho-H2AX, as described in the methods section. Time points same as Figure 3.3, 
except R48; 48 hours post-DEB exposure.  
A. 
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B. Dynamics of phosphorylated histone H2AX-containing foci in V79 (black bars), V-
H1(cross-hatched bars) and V-H4 (white bars) cells prior to and following exposure to 
DEB. Cells were exposed to 15 µM DEB for three hours and subsequently drug was 
removed and replaced with fresh growth media. The data represent the percentage of cells 
within randomly-selected microscope fields that contained 10 or more foci, plus the 
SEM, N=3. 
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3.4 Discussion 
In the present study, we investigated the dynamics of DEB-induced ICL 
formation and DNA double-strand break formation and removal in isogenic Chinese 
hamster lung fibroblasts. We focused on a wild type parental clone (V79) and two 
isogenic derivative cell lines with defects, respectively, in the NER gene XPD/ERCC2 
(V-H1) or the FANCA gene (V-H4). We focused on the latter clone because of the well-
known hypersensitivity of cells derived from FA patients to DNA cross-linking agents, as 
well as a number of recently published models postulating a role for the FA gene 
products in ICL (251;252). While, most models of ICL suggest that, with the exception 
of the XPF/ERCC1 heterodimer, NER proteins do not play a prominent role in ICL repair 
it is clear that in prokaryotes and lower eukaryotes NER is known to play an essential 
role in ICL repair, thus prompting us to include the V-H1 clone in this study (254;268-
270). 
Our results confirmed previous studies based on clonogenic cytotoxicity assays 
that the FANCA-deficient V-H4 cells were hypersensitive to cell death induced by DEB, 
compared to wild-type cells while the NER-deficient V-H1 cells were only slightly more 
sensitive than their wild-type counterparts (254;271;272). Interestingly, when a direct 
cell counting assay was used, our analysis revealed that while the V-H4 clones were 
again the most sensitive to DEB-induced cell death, the V-H1 clones were substantially 
more sensitive than were the wild-type V-79 cells. It is unclear, however, whether the 
enhanced sensitivity of V-H1 cells to DEB is due to a relative inability of these cells to 
repair drug-induced ICLs, or if it instead reflects a defect in NER-dependent repair of 
drug-induced monoadducts (75;267). 
 119 
 
 
To gain further insight into this question we employed a sensitive and precise 
nanoLC/ESI
+
-MS/MS methodology developed in our laboratory to directly quantify the 
formation and removal of DEB induced bis-N7G-BD crosslinks in V79, V-H1, and V-H4 
cells. Based on analysis of the linear regression curves generated from the data in the 
inset in Figure 3.3B we estimated the rates of ICL formation to be 80 110 and 140 GG 
crosslinks /cell/hr in the V79, V-H4, and V-H1 cells respectively. Since the mutant clones 
are isogenic to the parental V79 cells, the enhanced rate of formation in those clones is 
mostly due to the absence or malfunctioning of a robust, rapid ICL removal pathway that 
is functional in the wild-type V79 cells.  
Further analysis of the data in Figure 3.3 revealed a second, slower phase of 
adduct removal occurring during the initial 2 hrs post-drug removal. We noted that in V-
H1 clones bis-N7G-BD adducts were removed approximately three times as fast as 
compared to either V-H4 or wild-type cells. We further noted that between 2 and 48 hrs 
post DEB treatment there was a further slow decline in bis-N7G-BD crosslinks between. 
We hypothesize that this latter removal of adducts is due to spontaneous depurination of 
bis-N7G-BD from the DNA backbone  (115). It is notable that a substantial amount of 
bis-N7G-BD crosslinks remain present in all three cell lines 48 h post DEB exposure. We 
postulate that this represents a reservoir of crosslinks in cells that have survived the initial 
wave of DEB-induced cell death but have permanently exited the cell cycle (i.e. cells that 
are present and viable in the direct-cell counting experiment, but which do not proliferate 
and form colonies).  
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Interestingly, ICLs accumulated to the highest levels in V-H1 cells which 
exhibited only a slightly elevated sensitivity to DEB as measured in the clonogenic assay, 
while adduct levels were closer to those detected in wild-type cells, yet V-H4 cells were 
dramatically more sensitive to the colony-inhibiting effects of DEB than were the other 
lines (Figure 3.1A). It seems plausible that the increased sensitivity to DEB in V-H4 cells 
is due to a relative inability to rejoin double strand breaks formed during bis-N7G-BD 
removal, an interpretation consistent with our data (Figure 3.5) revealing increased 
accumulations of DNA in comet tails in V-H4 cells as compared to either V-H1 or V79 
cells showing increased DSB levels both during DEB treatment (15µM, 3h) and higher 
DSB accumulation post exposure to DEB until 24hr (Figure 3.5). Immunocytochemical 
detection of γH2AX foci also support the interpretation that DNA double strand breaks 
accumulate in V-H4 cells following DEB treatment (Figure 3.6).  
 Based on our results we propose a working model for ICL repair induced by 
DEB. Our model postulates that the majority of ICL repair occurs in cells in the S, and 
G2 phases of the cell cycle, and that minimal repair occurs in cells that are in the G1 
phase of the cell cycle when exposed to DEB. Our working assumption is that cells that 
sustain significant numbers of interstrand DNA adducts arrest at the G1/S boundary 
and/or enter G0. We propose that it this population of cells that are the reservoir of bis-
N7G-BD adducts that persist at time points 24-48 hrs post-DEB exposure (Figure 3.3, 
3.4), and that these are the cells–which are no longer capable of cell division–that are 
responsible for the higher apparent cell viability when direct cell counting is used to 
assess DEB-induced cytotoxicity.  
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 Our model further proposes that ICL repair in cells in the S and G2 phases of the 
cell cycle occurs via two at least partially distinct pathways. While both pathways are 
critically dependent on the Fanconi anemia recombinational repair machinery, there are 
some key differences. As outlined in Figure 3.7, our model postulates that the key factor 
determining which of these two pathways is pursued is whether the relevant portion of 
the genome in which the ICL forms has undergone replication or not. As the cartoon 
depicts, lesions within replicated portions of the chromosome–for which an undamaged 
sister chromatid exists (depicted as the ICL lesion on the right hand side of Figure 3.7)–
undergo recombinational repair between the damaged chromatid and the undamaged 
sister chromatid, triggered by an initial NER-dependent initiation event. The mechanism 
via which the double-strand break is formed remains unclear, but we propose the XPF-
ERCC1 nuclease as an attractive candidate (247). As was mentioned above, our model 
points that this recombination repair process is perturbed in FA cells. 
For lesions occurring within portions of the genome that have yet to be replicated, 
we propose that ICL repair is initiated by collision of replication forks, associated with 
translesion synthesis, which is followed by a recombination-mediated gap-repair. Our 
model is not specific regarding the identity of the nuclease(s) responsible for 
endonucleolytic cleavage, however a number of candidates including FAN1, 
XPF/ERCC1, MUS81-EME1 and SLX1-SLX4 have been proposed  (227;244;273). As 
others have suggested, we propose that this process is disrupted in cells lacking a 
functional FA pathway.  
 We postulate that the SCE-mediated repair pathway (right-hand lesion in Figure 
3.7) is responsible for the initial rapid phase of ICL removal that occurs during the three 
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hr DEB exposure. Notably, this pathway of removal appears to be absent-or at least 
significantly inactivated in NER-deficient XPD cells, suggesting that an initiating event 
may involve endonucleolytic cleavage by NER proteins at the site of the ICL.  
FANCA-deficient V-H4 cells display an intermediate rate of ICL removal during 
this initial drug-treatment period, leading us to postulate that conversion of the NER-
processed duplex into a double-strand break is at least partially dependent on the FA 
pathway. (It is noteworthy that the reaction intermediate depicted on the right hand side 
of figure 3.7C retains a chromosomal bis-N7G-BD crosslink.) Our model proposes that 
the SCE repair event depicted in Figure 3.7 D-F is dependent on a functional FA pathway 
and that in FANCA-deficient V-H4 cells DNA double-strand breaks accumulate that 
ultimately trigger cell death. This is consistent with the elevated numbers, and prolonged 
kinetics of comet tails and γH2AX foci in V-H4 cells. 
We postulate that the second, delayed onset phase of ICL removal in cells treated 
with DEB occurs as outlined in the left-hand side of the cartoon shown in Figure 3.7. We 
suggest that the replication fork collision pathway occurs more slowly than the more 
rapid SCE based recombination repair pathway depicted on the right-hand side of the 
cartoon, thus explaining the delay kinetics of removal. We further postulate that this latter 
repair pathway is able to remove ICLs that are not recognized via the NER-dependent 
pathway, perhaps as part of the G2/M checkpoint machinery. This would be consistent 
with the observation (Figure 3.3, 3.4) that while V-H1 clones exhibit a severely 
diminished ‘fast’ ICL repair phase, the subsequent phase of GG-crosslink removal occurs 
extremely efficiently, compared to that detected in either wild-type or V-H4 clones. 
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Figure 3.7 Model of ICL repair in Chinese hamster lung fibroblasts. The cartoon depicts 
a chromosome in mid-replication, containing duplicated regions, as well as a central, un-
replicated portion. (A.) The Gray lines indicate the newly synthesized strands of DNA 
with arrowheads indicating the growing 3’ ends. The red slashes depict interstrand 
crosslinks, one each within non-replicated or replicated portions of the chromosome. 
Right Hand Side: (B.) The NER machinery introduces endonucleolytic nicks bracketing 
the lesion on one strand of the affected duplex. (C. -D.) The reaction intermediate from 
(B) is converted to a double-strand break with protruding 3’ ends. (E.-F.) 
Recombinational repair dependent on a functioning cellular FA machinery mediates 
double-strand break repair via sister chromatid exchange. Left Hand Side: (B.) 
Replication forks stall on either side of the ICL lesion. (C.) A currently unidentified 
nuclease (see text) unhooks the ICL, followed by (D.) translesion synthesis, and (E.-F.) 
FA machinery mediated recombinational repair. 
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 The most significant distinction between the model outlined in Figure 3.7 and 
those previously proposed to explain ICL repair (227;240;244;273) involves the 
incorporation of a NER-dependent ‘fast’ ICL repair pathway distinct from the previously 
developed ‘replication fork’ dependent ICL repair model. It is noteworthy that it was only 
through the development of methodology to quantitatively monitor chromosomal bis-
N7G-BD adducts that we were able to detect this novel connection between the NER 
pathway and removal of interstrand DNA crosslinks. We note that this pathway of ICL 
repair appears to be functionally redundant with respect to cellular survival following 
exposure to DNA crosslinking agents such as DEB–at least when rapidly dividing 
immortalized cells are examined using a clonogenic assay–thereby explaining why others 
have failed to detect the NER-ICL connection highlighted by our data. We are currently 
pursuing additional experiments to gain further insight into the potential interplay 
between the newly identify NER-dependent ICL repair pathway and the FA machinery. 
Hence, from our results we postulate the involvement of NER and FA pathway in the 
repair of DEB induced ICLs. 
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4 IV. CAPILLARY HPLC-ACCURATE MASS MS/MS QUANTITATION OF N7-(2, 
3, 4-TRIHYDROXYBUT-1-YL)-GUANINE ADDUCTS OF 1,3-BUTADIENE IN 
HUMAN LEUKOCYTE DNA 
Reprinted with permission from: Dewakar Sangaraju, Peter Villalta, Melissa Goggin, 
Maria O. Agunsoye, Colin Campbell, and Natalia Tretyakova. Chem. Res. Toxicol. 
2013, 26(10), 1486-97. © 2013 American Chemical Society 
4.1 Introduction 
1,3- Butadiene (BD) is an important industrial and environmental chemical 
classified as an animal (84;85) and human carcinogen (86;87;91;209). Humans are 
commonly exposed to BD due to its widespread use in polymer industries (274), its 
presence in cigarette smoke (208), urban environment (275), automobile exhaust (207), 
and its formation upon wood burning and forest fires (276). Inhalation exposure to BD 
causes multi-site tumors in laboratory rats and mice (84;85) and is associated with an 
increased incidence of leukemia in occupationally exposed workers (86;87;91;209). The 
adverse health effects of BD are mainly attributed to its cytochrome P450-mediated 
metabolism to electrophilic epoxides 3,4-epoxy-1-butene (EB) and 1,2-dihydroxy-3,4-
epoxybutane (EBD), and 1,2,3,4-diepoxybutane (DEB) (95;210). DEB and EBD are 
known to exist in either racemic or meso forms of isomers in vivo 
(75;108;117;119).(Scheme 4.1). Among these, EBD is the most abundant in vivo 
(105;151;267).  
Epoxide metabolites of 1, 3-butadiene can alkylate DNA to form a range of nucleobase 
adducts (65;75;105;107;113;215). Specifically, EBD binds to the N7 position of guanine 
to give N7-(2, 3, 4 –trihydroxybut-1-yl) guanine (N7-THBG) adducts (Scheme 4.1) (75). 
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N7-THBG are also induced by DEB via a two-step process including hydrolysis of one of 
the two epoxide rings (104). Both meso and racemic forms of N7-THBG are observed in 
vivo (94;105;267). N7-THBG are the most abundant nucleobase adducts in DNA treated 
with EBD or DEB in vitro (104;215) and in tissues of laboratory animals exposed to BD 
by inhalation (75;115;215). Because N7-guanine alkylation generates a positive charge 
on the modified nucleobase, it destabilizes the N-glycosidic bond, leading to spontaneous 
depurination of N7-THBG and the formation of abasic site (Scheme 4.1) (115). The 
hydrolytic half-lives of N7-THBG adducts in vivo (mouse and rat liver DNA) are 3.6-5.5 
days, depending on chirality (277). In the laboratory, N7-THBG nucleobases can be 
readily released from the DNA backbone by heating, facilitating their analysis by mass 
spectrometry (104). Although N7-THBG adducts may not be mutagenic because they 
retain normal Watson-Crick base pairing with C (278), they can be used as mechanism 
based biomarkers of BD metabolism to DNA-reactive epoxides. In the present study, N7-
THBG was selected as a DNA based biomarker of human exposure to BD due to its high 
prevalence in vivo as compared to other BD-DNA lesions (75;215). Previous studies have 
quantified N7-THBG adducts in tissues of laboratory mice and rats exposed to BD by 
inhalation using HPLC-ESI
+
-MS/MS (75;104). However, the sensitivity of existing 
methods is insufficient for studies in humans due to significantly lower amounts of DNA 
adducts observed in human tissues (< 1-2 adducts per 10
9
 nucleotides in humans versus 
1-10 adducts per 10
7
 nucleotides in laboratory animals exposed to BD). 
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Scheme 4.1: BD bioactivation to epoxide metabolites and the formation of thermally 
labile N7-THBG adducts in DNA. 
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In the present work, a highly sensitive and specific capillary HPLC - accurate 
mass ESI
+
 MS/MS methodology utilizing an Orbitrap Velos mass spectrometer was 
developed for quantitation of N7-THBG adducts in human white blood cells (WBCs). 
Separation of the two isomeric forms of N7-THBG adduct was not achieved and we 
quantified total N7-THBG formed as single peak in various in vivo samples. The method 
was initially applied to human fibrosarcoma (HT1080) cells treated with sub-micromolar 
concentrations of DEB (10 nM – 100 µM). The validated method was subsequently used 
to determine the concentrations of N7-THBG adducts in DNA isolated from PBLs of 
smokers, nonsmokers, occupationally exposed workers, and individuals participating in a 
smoking cessation study.  
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4.2 Materials and methods 
Note: DEB is a known human carcinogen and must be handled with adequate safety 
precautions. Phenol and chloroform are toxic chemicals that should be used only in a 
well-ventilated fume hood with appropriate personal protective equipment. 
N7-THBG and [
15
N5]-N7-THBG were synthesized in our laboratory as described 
elsewhere (215). Puregene DNA purification reagents were obtained from Qiagen 
(Valencia, CA). LC-MS grade water, methanol and acetonitrile were purchased from 
Fisher Scientific (Pittsburgh, PA). Isolute ENV+ 50 mg/1 mL SPE cartridges were 
provided by Biotage (Charlotte, NC). DNA oligodeoxynucleotides (5'-
TCAGATTCGCGCCGGCTGCGATAAGCT-3') were purchased from Integrated DNA 
Technologies (Coraville, IA) or synthesized in our laboratory using automated solid 
phase synthesis. All other chemicals and solvents were obtained from Sigma-Aldrich 
(Millwaukee, WI, St. Louis, MO). Human blood buffy coat samples were acquired from 
the Biorespository Facility, Masonic Cancer Center, University of Minnesota, 
Minneapolis, the NCI CRCHD repository, and the American Chemistry Council, 
Washington DC. 
Cell culture 
 Human fibrosarcoma cells (HT1080) were grown in Dulbecco's modified Eagle's 
media supplemented with 9% fetal bovine serum (Atlanta Biologicals). Cells were 
cultured in a humidified atmosphere of 5% carbon dioxide, 95% air, at 37 °C. 
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N7-THBG formation in human cell culture  
HT1080 cells were plated in 15 cm dishes using Dulbecco’s modified Eagle’s 
medium containing 9% FBS and permitted to adhere overnight. On the following 
morning, cells (in duplicate) were treated with increasing concentrations of DEB (0, 10 
nM, 50 nM, 100 nM, 1 µM, 10 µM, 50 µM or 100 µM) for 3 h at 37
 
°C. Control and 
treated cells (N = 2) were harvested, washed with ice cold phosphate-buffered saline 
(PBS), and suspended in PBS for DNA extraction as described below.  
Study subjects 
 The study was approved by the University of Minnesota Human Research 
Protection Programs Institutional Review Board. Blood samples from 13 smokers and 13 
nonsmokers were obtained from the Tobacco Research Biorepository Facility, Masonic 
Cancer Center, University of Minnesota. All human subjects were age 18 years or older, 
not pregnant or breast feeding. They consumed less than 21 alcoholic drinks per week, 
and were in good physical and mental health. Smokers included in the study had been 
smoking for at least 5 years and consumed at least 7 cigarettes per day (CPD), with no 
change greater than 50% in CPD or brand within the last year, and had not used any other 
tobacco products in the last 6 months. Individuals with nonsmoking status were required 
to have smoked less than 100 cigarettes in their lifetime and were not using any tobacco 
products regularly. Individual smoking status was confirmed by expired carbon 
monoxide (CO) levels. CO levels were determined by having participants take a deep 
breath and hold it for 20 s before exhaling into a carbon monoxide monitor (Bedfont 
Scientific, Upchurch, UK). Smokers had CO levels of ≥10 ppm (range 7-29 ppm), while 
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nonsmokers had CO levels ≤ 3 ppm (range 0-3 ppm). The average age of smokers was 41 
± 12 (range 19-61) and that of nonsmokers was 35 ± 12 years (range 20-61). 
Human blood buffy coat samples from a smoking cessation study were obtained 
from National Cancer Institute. Subjects included were between the ages of 18 and 65, 
smoked at least 10 cigarettes daily for the past year, had carbon monoxide (CO) levels of 
>10, and were in good physical and mental health. Fasting blood was collected through 
venipuncture at various time points during the study. Blood buffy coat samples were 
obtained at 14 and 7 days prior to smoking cessation (baseline levels) and at two time 
points post smoking cessation (28 and 84 days). Smoking status was confirmed through 
CO measures and self-reported tobacco use diaries. To obtain sufficient sample size, 
buffy coat samples from 5 subjects were pooled for each time point (N = 2). DNA was 
isolated as described above. Samples were stored at – 80 °C until further analysis. 
Human blood buffy coat samples from 10 workers with known occupational 
exposure to BD and 10 matched controls (administrative workers) were obtained from the 
American Chemistry Council, Washington DC. BD exposures were determined by 
personal monitoring tubes for 8-h work shifts on 10 separate occasions over a 4-month 
interval for each study subject. Ambient air samples were analyzed for BD 
concentrations. Co-exposures to toluene, styrene, and benzene were measured by 
personal monitoring in a subset of subjects on a single occasion and by ambient air 
sampling and other details of the study population are previously reported (125;132). The 
experimental protocol was approved by the Institutional Review Boards at Regional 
Institute of Hygiene of Central Bohemia, the University of Vermont. Samples were 
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shipped to the University of Minnesota on dry ice and stored at – 80 °C until further 
analysis. 
DNA isolation  
DNA isolation from human blood samples was performed using the commercial 
protocol for DNA purification from buffy coat (Qiagen, Valencia, CA), (223) with the 
following modifications. Human whole blood buffy coat fractions obtained from 10 mL 
of whole blood were lyzed in the presence of RBC lysis solution (3 mL). White blood 
cells were collected as a pellet via centrifugation at 2000 g for 10 min. RBC lysis solution 
(3 mL) was added to the pellet, and the samples were centrifugated at 2000g for 10 min. 
The WBC pellet was mixed with 2 mL of cell lysis solution and 8 µL of proteinase K 
solution (20 mg/mL) and incubated at room temperature overnight upon slow mixing. On 
the following day, a solution of RNase A (4 mg/mL) was added (8 μL), and the samples 
were incubated at room temperature for 2 h. Protein precipitation solution (700 µL) was 
added to the cell lysate, and the mixture is vortexed at a high speed for 20 seconds and 
centrifugated at 2000g for 15 min to remove proteins. DNA was precipitated with cold 
isopropyl alcohol (3 mL) and washed twice with 1 mL of 70% ethanol in water. DNA 
was dried under a stream of nitrogen and stored at - 20
°
C until further analysis. Typical 
DNA yields from 10 mL of whole blood were 0.1-0.15 mg.  
DNA from control and DEB-treated human fibrosarcoma (HT1080) cells was 
isolated using standard phenol-chloroform extraction (217). DNA concentrations were 
estimated by UV spectrophotometry, and DNA purity was assessed from A260 /A280 
absorbance ratios, which was typically between 1.6 and 1.7. DNA amounts were 
determined by dG quantitation in enzymatic hydrolysates as described below. 
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dG quantitation  
DNA aliquots (~ 2 µg) were enzymatically digested with DNA Degradase Plus 
(Zymo Research, Irvine, CA) at 37 °C overnight. HPLC-UV analysis of dG was 
conducted by HPLC-UV using Eclipse XDB-C8 column (4.6 x 150 mm, 5 μm, from 
Agilent Technologies, Palo Alto, CA) eluted with a gradient of 150 mM ammonium 
acetate (A) and acetonitrile (B) (217). 
Sample preparation and adduct enrichment  
DNA samples (35-150 µg in water) were spiked with 50 fmol of 
15
N5-N7-THBG 
(99.9% purity, internal standard for mass spectrometry) and heated at 70 ºC for 1 h to 
release N7-THBG adducts from the DNA backbone. Partially depurinated DNA was 
removed by ultrafiltration with Nanosep 10K filters (Pall Life Sciences, Ann Arbor, MI) 
at 5000 g for 10 min. The filtrates containing N7-THBG and its internal standard were 
subjected to solid phase extraction (SPE) on Isolute ENV+ 50 mg/1 mL cartridges from 
Biotage (Charlotte, NC). SPE cartridges were conditioned with 2 mL of CH3OH and 2 
mL of H2O. Samples were loaded at neutral pH, washed with 1 mL of H2O and 1 mL of 
0.1% formic acid in water, and eluted with 50% CH3CN in water. SPE fractions 
containing N7-THBG were collected, evaporated to dryness, and dissolved in water (24 
µL) for HPLC-ESI
+
-HRMS/MS analysis. One third of the sample (8 µL, containing 
between 10 and 50 µg DNA) was injected on the column for HPLC-ESI
+
-HRMS/MS 
analysis as described below. 
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HPLC-ESI
+
-HRMS/MS analysis of N7-THBG 
A Nano2D-LC HPLC system (Eksigent, Dublin, CA) was interfaced to an LTQ 
Orbitrap Velos instrument (Thermo Scientific, Waltham, MA). HPLC solvents were LC-
MS grade water containing 0.05% acetic acid (A) and LC-MS grade acetonitrile (B). 
Samples (8 µL) were injected on to Synergi Hydro RP 80R (250 × 0.5 mm, 4 µm) 
analytical column (Phenomenex, Torrance, CA). The column was eluted at a flow rate of 
10 µL/min. Solvent composition was maintained at 1% B for 3 min and then linearly 
increased to 7% B in 12 min, further to 12% B in 1 min, to 20 % B in 2 min, to 50% B in 
1 min, and kept at 50% B for 2 min. Solvent composition returned to 1% B for an 8 min 
equilibration period at a flow rate of 10 μL/min. Under these conditions, both meso and 
racemic isomers of N7-THBG eluted as a single sharp peak at 17 and 18 min. 
Samples were analyzed in the ESI
+
 mode using an LTQ Orbitrap Velos 
instrument (Thermo Scientific, Waltham, MA). The source temperature was set at 350
°
C, 
sheath gas was at 40.0, the ESI source voltage was at 4.0 kV, and S-Lens RF level was 
set at 80%. N7-THBG adducts were quantified in the SRM mode by monitoring the 
transitions m/z 256.1 [M + H]
+ → m/z 152.05669 [Gua + H]+ and [15N5]-N7-THBG at m/z 
261.1 → m/z 157.04187 for the analyte and its 15N5 labeled internal standard, 
respectively. CID was achieved using the HCD collision cell at the isolation width of 1 
amu, collision energy of 50%, and mass resolution of 27,000.Accurate mass monitoring 
of the specified fragment ions was conducted at 5 ppm mass accuracy (152.05669 ± 
0.0008 and 157.04187 ± 0.0008, respectively) with the Orbitrap Velos FTMS detector. A 
full scan event was also performed over m/z 50-270 to monitor for any co-eluting matrix 
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components. HPLC-ESI
+
-HRMS/MS quantitation was conducted using the peak areas in 
extracted ion chromatograms corresponding to the analyte and the internal standard.  
HPLC-ESI
+
-HRMS/MS standard curves were constructed by analyzing aqueous 
solutions containing fixed amount of 
15
N5-N7-THBG (50 fmol) and increasing amounts 
of N7-THBG (1.0, 5.0, 10.0, 15.0, 25.0, and 50.0 fmol) (in triplicate), followed by 
regression analysis of the actual and the observed amounts of N7-THBG. Solvent blanks 
were periodically injected to monitor for potential analyte carry-over. 
Method validation  
DNA from untreated human fibrosarcoma (HT1080) cells (150 µg aliquots, in 
triplicate) was spiked with 0, 1, 5, 10, 15, 25 or 50 fmol of N7-THBG and 50 fmol of 
15
N5-N7-THBG internal standard. Following neutral thermal hydrolysis at 70 °C for 1 h, 
samples were filtered through Nanosep-10K ultra centrifugation devices to remove 
partially depurinated DNA. Samples were then enriched for N7-THBG and its internal 
standard by solid phase extraction on Isolute ENV+ and subjected to capillary HPLC-
ESI
+
-HRMS/MS analysis as described above. N7-THBG amounts were expressed as 
adduct numbers per 10
9
 normal nucleotides, and N7-THBG amounts endogenously 
present in human HT1080 cells (2.03 fmol/150 µg DNA) were subtracted from each 
value. The observed amounts of N7-THBG were plotted against the theoretical values, 
followed by regression analysis. DNA amounts were determined by HPLC-UV analysis 
of dG in DNA hydrolysates.
26
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Determination of LOD/LOQ, precession, and accuracy 
The LOD values of the new HPLC-ESI
+
-HRMS/MS method were determined by 
spikingsynthetic oligodeoxynucleotide (5'-TCAGATTCGCGCCGGCTGCGATAAGCT-
3',150 µg) with increasing amounts of N7-THBG (0, 0.3, 0.5, or 1 fmol) and a fixed 
amount of 
15
N5-N7-THBG (50 fmol, internal standard for mass spectrometry), followed 
by sample processing and HPLC-ESI
+
-HRMS/MS analysis by the standard methodology. 
Synthetic DNA was employed in these experiments because DNA from all biological 
sources examined contained endogenous N7-THBG (2 -3 fmol/150 µg DNA). The LOD 
value was determined as the analyte amount that consistently produced HPLC-ESI
+
-
HRMS/MS signal-to-noise ratios above 3. The limit of quantitation was defined by 
identifying minimum analyte amounts that produced a coefficient of variation less than 
15% and a signal-to-noise ratio (S/N) greater than 10. To evaluate the inter-day and intra-
day accuracy and precision of the new method, N7-THBG (1.0 fmol) and 
15
N5-N7-THBG 
(50.0 fmol) were spiked into synthetic oligodeoxy-nucleotide solution (150 µg). Samples 
were processed as described above and analyzed three times per day on three consecutive 
days. Method accuracy was calculated from the equation (Am/Aa × 100%), where Am is 
the measured amount of N7-THBG and Aa is the actual amount added. 
SPE recovery was determined by adding [
15
N5]-N7-THBG (50 fmol) to synthetic 
oligodeoxynucleotide solution (150 μg) and processing the samples as described above. 
N7-THBG standard (75 fmol) was added immediately prior to HPLC-ESI
+
-HRMS/MS 
analysis, and the recovery was determined by comparing the theoretical and the observed 
[
15
N5]-N7-THBG:N7-THBG peak area ratios.  
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4.3 Results 
4.3.1 Experimental approach 
Human exposure to BD is common due to it ubiquitous presence in urban air 
(207;275;276), cigarette smoke (208;279), and its extensive use in plastic and rubber 
industries (86;87;209;274). Classified as a human carcinogen, BD induces tumors in 
laboratory animals and increases the risk for hematopoietic cancer in occupationally 
exposed individuals (91). The goal of the present study was to develop a non-invasive, 
mechanism-based biomarker of BD exposure and metabolism to DNA-reactive epoxides. 
N7-THBG adducts (Scheme 4.1) have been chosen because they are the most abundant 
BD-DNA lesions in vivo (75;104;115;215).  
Ultra-sensitive analytical methodology was required to enable the detection and 
accurate quantification of N7-THBG in human samples. In our approach, DNA isolated 
from human blood buffy coat (35-150 µg) is spiked with 
15
N5-N7-THBG internal 
standard, and the adducts of interest are released from the DNA backbone by thermal 
hydrolysis (Scheme 4.2) (74;75;104;215). This is possible due to the intrinsic instability 
of the N-glycosidic bond on N7-alkylguanine lesions in DNA (278). Initial experiments 
have compared the efficiency of N7-THBG release following neutral thermal hydrolysis 
for 1 h at 70 °C versus heating at 80 °C for 1 h as reported previously (215). We found 
that thermal hydrolysis at a lower temperature (70 °C) was equally effective at releasing 
N7-THBG, but produced lower background of unmodified bases than hydrolysis at 80 °C 
(results not shown). Following thermal hydrolysis, partially depurinated DNA was 
removed by ultrafiltration, and N7-THBG and its internal standard were purified by solid 
phase extraction on Isolute ENV+ (50 mg/1 mL) cartridges (Scheme 4.2). SPE recovery 
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(92.6 ± 1.8%) was determined by spiking synthetic oligodeoxynucleotide (150 µg) with 
known amounts of the analyte. We found that Isolute ENV+ cartridges (Biotage) 
provided the best recovery as compared to other SPE stationary phases tested. 
4.3.2 HPLC-ESI
+
-HRMS/MS method development for N7-THBG 
N7-THBG is a highly polar molecule due to the presence of hydrophilic 2,3,4-
trihydroxybut-1-yl substituent on the guanine base, leading to its poor retention on 
reversed phase HPLC columns. Our HPLC-ESI
+
-HRMS/MS method development efforts 
for N7-THBG have explored a wide range of stationary phases, including Synergi Polar 
RP, Synergi Max RP, and Synergi Hydro RP from Phenomenex (Torrance, CA), 
Hypercarb (Thermo Fisher Scientific, West Palm Beach, FL), and Zorbax SB C18 
(Agilent Technologies, Palo Alto, CA). The best results in terms of analyte retention and 
HPLC peak shape were achieved with Synergi Hydro RP column (Phenomenex). Among 
HPLC mobile phases tested, a gradient of 0.05% acetic acid in water and acetonitrile has 
afforded the best chromatography and optimal ionization efficiency.  
Our initial HPLC-ESI
+
-MS/MS method for N7-THBG was based on column 
switching, with Synergi Max RP 80R (150 × 0.5 mm, 4 µm) as a trap column (5 min at 
10 µL/min of 0.05% acetic acid in water ) and Synergi Hydro RP (250 × 0.5 mm, 4 µm) 
as an analytical column. HPLC separation was achieved using gradient elution with 
acetonitrile and 0.05% acetic acid in water at 10 µL/min. A TSQ Vantage triple 
quadrupole mass spectrometer was operated in the SRM mode by monitoring the neutral 
loss of guanine from the analyte and the 
15
N5-lebeled internal standard, respectively (m/z 
256.1[M +H]
+ → 152.1 [Gua + H]+) and 15N5 -guanine (m/z 261.1 [
15
N5-M + H]
+
 → m/z 
157.1 [
15
N5-Gua + H]
+
 ).  
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Scheme 4.2: Analytical procedure for isotope dilution HPLC-ESI
+
-HRMS/MS analysis 
of N7-THBG in human leukocyte DNA. 
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These SRM transitions were selected based on ESI-MS/MS infusion results for authentic 
standards (74;75;104;215). However, the sensitivity of this method (LOQ, 5 fmol) was 
insufficient for human biomonitoring due to poor signal to noise ratios and the high 
sample matrix background in human samples (Figure 4.1). To enable N7-THBG 
quantification in human DNA, we have developed a new method that takes advantage of 
the high resolution capabilities of the Orbitrap Velos mass spectrometer (HPLC-ESI
+
-
HRMS/MS-MS). In our approach, SPE-purified samples (8 µL out of the total 24 µL) are 
directly injected onto capillary HPLC column for ESI
+
-HRMS/MS analysis, avoiding the 
need for lengthy column switching. The same SRM transitions listed above are 
monitored, but the fragment ions are detected in the accurate mass mode: m/z 256.1[M 
+H]
+ → 152.05669 [Gua + H]+ for N7-THBG and m/z 261.1 [15N5-M + H]
+
 → 157.04187 
[
15
N5-Gua + H]
+
 (Figure 4.2). As shown in Figure 4.3, the use of high resolution MS 
dramatically improves the signal to noise ratios for N7-THBG (LOD, 100 amol), 
facilitating its detection in human DNA. An additional SRM transition (m/z 256.1[M 
+H]
+ → 135.03014 [Gua –NH2 + H]
+
 and m/z 261.1 [
15
N5-M + H]
+
 → 139.01828 [15N5-
Gua –NH2 + H]
+
 was employed for confirmation purposes. 
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Figure 4.1: Chromatogram of N7-THBG in smokers DNA sample with poor sensitivity 
and S/N ratio of a column switching TSQ vantage triple quadrupole SRM method. S/N 
ratio is 4 for 1.82 fmol on column.  
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Figure 4.2 HPLC-ESI
+
-HRMS/MS extracted ion chromatograms (A) and MS/MS spectra 
of synthetic N7-THBG (4 fmol) and [
15
N5]-N7-THBG (50 fmol) (B). 
 
 
 
 143 
 
Figure 4.3 HPLC-ESI
+
-HRMS/MS analysis of N7-THBG in leukocyte DNA of a smoker  
(A, 34 μg DNA hydrolysate on column) and an occupationally BD exposed worker (B, 
25 μg DNA on column). DNA isolated from human blood buffy coat (80-100 μg total) 
was spiked with 
15
N5-N7-THBG internal standard and subjected to thermal hydrolysis, 
sample processing, and high resolution HPLC-ESI
+
-MS/MS analysis on an Obitrap Velos 
mass spectrometer. 
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4.3.3 Method validation  
The new capillary HPLC-ESI
+
-HRMS/MS method was validated by analyzing 
control DNA from untreated human fibrosarcoma (HT1080) cells spiked with 1.0 -50.0 
fmol N7-THBG and 50.0 fmol 
15
N5-N7-THBG internal standard. The calculated N7-
THBG amounts were corrected for the analyte endogenously present in HT1080 cells 
(2.03 fmol/150 µg DNA). An excellent correlation between the spiked and the observed 
amounts of the analyte was obtained, with an R
2
 value of 0.998 (Figure 4.4). Method 
accuracy and precision were determined by analyzing replicate samples of N7-THBG 
(1.0 fmol) spiked into 150 µg of synthetic oligonucleotide solution. Method accuracy was 
calculated as 92.3 ± 6.7% (n = 5), with the interday and intraday precision less than 13% 
RSD (Table 4.1). 
In order to evaluate HPLC-ESI
+
-HRMS/MS method sensitivity, aliquots of 
synthetic DNA oligodeoxynucleotide (150 µg) were spiked with known amounts of N7-
THBG standard (0.1, 0.3. 0.5, or 1.0 fmol), followed by hydrolysis and sample 
processing by standard methodology (Scheme 4.2). We chose synthetic DNA for these 
experiments because all DNA samples of biological origin, e.g. calf thymus DNA, 
salmon sperm DNA, human placental DNA, and DNA isolated from human fibrosarcoma 
(HT1080) cells, contained significant amounts of N7-THBG (20-40 N7-THBG adducts 
/10
9
 nucleotides).  
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Table 4-1 Accuracy and precision results for N7-THBG at 1 fmol spiked in 150µg of 
oligonucleotide solution. 
Day  Parameter value 
Day 1 Mean 0.99 
 RSD (%) 3.35 
 Accuracy (%) 99.8 
 N 3 
Day 2 Mean 1.10 
 RSD (%) 12.3 
 Accuracy (%) 110.2 
 N 3 
Day 3 Mean 1.01 
 RSD (%) 12.99 
 Accuracy (%) 101.7 
 N 3 
Interday Mean 1.03 
 RSD (%) 10.3 
 Accuracy (%) 103.9 
 N 9 
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Figure 4.4 Correlation between the theoretical and the observed amounts of N7-THBG in 
spiked DNA. DNA isolated from untreated human fibrosarcoma cells (150 µg) was 
 spiked with 0, 1, 5, 10, 15, 25, or 50 fmol of N7-THBG and 50 fmol of 
15
N5-N7-THBG 
 internal standard, followed by sample processing and capillary HPLC-ESI
+
-HRMS/MS 
 analysis as shown in Scheme 4.2 and described in text. N7-THBG amounts observed in  
control sample (20 adducts/10
9 
nucleotides) were subtracted from each value. The 
 calculated N7-THBG amounts were plotted against the theoretical values. 
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The HPLC-ESI
+
-HRMS/MS limit of detection for N7-THBG spiked into 150 µg 
synthetic oligodeoxynucleotide solution was determined as 0.3 fmol (0.6 adducts/10
9
 
nucleotides), which gave the signal to noise ratio ≥ 3. No N7-THBG was detected in 
unfortified oligodeoxynucleotide samples, confirming that there was no analyte carryover 
and no artifactual N7-THBG production during the sample preparation and analysis. 
Method limit of quantitation was defined as the lowest N7-THBG amounts that afforded 
the signal to noise ratios of > 10 and intra/inter day precision within 15 % CV. We found 
that the LOQ value of our capillary HPLC-ESI
+
-HRMS/MS method for N7-THBG was 1 
fmol analyte in 150 µg of DNA (2 adducts per 10
9
 nucleotides).  
4.3.4 N7-THBG quantitation in HT1080 cell culture  
To examine N7-THBG formation in a cell culture model, HT1080 cells were 
treated with increasing concentrations of DEB (10 nM – 100 µM). DNA was extracted 
and analyzed by HPLC-ESI
+
-HRMS/MS methods described above. Adduct 
concentrations were unchanged from the background values in cells treated with 0 - 100 
nM DEB, but increased linearly from 31.48 ± 4.84 adducts /10
9 
nucleotides in cells 
treated with 1 µM DEB to 966.55 ± 128.05 adducts/10
9 
nucleotides in cells treated with 
100 µM DEB (Figure 4.5).  
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Figure 4.5 Concentration-dependent formation of N7-THBG adduct levels in HT1080 
 cells treated with increasing amounts of DEB (1-100 µM). N7-THBG amounts observed  
in control sample (20 adducts/10
9 
nucleotides) were subtracted from each value. 
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4.3.5 N7-THBG quantitation in blood of confirmed smokers and non-smokers and 
the effect of smoking cessation  
Having confirmed the effectiveness of the new method in a cell culture model 
(Figure 4.5), we proceeded to quantify N7-THBG adducts in leukocyte DNA of known 
smokers and the corresponding controls. Cigarette smoke contains high amounts of BD 
(~ 46 μg/ cigarette in main-stream smoke and 283 μg/cigarette in side-stream smoke) 
(90), leading to significant exposure of smokers to this carcinogen. DNA samples from 
smokers and nonsmokers (13 per group) were analyzed. 
HPLC-ESI
+
-HRMS/MS analysis has revealed the presence of N7-THBG in DNA 
hydrolysates from human samples (Figure 4.2). N7-THBG amounts in DNA were 
expressed as the number of adducts per 10
9 
nucleotides, with DNA amounts determined 
from HPLC analysis of dG in DNA hydrolysates. (113) The concentrations of N7-THBG 
in leukocyte DNA of smokers were 8.20 ± 5.12 adducts /10
9 
nucleotides (range 2.22 – 
19.03), while the corresponding values for nonsmokers were 7.08 ± 5.29 adducts /10
9 
nucleotides (range 0.77 – 15.73) (Table 4.2). Although smoker DNA contained higher 
numbers of adducts, the differences in N7-THBG concentrations in DNA of smokers and 
non-smokers were not statistically significant in this pilot study (p = 0.60, two-sample t- 
test).  
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Table 4-2 Effect of smoking on N7-THBG concentration in human leukocyte DNA 
Smokers 
sample  gender age DNA 
analyzed 
(µg)
a
 
Cigarettes 
/day 
Adducts/10
9 
nucleotides 
1 M 52 77.3 11 11.23 
2 F 35 77.8 26 <0.9 
3 M 57 82.6 7 2.22 
4 M 48 38.3 9 5.73 
5 F 19 79.6 23 2.71 
6 F 32 73.9 13 6.03 
7 F 61 78.8 24 19.03 
8 M 23 89.9 19 6.39 
9 F 51 101.6 12 14.97 
10 F 54 107.5 26 10.28 
11 M 43 100.7 29 5.36 
12
c
 F 33 38.8 19 3.97 
13
c
 F 44 42.1 15 10.58 
      Mean ± SD                              42.5 ± 13.1       144.2 ± 20.8     17.9 ± 7.3      8.20 ± 5.12 
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nonsmokers 
sample  gender Age DNA 
analyzed 
(µg)
a
 
Adducts/10
9 
nucleotides 
14 F 27 93.3 0.79
b
 
15 M 24 87.2 3.01 
16 F 33 92.7 5.92 
17 F 20 103.0 1.17
b
 
18 F 34 92.9 <0.9 
19 M 24 108.2 15.73 
20 F 22 154.5 11.54 
21 M 53 122.9 8.45 
22 F 53 111.7 16.05 
23
c
 F 44 102.4 6.83 
24
c
 M 28 107.9 0.91
b
 
25
c
 M 28 59.7 7.40 
26
c
 M 35 35.9 7.14 
      Mean ± SD                               32.7 ± 11.0       97.9 ± 28.5     7.07 ± 5.29    
 
a 
One third of the total DNA amount was injected on column for HPLC-accurate mass 
MS/MS analysis. 
b 
Adduct amounts less than LOQ but greater than LOD. 
c 
Samples 
analyzed using an N7-THBG internal standard contaminated with 0.72 fmol of N7-
THBG analyte which was subtracted from the quantified amount. 
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In order to directly evaluate the influence of smoking on N7-THBG adduct 
concentrations, N7-THBG was quantified in DNA of 10 individuals participating in a 
smoking cessation study. Two baseline samples were obtained before smoking cessation, 
and two additional samples were collected 28 and 84 days post smoking cessation. To 
afford sufficient DNA amounts (150 µg), samples from five smokers were pooled prior to 
DNA extraction, and combined samples were subjected to HPLC-ESI
+
-HRMS/MS 
analysis of N7-THBG as described above. N7-THBG amounts post cessation were 
normalized to the baseline values. As shown in Figure 4.6, smoking cessation did not 
influence N7-THBG concentrations in human leukocyte DNA, suggesting that N7-THBG 
adducts in humans are not associated with smoking.  
4.3.6 Influence of Occupational BD Exposure on N7-THBG Levels in Human DNA  
To evaluate the effects of occupational exposure on adduct N7-THBG prevalence in 
human DNA, blood samples were obtained from ten individuals exposed to BD in a 
workplace (average BD concentration, 1.51 ± 1.12 ppm) and the corresponding controls 
(average BD concentration, 0.009 ± 0.012 ppm). We found that N7-THBG adduct 
concentrations were significantly elevated in leukocyte DNA of individuals 
occupationally exposed to BD (9.72 ± 3.80 adducts/ 10
9
 nucleotides) as compared to 
matched controls (3.08 ± 2.15 adducts/ 10
9
 nucleotides, p = 0.00014) (Table 4.3). 
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Figure 4.6 Percent reduction in N7-THBG adducts in leukocyte DNA of 10 individuals 
following smoking cessation. For each time point, DNA from 5 different subjects was 
pooled together to obtain sufficient sample size. Samples were collected 2 times before 
smoking cessation and 28, and 84 days following smoking cessation. The day when the 
smokers quit smoking is designated as day 0. Number of adducts per 109 nucleotides 
(mean ± SD) are shown below each point. 
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Table 4-3 Effect of occupational BD exposure on of N7-THBG concentrations in human 
leukocyte DNA 
Controls BD exposed 
sample  BD 
exposure 
(ppm) 
DNA 
analyzed 
(µg)
a
 
Adducts/10
9 
nucleotides 
sample  BD 
exposure 
(ppm) 
DNA 
analyzed 
(µg)
a
 
Adducts/10
9 
nucleotides 
1 0.005 91.7 1.02
b
 11 2.2 83.3 6.55 
2 0.003 94.6 0.55
b
 12 3.1 103.9 9.93 
3 0.004 94.8 6.64 13 1.2 86.6 6.65 
4 0.005 98.7 1.56
b
 14 3.3 69.1 7.29 
5 0.006 81.9 3.81 15 2.1 71.3 10.11 
6 0.040 76.84 2.64 16 0.92 82.98 8.68 
7 0.005 78.80 5.97 17 0.21 76.84 15.7 
8 0.007 45.94 3.07 18 0.24 78.80 4.37 
9 0.010 84.65 4.61 19 0.99 45.94 12.8 
10 0.007 75.84 0.90
b
 20 0.83 84.65 15.1 
Mean   0.009 ± 0.01   82.4 ± 15.2   3.08 ± 2.15               1.51 ± 1.11       78.3 ± 14.9   9.72 ± 3.79                            
± SD     
 
a
 One third of total DNA amount was injected on column for HPLC-accurate mass 
MS/MS analysis. 
b 
Adduct amounts less than LOQ but greater than LOD. 
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4.4 Discussion 
A recognized human and animal carcinogen, BD is metabolically activated to DNA-
reactive epoxides which produce a range of nucleobase adducts including nucleobase 
monoadducts N7-(2-hydroxy-3-buten-1-yl)guanine (HB-Gua I), N7-(1-hydroxy-3-buten-
2-yl)guanine (HB-Gua II), N7-(2,3,4-trihydroxy-3-buten-2-yl)guanine (THB-G), 1,N
6
-(2-
hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (1,N
6
-γ HMHP-dA), 1,N6-
(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (1,N
6
-α HMHP-dA), 
DNA-DNA cross-links such as 4-bis-(guan-7-yl)-2,3-butanediol (bis-N7G-BD) and 1-
(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD), and numerous DNA-protein 
cross-links (91;107;115;116;198;266). If not repaired, BD-induced lesions can lead to 
heritable mutations by inducing polymerase errors (14;280;281). N7-THBG are the most 
abundant DNA adducts generated upon exposure to BD (75;104;115;215), and thus have 
been selected for development of mechanism-based human biomarkers of BD exposure 
and activation to DNA-reactive epoxides in the present study. 
Several reports have previously quantified N7-THBG formation in tissues of 
laboratory rats and mice exposed to BD by inhalation. The first method for N7-THBG 
employed analytical flow HPLC-ESI
+
-MS/MS to detect these adducts in livers of rats and 
mice exposed to 1250 ppm BD for 14 days (104). Neutral thermal hydrolysis was used to 
release N7-THBG bases from the DNA backbone, followed by ultra-filtration, solid 
phase extraction, and HPLC-ESI
+
-MS/MS analysis (104). N7-THBG adducts were 
observed in liver DNA of mice (7.6 ± 1.5 adducts/10
6 
nucleotides) and rats (4.1 ± 1.5 
adducts/10
6 
nucleotides) (104). Oe et al. further optimized the HPLC-ESI
+
-MS/MS 
methodology to separately quantify SS,RR and meso forms of N7-THBG in DNA of rats 
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and mice treated with 1250 ppm of BD (267). (±) N7-THBG concentrations in liver DNA 
increased from 0.1 per 10
6 
nucleotides to 1.6 adducts per 10
6
 nucleotides in rats and from 
1.3 adducts per 10
6 
nucleotides to 3.9 adducts per 10
6
 adducts in mice between 1 and 10 
days of inhalation exposure to BD. Meso N7-THBG levels in the liver increased from 0.1 
per 10
6
 nucleotides to 0.8 adducts per 10
6
 per 10
6
 nucleotides in rats and from 0.6 per 10
6
 
nucleotides to 2.2 adducts per 10
6
 nucleotides in mice upon continuous exposure to 1250 
ppm BD for 1 or 10 days, respectively. Koc et al conducted a molecular dosimetry study 
of N7-THBG in mice and rats exposed to 0-625 ppm BD (75). They observed a non-
linear increase in N7-THBG adduct levels in liver, lung and kidney DNA of laboratory 
mice and rats exposed to BD. This was attributed to saturation of metabolic activation of 
BD starting at 62.5 ppm (75). However, to our knowledge, N7-THBG has not been 
previously detected in humans.  
N7-THBG adducts are relatively stable in double-stranded DNA, with an in vitro 
hydrolytic half-life is about 50h in vitro by first order kinetics (215). In vivo half-lives of 
N7-THBG in tissues of laboratory mice and rats exposed to 1250 ppm of 1,3-butadiene 
are between 3.6 to 5.5 days, depending on adduct stereochemistry (277). N7 guanine 
adducts are shown to be repaired and removed either by spontaneous hydrolysis or base 
excision repair generating abasic sites in the DNA (282). 
Human exposure to BD includes environmental sources (1-10 ppb in urban air) 
(283;284), automobile exhaust (20-60 ppb) (207;284), smoking (on average 46 μg/ 
cigarette in main-stream smoke and 283 μg/cigarette in side-stream smoke) (90) and 
workplace sources at butadiene monomer and polymer plants (< 2 ppm in the workplace) 
(216). Since these levels of exposure are orders of magnitude lower than those employed 
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in inhalation studies of laboratory animals, human studies of BD-DNA adducts demand 
significantly more sensitive analytical methodologies.  
Our initial studies have revealed that traditional HPLC-ESI
+
-MS/MS analysis on a 
triple quadrupole mass spectrometer did not have adequate sensitivity and specificity for 
N7-THBG detection in DNA isolated from human leukocytes (Figure 4.1). This difficulty 
may be a result of low N7-THBG concentrations, the polar nature of the analyte, and its 
relatively low molecular weight (m/z 256.1), leading to increased background and poor 
HPLC-ESI
+
-MS/MS signal to noise ratios. To overcome this challenge, we have taken 
advantage of the high resolution capabilities of the Orbitrap Velos mass spectrometer. A 
highly sensitive isotope dilution HPLC-ESI
+
-HRMS/MS method has been developed that 
is characterized by greatly improved signal to noise ratios, high accuracy, and excellent 
precision as compared to traditional HPLC-ESI
+
-MS/MS (compare Figures 4.1 and 4.3). 
To our knowledge, this the first report of N7-THBG formation in human DNA. The LOD 
and LOQ values of the new method (0.3 fmol and 1 fmol, respectively, when spiked into 
150 µg of DNA) are sufficiently low to enable sensitive and accurate N7-THBG 
quantitation in humans. Our HPLC-ESI
+
-HRMS/MS method does not separate two 
isomeric forms of N7-THBG, so the total amount of adducts were determined. 
The new method was first employed to quantify N7-THBG in DNA of human 
fibrosarcoma (HT1080) cells treated with a range of DEB concentrations (0, 10 nM, 50 
nM, 100 nM, 1 µM, 10 µM, 50 µM and 100 µM). Unexpectedly, we found that untreated 
cells contained measurable amounts of N7-THBG (~ 20 adducts per 10
9
 nucleotides). 
Careful method validation and multiple control experiments have confirmed that this was 
not a result of contamination or analyte carryover. These results suggest N7-THBG 
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adduct can be formed endogenously. It has been hypothesized that 1,2-dihydroxy-3,4-
epoxybutane (EBD) might be formed from dietary and/or endogenous sources linked to 
catabolism of carbohydrates (129;140). Consistent with this observation, structurally 
analogous N-(2,3,4-trihydroxy-butyl)valine (THB-Val) hemoglobin adducts have been 
detected in control subjects with no known exposure to BD (127). Similarly, DNA 
adducts such as N7-methylguanine (285), N7-ethylguanine (223), 1,N
2
-etheno-2'-
deoxyguanosine (221;222), 1,N
2
-propanodeoxyguanosine (23), etheno adducts such as 
1,N
6
-ethenodeoxyadenosine (εdA), heptanone-etheno-2'-deoxyguanosine (286), and 3,N4-
ethenodeoxycytine (εdC) are also endogenously found in human DNA (287;288).  
To determine the influence of smoking on N7-THBG concentrations in human 
DNA, HPLC-ESI
+
-HRMS/MS analysis was conducted using DNA isolated from blood of 
13 smokers and 13 non-smokers. N7-THBG concentrations were similar in DNA of 
smokers and non-smokers (8.21 ± 5.12 and 7.08 ± 5.29 adducts /10
9 
nucleotides, 
respectively; P = 0.60, based on a two-sample t test) (Table 4.2). Furthermore, N7-THBG 
levels remained unchanged upon smoking cessation (Figure 4.6), suggesting that N7-
THBG adduct levels in human leukocytes are not related to smoking. Environmental 
and/or endogenous sources may be responsible for this observation. In contrast, N7-
THBG levels were significantly increased in leukocyte DNA of occupationally exposed 
individuals (9.73 ± 3.80 adducts/ 10
9
 nucleotides in workers exposed to 1.51 ± 1.12 ppm, 
N = 10) as compared to matched controls exposed to 0.009 ± 0.012 ppm (3.07 ± 2.15 
adducts/ 10
9
 nucleotides, N = 10) (Table 4.3). This is not unexpected because 
occupational exposures to BD (~ 1- 2 ppm in our study) are much higher than those 
associated with smoking. However, it should be noted that in addition to BD, smokers are 
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exposed to ~ 60 of other known carcinogens, which can act in a synergistic manner to 
contribute to lung cancer development (208;279). 
Our quantitative results for N7-THBG in human leukocyte DNA are consistent 
with previously published results for other human BD-DNA adducts. For example, 
Hemminki et al. have employed 
32
P-post-labelling to quantify N1-(2, 3, 4-trihydroxybut-
1-yl)adenine (N1-THB-Ade) adducts in occupationally exposed individuals (112). These 
authors have found statistically higher levels of N1-THB-Ade adducts in male workers 
occupationally exposed (4.5 ± 7.7 adducts/10
9
 nucleotides) as compared to controls (0.8 
± 1.2 adducts/10
9
 nucleotides) (112). The differences in N1-THB-Ade adduct levels in 
smokers and nonsmokers were not statistically significant (112). Since N7-THBG 
concentrations in DNA of smokers and non-smokers determined in our study are similar 
(Table 4.2) and are not influenced by smoking cessation (Figure 4.6), this suggests the 
presence of an endogenous source of N7-THBG in humans. Indeed, background levels of 
N7-THBG were also found in DNA isolated from freshly cultured human fibrosarcoma 
(HT1080) cells. Future studies are needed to establish the origins of endogenous N7-
THBG in humans. However, occupational exposure to BD does increase N7-THBG 
concentrations in human blood (Table 4.3), suggesting that it can be a useful biomarker 
useful in BD risk assessment.  
In summary, we have developed and validated an isotope dilution HPLC-ESI
+
-
HRMS/MS method for N7-THBG in human leukocyte DNA. The method has adequate 
accuracy and sensitivity for human biomonitoring. Future studies involving larger 
numbers of subjects need to be performed to further validate N7-THBG as a biomarker 
for BD exposure and metabolic activation to DNA-reactive metabolites. 
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5 V. NANO LC/ESI
+
-HRMS
3
 QUANTITATION OF DNA ADDUCTS INDUCED BY 
1,3-BUTADIENE 
Reprinted with permission from: Dewakar Sangaraju, Peter W. Villalta, Susith 
Wickramaratne, James Swenberg, and Natalia Tretyakova . J Am Soc Mass Spectrom. 
2014, 25(7), 1124-35 © 2014 Springer, Part of Springer Science + Business Media 
 
5.1 Introduction 
Humans are exposed to numerous exogenous and endogenous chemicals present 
in automobile exhaust, urban air, water, food, and cigarette smoke  (1-3). Among these is 
1,3-butadiene (BD), a prominent industrial and environmental pollutant classified as a 
known carcinogen  (84;85;91;276). Human exposure to BD is due to its presence in 
automobile exhaust (20-60 ppb)  (284), cigarette smoke (8.5-48.2 µg/cigarette)  (289), 
wood fires (0.14-0.17 ppb)  (290), and occupational sources in BD monomer and polymer 
industries  (127;216;274).  
BD undergoes cytochrome P450-mediated metabolic activation to three epoxide 
metabolites: 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB), and 1,2-dihydroxy-
3,4-epoxybutane (EBD) (Scheme 5.1) (92). These electrophilic epoxides are held 
responsible for the carcinogenicity and mutagenicity of BD because of their propensity to 
react with DNA to form covalent nucleobase adducts  (104;105;114;115;267), which can 
cause DNA polymerase errors  (14;98;291;292). Sensitive and specific quantitative 
methods for BD-DNA adducts in vivo are needed because they can be used in human 
cancer risk assessment  (18;293).  
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3,4-Epoxy-1-butene (EB) is the second most abundant epoxide formed upon 
metabolic activation of BD. EB reacts with the N7-position of guanine in DNA to form 
N-7-(2-hydroxy-3-buten-1-yl) guanine (EB-GI) and N-7-(1-hydroxy-3-buten-2-yl) 
guanine (EB-GII) adducts (Scheme 5.1)  (104;265). EB-GI and EB-GII can be used as 
biomarkers of BD exposure and bioactivation, along with the corresponding hemoglobin 
adducts (N-(2-hydroxy-3-buten-1-yl)-valine (HB-Val))  (119) and urinary metabolites (2-
(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene and 1-(N-acetyl-L-cystein-S-yl)-2-
hydroxybut-3-ene (MHBMA)  (140). While globin adducts and urinary metabolites have 
been extensively used as biomarkers of BD exposure and metabolic activation  
(116;117;119;120;140;141), one important advantage of DNA adducts is that they 
represent the biologically relevant dose of BD and thus are directly associated with BD-
mediated mutagenesis and cancer.  
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Scheme 5.1 Bioactivation of BD to electrophilic epoxides and the formation of EB 
Guanine adducts in DNA. EH, epoxide hydrolase; EB-GI, N-7-(2-hydroxy-3-buten-1-yl) 
guanine; EB-GII, N-7-(1-hydroxy-3-buten-2-yl) guanine.  
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In the present study, a nanoHPLC-high resolution tandem mass spectrometry 
(nanoLC/ESI
+
-HRMS
3
) methodology utilizing an Orbitrap Velos mass spectrometer was 
developed to allow for sensitive and specific quantitation of EB-GII adducts in vivo. EB-
GII adducts were quantified by isotope dilution with the corresponding 
15
N-labeled 
internal standard. The new method was fully validated and applied to determine the 
concentrations of EB-GII in human fibrosarcoma (HT1080) cells treated with increasing 
concentrations of EB (50 nM to 10 μM), in liver tissues of laboratory rats exposed to BD 
by inhalation, and in human blood DNA.  
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5.2 Materials and Methods 
Note: EB is a known carcinogen and must be handled with adequate safety precautions. 
Phenol and chloroform are toxic chemicals which should be used only in a well-
ventilated fume hood with appropriate personal protective equipment. 
Puregene DNA purification reagents were obtained from Qiagen (Valencia, CA). 
LC-MS grade water, methanol and acetonitrile were purchased from Fisher Scientific 
(Pittsburgh, PA). All other chemicals and solvents were obtained from Sigma-Aldrich 
(Millwaukee, WI, St. Louis, MO). Nonsmoker blood buffy coat fractions were purchased 
from BioChemed (Winchester, VA). Blood samples from known smokers and 
nonsmokers were acquired from the NCI CRCHD repository (PI: Dr. Peter Shields). 
Synthesis of EB-guanine standards and the corresponding 
15
N5 internal standards  
EB-GI and EB-GII were prepared as previously reported  (265;294). Briefly, dG 
(105 mg, 0.393 mmol) was reacted with 3,4-epoxy-1-butene (EB) (266 mg, 3.93 mmol) 
in 5 mL of glacial acetic acid at 50 °C for 5 h. The reaction mixture was precipitated with 
one volume of acetone and 4 volumes of ether, and the resulting white precipitate was air 
dried and dissolved in 1.5 mL of 1N HCl. The reaction mixtures was heated at 80 °C for 
5 h to induce depurination, cooled down, and neutralized with NaOH. EB-GI and EB-GII 
were isolated by reverse phase HPLC on a Synergi Hydro RP 80R semipreparative 
column (250 mm × 10 mm, 4µ) (Phenomenex, Torrance, CA) using a gradient of water 
and acetonitrile at 2 mL/min. Under these conditions, EB-GI and EB-GII eluted at 22.5 
and 24.1 min, respectively. Both adducts were characterized by UV spectrophotometry, 
1
H NMR, and MS/MS, which were consistent with literature data  (265). 
15
N5-EB-GI and 
15
N5-EB-GII were prepared analogously starting with 
15
N5–dG. Molar concentrations of 
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EB-G and 
15
N5-EB-G standard solutions were determined by UV spectrophotometry 
using the molar extinction coefficient (ε) of 8030 M-1 cm-1 at 284 nm at neutral pH  (294). 
Isotopic purity of 
15
N5-EB-GI and II as determined by mass spectrometry was 99.97 and 
99.93 %, respectively.  
HT1080 cell culture experiments 
Human fibrosarcoma cells (HT1080) were grown in Dulbecco's modified Eagle's 
media supplemented with 9% fetal bovine serum (Life technologies, Grand Island, NY). 
Cells were cultured in a humidified atmosphere of 5% carbon dioxide and 95% air, at 37 
°C. HT1080 cells were plated into 15 cm dishes using Dulbecco’s modified Eagle’s 
medium containing 9% FBS and permitted to adhere overnight at 37 °C. On the 
following morning, cells (in duplicate) were treated with increasing concentrations of EB 
(0, 500 nM, 1 µM, 5 µM or 10 µM) for 3 h at 37
 
°C. The EC50 for EB in HT1080 cells 
treated with 0.25 to 50 m for 48 h was 13.8 mM as determined by the alamar blue assay 
(Life technologies, Grand Island, NY). Control and treated cells (N = 3) were harvested, 
washed with ice cold phosphate-buffered saline (PBS), and suspended in 5mL of PBS for 
DNA extraction as described below.  
Animals and Treatment 
In the first study, male and female F344 rats (N = 3 per group) were exposed to 
0.5, 1.0, or 1.5 ppm for 2 weeks (6 h/day, 5 days/week) using whole-body exposure 
chambers at the Lovelace Respiratory Research Institute (LRRI, Albuquerque, NM) as 
reported previously  (131).  
In a separate study, female F344 rats (3 per group) were exposed to 1250 ppm BD 
by whole-body exposure chamber inhalation for 10 days (7 h/day) at LRRI. The animals 
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were sacrificed either immediately at the end of the exposure period or 1, 3, or 6 days 
post exposure as reported previously  (115). Liver tissue was collected, flash frozen, and 
shipped to the University of MN on dry ice, where they were stored at – 80 °C until DNA 
extraction. All protocols are approved by the Institutional Animal Care and Use 
Committee at LRRI.  
Human study subjects 
Human smoker and nonsmoker blood buffy coat (white blood cells) samples were 
obtained from the National Cancer Institute. These samples were a part of the NCI 
3ARM study supported by National Cancer Institute contract HHSN261200644002 
(Laboratory Assessment of Tobacco Use Behavior and Exposure to Toxins Among Users 
of New Tobacco Products Promoted to Reduce Harm; PI: Peter Shields, M.D.). National 
Cancer Institute, Washington, DC. Nonsmoker (N = 5) and smoker subjects (N = 3) were 
between the ages of 18 and 65. Smokers smoked at least 10 cigarettes daily for the past 
year had exhaled carbon monoxide (CO) levels of > 10 ppm. The nonsmokers have 
smoked less than 100 cigarettes in their life time. Smoking status was confirmed through 
CO measures and self-reported tobacco use diaries. All subjects were in good physical 
and mental health. Fasting blood was collected through venipuncture at various time 
points during the study. Samples were stored at − 80 °C until further analysis. 
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DNA isolation  
DNA from control and EB-treated human fibrosarcoma (HT1080) cells was 
isolated using standard phenol-chloroform extraction  (217). DNA concentrations were 
estimated by nanodrop UV spectrophotometer (Thermo Scientific, Waltham, MA), and 
the DNA purity was assessed from A260 /A280 absorbance ratios, which was typically 
between 1.8 and 1.9. DNA amounts were accurately determined by dG quantitation in 
enzymatic hydrolysates as described previously  (217;295). 
DNA from human blood samples was isolated using the manufacturer’s protocol 
for DNA purification from buffy coat (Qiagen, Valencia, CA) (223) with minor 
modifications (295). DNA isolation from rat liver was performed using the 
manufacturer’s protocol for DNA purification from tissue (Qiagen, Valencia, CA). 
Briefly, 100-200 mg of liver tissue was homogenized in 4 mL of cell lysis buffer. Cell 
lysis was performed overnight following addition of 15 µL of proteinase K solution (20 
mg/mL). On the following day, RNA digestion was performed by addition of 15 µL of 
RNase A solution (4 mg/mL) and incubation at room temperature for 2 h. Protein 
precipitation solution (1 mL) was added to the cell lysate, and the mixture was vortexed 
at a high speed for 20 s and centrifuged at 2000g for 15 min for removal of proteins. 
DNA was precipitated with isopropyl alcohol (5 mL) and washed twice with 1 mL of 
70% ethanol in water.  
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Sample preparation and EB-GII enrichment (Scheme 5.2)  
DNA samples (3-76 µg in water) were spiked with 3 fmol of 
15
N5-EB-GII internal 
standard and heated at 90 ºC for 0.5 h to release EB-GII adducts from the DNA backbone 
as free bases. Partially depurinated DNA was removed by ultrafiltration with Nanosep 
10K filters (Pall Life Sciences, Ann Arbor, MI) at 5000 g for 10 min. The filtrates 
containing EB-GII and its internal standard were subjected to offline HPLC purification 
using an Agilent 1100 series HPLC equipped with a UV detector and an automated 
fraction collector (Agilent Technologies, Palo Alto, CA). Offline HPLC purification was 
carried out using Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm, from Agilent 
Technologies, Palo Alto, CA) eluted at flow rate of 1 mL/min with a gradient of 0.4% 
formic acid in Milli-Q water (A)and HPLC grade acetonitrile (B). UV absorbance was 
monitored at 254 nm. Solvent composition was maintained at 0% for 5 min and then 
linearly changed to 3% in 10 min and further to 40% B in 5 min. The solvent composition 
was returned to 0% acetonitrile in 5 min and held at 0% for 15 min for column 
equilibration. Either 2′-deoxyadenosine (dA, 0.60 nmol) or 2′-deoxythymidine (dT, 0.62 
nmol on column) was added as retention time markers, which eluted at 13.2 or 18.3 min, 
respectively. EB-GII typically eluted at 16.4 min. HPLC fractions containing EB-GII and 
its internal standard (15.8 – 17.8 min, 1 mL each) were collected in 1.2 mL MS total 
recovery vials (Thermo Fischer Scientific, Waltham, MA), concentrated under vacuum, 
and re-dissolved in water (10 μL) for nano-HPLC-nanoESI+-HRMS3 analysis. Typical 
injection volume was 5 µL. 
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Scheme 5.2 Analytical procedure for isotope dilution nanoLC/ESI
+
 HRMS
3
 analysis of 
EB-GII in DNA. 
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NanoLC/ESI
+
-HRMS
3
 analysis of EB –GII  
A Nano2D-LC HPLC system (Eksigent, Dublin, CA) with 5 µL injection loop 
was interfaced to an LTQ Orbitrap Velos instrument equipped with a nanospray source 
(Thermo Fisher Scientific Corp., Waltham, MA). HPLC solvents were LC-MS grade 
water containing 0.01% acetic acid (A) and LC-MS grade acetonitrile containing 0.02% 
acetic acid (B). Samples (5 µL) were injected onto a trapping column (Symmetry C18 
nanoAcquity, 0.18 × 20 mm, Waters Corp., Millford, MA) in line with a nano-LC 
column (0.075× 200 mm). The nano-LC column was prepared by manually packing a 
fused-silica emitter (New Objective, Woburn MA) with Synergi Hydro-RP, 80Å, 4 μm 
chromatographic packing (Phenomenex, Torrance, CA). Following sample injection (5 
µL), the HPLC flow (2% B) was maintained at 1 µL/min for 5.5 min to enable sample 
loading onto the trapping column. The HPLC flow was then decreased to 300 nL/min and 
maintained at 2% B for 0.5 min. The organic phase content linearly increased to 25% B 
in 19 min and further to 50% B in 10 min, returned to 2% B in 2 min, and equilibrated for 
7 min. Under these conditions, EB-GII eluted as a sharp peak at 20 min. 
HPLC/ESI
+
-HRMS
3
 analyses were conducted in the nanoESI
+
 mode using an 
LTQ Orbitrap Velos instrument (Thermo Scientific, Waltham, MA). Typical instrument 
settings included the spray voltage at 2.0 kV, capillary temperature at 350 °C, and S-Lens 
RF level at 40%. MS analysis was performed by fragmenting [M + H]
+ 
ions of EB-GII 
(m/z 222.1) via collision induced dissociation (CID) in the linear ion trap, with a 
normalized collision energy set at 25 units and the isolation width of 1.0 amu. The 
resulting MS/MS fragment ions at m/z 152.1 corresponding to protonated guanine [Gua + 
H]
+
 were subjected to further fragmentation in the high collision dissociation (HCD) cell 
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using nitrogen as collision gas, normalized collision energy of 75 units, and an isolation 
width of 1.0 amu. The resulting MS
3
 fragment ions were detected in the mass range of 
m/z 50 to m/z 270 using the Orbitrap mass analyzer at a resolution of ~ 25,000. EB-GII 
was quantified using extracted ion chromatograms from the combined signal of m/z 
135.0301 ([Gua – NH3]
+
) and m/z 153.0411 ([Gua – NH3 + H2O]
+
) at a mass tolerance of 
5 ppm. The MS
3
 fragments at m/z 153.0411 ([Gua – NH3 + H2O]
+
) correspond to the 
adduction of water to m/z 135.0301 ([Gua – NH3]
+
) in the collision cell  (296).The 
15
N5 
labeled internal standard ([
15
N5]-EB-GII) was quantified using an analogous MS
3
 scan 
event consisting of fragmentation of m/z 227.1 ([M + H]
+
)
 
to m/z 157.1 [
15
N5-Gua + H]
+
 
and further to m/z 139.0183 ([
15
N5-Gua – NH3]
+
). Extracted ion chromatograms 
corresponding to the sum of m/z 139.0183 ([
15
N5-Gua – NH3]
+
) and m/z 157.0283 ([
15
N5-
Gua – NH3 + H2O]
+
) at 5 ppm were generated and used for quantitation (Figure 5.1). A 
full scan event was also performed over the mass range of m/z 100-500 at a resolution of 
7500 to monitor for any co-eluting matrix components. EB-GII amounts in DNA were 
expressed as adduct numbers per 10
8
 normal nucleotides.  
NanoLC/ESI
+
-HRMS
3
 standard curves were constructed by analyzing aqueous 
solutions containing fixed amounts of 
15
N5-EB-GII (5 fmol) and increasing amounts of 
EB-GII (0.1, 0.5, 1, 3, 5, and 10.0 fmol) (in triplicate ), followed by regression analysis of 
the actual and the observed amounts of EB-GII. 5 µL injections were made out of a 25 
µL sample volume. Solvent blanks were periodically injected to monitor for any potential 
analyte carry-over. 
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Figure 5.1 Nano-HPLC-nanoESI
+
-HRMS
3 
extracted ion chromatograms and MS
3
 spectra 
of synthetic EB guanine II (0.1 fmol) (A) and [
15
N5]-EB guanine II (5 fmol) (B). 
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Figure 5.2 Nano-HPLC-nanoESI
+
-HRMS
3
 method validation: correlation between the 
spiked and the observed amounts of EB-GII spiked into blank DNA. DNA isolated from 
nonsmoker blood leukocytes (150 µg) was spiked with 0, 0.2, 0.5, 1, 3, 5, 7 or 10 fmol of 
EB-GII and 3 fmol of 
15
N5- EB-GII (internal standard), followed by sample processing 
and nano-HPLC-nanoESI
+
-HRMS
3
 analysis. 
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Method validation  
DNA isolated from unexposed human leukocyte DNA (150 µg aliquots, in 
triplicate) was spiked with fixed amount of 
15
N5-EB-GII (3 fmol, internal standard) and 
increasing amounts of EB-GII (0, 0.2, 0.5, 1, 3, 5, 7 or 10 fmol). Samples were processed 
by neutral thermal hydrolysis, ultrafiltration, and off-line HPLC as described above and 
subjected to nanoLC/ESI
+
-HRMS
3
 analysis. The observed amounts of EB-GII were 
plotted against the theoretical values, followed by regression analysis (Figure 5.2).  
Determination of method LOD, LOQ, precision, and accuracy 
The LOD values of the quantitative method for EB-GII were determined by 
spiking blank human DNA (150 µg) with increasing amounts of EB-GII (0, 0.05, 0.1, or 
0.2 fmol) and a fixed amount of 
15
N5-EB-GII (3 fmol), followed by sample processing 
and nanoLC/ESI
+
-HRMS
3
 analysis by standard methodology. The LOD value was 
determined as the analyte amount that consistently produced signal-to-noise ratios above 
3. The limit of quantitation was defined as minimum analyte amount that produced a 
coefficient of variation less than 15% and a signal-to-noise ratio (S/N) greater than 10.  
To evaluate the inter-day and intra-day accuracy and precision of the new method, 
EB-GII (0.2 fmol) and 
15
N5-EB-GII (3.0 fmol) were spiked into blank human DNA (150 
µg). Samples were processed as described above and analyzed three times per day on 
three consecutive days. Method accuracy was calculated from the equation (Am/Aa × 
100%), where Am is the measured amount of EB-GII and Aa is the actual analyte amount 
added. 
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5.3 Results and Discussion 
Because of their critical role in cancer development, DNA adducts represent 
mechanism-based biomarkers of carcinogen exposure, and their quantitation is 
particularly useful for cancer risk assessment. DNA adducts are also valuable in 
mechanistic studies linking tumorigenic effects of environmental and industrial 
carcinogens to specific electrophilic species generated from their metabolism. As 
discussed above, BD is among the most important industrial and environmental 
chemicals classified as known carcinogens  (87;297). Humans can be exposed to BD in 
an occupational setting at BD monomer/polymer industries (216) or as a result of 
inhaling cigarette smoke  (289), automobile exhaust  (284), and smoke from cooking and 
wood fires  (290). This is a cause of concern because of the established carcinogenicity of 
BD  (84;85;91;276). 
The long term goal of this work is to develop sensitive biomarkers of human 
exposure to BD. We recently reported an isotope dilution accurate mass spectrometric 
method for another BD-DNA adduct, N7-(2,3,4-trihydroxybut-1-yl)-guanine (N7-
THBG), which was detected in leukocyte DNA of smokers, nonsmokers, and 
occupationally exposed workers  (295). Unexpectedly, N7-THBG was also observed in 
samples from individuals with no known exposure to BD, and no significant decrease in 
N7-THBG levels was observed upon smoking cessation  (295). Therefore, THBG may be 
formed endogenously and does not accurately reflect human exposure to BD.  
In an effort to develop a new BD-specific DNA biomarker, we turned our 
attention to structurally analogous EB-G adducts (Scheme 5.1). EB-GI and EB-GII are 
formed upon N7-guanine alkylation by 3,4-epoxybut-1-ene (EB). Because EB is formed 
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in lower amounts than 3,4-epoxy-1,2-butanediol (EBD), in vivo concentrations EB-GI 
and EB-GII adducts are approximately 10-fold lower than those of THBG following 
exposure to BD  (75), calling for a highly sensitive methodology.  
 Our method for quantitative analysis of EB-G adducts in vivo starts with DNA 
extraction from cells or tissues (Scheme 5.2). DNA purity is estimated by UV 
spectrophotometry (A 260/280 ratios) to minimize any contamination with cellular 
proteins. DNA samples (7-76 µg) are spiked with isotopically labeled internal standard 
(
15
N5-EB-GII) to account for any analyte loss during sample workup and to allow for 
absolute quantification. Since N7-guanine alkylation generates a positive charge on the 
adducted base and destabilizes the N-glycosidic bond, EB-G adducts can be selectively 
released from the DNA backbone as free bases by neutral thermal hydrolysis (Scheme 
5.2)  (75;278). This step was optimized upon analyzing EB-treated calf thymus DNA. A 
range of depurination conditions were tested, including heating at 90 °C for 0.5 h (pH 
6.8), 70 °C for 1 h (pH 6.8), and acidic thermal hydrolysis at 90 °C for 0.5 h (0.1N HCl). 
Since all three conditions were equally effective at releasing EB-G adducts from the 
DNA backbone (not shown), neutral thermal hydrolysis at 90 °C for 0.5 h in water was 
selected to minimize the depurination of unmodified nucleobases. Following 
ultrafiltration to remove partially depurinated DNA, EB-GII adducts were enriched by 
offline HPLC. Retention time markers (dT or dA) were added to account for any sample-
dependent retention time shifts. Under our HPLC conditions, dA, EB-GI, EB-GII, and dT 
typically eluted at 13.2, 15.3, 16.4, and 18.3 min, respectively. In our experience, offline 
HPLC purification is the best option for isolating trace amounts of DNA adducts from 
DNA hydrolysates prior to LC-MS analysis because it affords nearly quantitative analyte 
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recovery, can be readily automated, and avoids the introduction of solid phase particles 
which can clog nano HPLC columns  (198). However, cross-contamination and analyte 
carryover can be a serious problem, so multiple HPLC blanks must be introduced 
throughout the analysis. 
5.3.1 NanoLC/ESI
+
-HRMS
3
 method development 
Our ultimate goal was to develop a quantitative method sensitive enough to detect 
EB-G adducts in tissues of laboratory animals exposed to sub-ppm levels of BD and in 
leukocyte DNA of smokers and occupationally exposed individuals. NanoHPLC-
nanospray HPLC-MS methodology was employed because of its enhanced sensitivity as 
compared to conventional capillary LC-MS. Nanospray ionization is more efficient than 
conventional electrospray because of an improved ionization efficiency and an increased 
ion transport from the source into the mass spectrometer  (298). A number of stationary 
HPLC phases were tested, including Zorbax SB-C18 (Agilent Technologies), Hypercarb 
(Phenomenex), Luna C18 (Phenomenex), Synergi Hydro- RP 80Å (Phenomenex), and 
Synergi Polar-RP (Phenomenex). These solid phases were manually packed into 
commercial fused-silica Self-Pack PicoFrit emitters (200 mm x 75 µm, New Objective), 
with a 15 µm tip orifice diameter. The best results in terms of analyte retention and 
HPLC peak shape were obtained when using a Synergi Hydro-RP column eluted with a 
gradient of 0.01% acetic acid in water (A) and 0.02% acetic acid in acetonitrile (B) 
(Figure 5.1) This system has afforded a good EB-GII peak shape (Peak Asymmetry 
factor=1.16, tailing factor = 1.08), along with good retention time (RT 20.7 min) and 
theoretical plates (N) close to 40000, without any co-eluting peaks (Figure 5.1).  
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Our initial method development efforts have attempted to employ nanoHPLC-
ESI-MS/MS on a triple quadrupole mass spectrometer. However, preliminary 
experiments with EB-G I and EB-G II pure standards spiked into synthetic DNA 
indicated that the sensitivity of this approach was insufficient for BD-DNA adduct 
detection in human samples. Other published HPLC-ESI-MS/MS methods for EB-
guanine adducts  (75) similarly reported moderate sensitivity for this analyte (typical 
LOD, 0.5 adducts/10
6
nucleotides). To achieve detection limits in the low fmol to amol 
range (1 per 10
8
-1 per 10
9
 nucleotides) as required for our in vivo studies, we employed 
nanoLC/ESI
+
-HRMS
3 
methodology on an Orbitrap Velos mass spectrometer. We and 
others have recently reported the use of high resolution mass spectrometry for DNA 
adduct analysis in complex samples and have shown that it dramatically reduces the 
matrix background, leading to greatly improved signal to noise ratios  (54;69;223).  
An LTQ Orbitrap Velos mass spectrometer was operated in the high resolution MS
3
 scan 
mode to allow for highly selective detection of EB-GII adducts in a complex biological 
matrix. Protonated molecules of the analyte were trapped and fragmented in the linear ion 
trap (LTQ), and specific MS
2
 fragments were axially ejected, fragmented in the HCD 
cell, and collected in a C-shaped ion trap (C-Trap) to be analyzed in the Orbitrap for 
accurate mass analysis. Initial fragmentation of protonated molecules of EB-GII and 
15
N5-EB-GII (m/z 222.1 [M + H]
+ → m/z 152.1 [Gua + H]+ and m/z 227.1 [15N5-M + H]
+ 
→ m/z 157.1 [15N5-Gua + H]
+
 ) was performed in the linear ion trap via CID, while 
subsequent
 
fragmentation (m/z 152.1 [Gua + H]
+ → m/z 135.0301 [Gua – NH3]
+
, 
153.0402 [Gua – NH3+ H2O]
+
) and m/z 157.1 [
15
N5-Gua + H]
+
 → m/z 139.0183 ([15N5-
Gua – NH3]
+
), 157.0283 (
15
N5-Gua – 
15
NH3 + H2O) was performed in the HCD cell 
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(Scheme 5.3). The ions at 153.0402 [Gua – NH3+ H2O]
+
 are generated via neutral gain of 
H2O by [Gua – NH3]
+
 ions (Scheme 5.3), a process that have been shown to takes place in 
the MS collision cell due to the presence of residual water  (296). MS
3
 fragment ions 
were analyzed in the accurate mass mode over a range m/z 50-270 at a resolution of ~ 
25,000. We found that the MS
3
 scan mode afforded better signal to noise ratios as 
compared to the MS
2
 due to its selectivity for the analyte of interest in the presence of co-
eluting contaminant peaks (Figure 5.3B). Using nanoLC/ESI
+
-HRMS
3
 methodology, the 
sensitivity for EB-G adducts was dramatically improved as compared to standard SRM 
on a triple quadrupole mass analyzer (Compare Figures 5.3A and B), with excellent S/N 
ratios for the low and sub fmol analyte amounts. As an additional benefit, MS
3 
spectra are 
available for each sample, providing additional confirmation of analyte identity. 
Quantitation is based on peak areas corresponding to the analyte and its internal standard. 
Standard curves obtained by nanoLC/ESI
+
-HRMS
3
 analysis of known amounts of pure 
standards of EB-G and its 
15
N5-labeled internal standard (Y = 1.0044X+0.0012, R2 = 
0.9984) 
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Scheme 5.3 Dissociation scheme to explain the formation of fragment ions at 153.04106  
[Gua - NH3 + H2O]
+
. Adopted from  (296). 
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Figure 5.3 Comparision of EB-GII detection using nanoLC-ESI
+
-MS/MS on a triple 
quadrupole mass spectrometer (A) and nanoLC/ESI
+
-HRMS
3
 using Orbitrap Velos (B). 
EB-GII internal standard (3.0 fmol) was spiked into blank DNA oligonucleotide solution 
(150 μg). The sample was subjected to neutral thermal hydrolysis and HPLC cleanup by 
standard methods. Sample aliquots (5 μL) were injected on the same nanoHPLC column 
connected to TSQ Ultra (A) or Orbitrap Velos (B) for mass spectrometry analysis.  
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Our initial studies have attempted to quantify both regioisomers of the adduct, EB-
GI and EB-GII (Scheme 5.1). Under our offline HPLC conditions, pure standards of EB-
GI and EB-GII eluted as sharp peaks well resolved from each other (not shown). 
However, when the two analytes were spiked in synthetic oligodeoxynucleotide or into 
blank human DNA (150 µg), processed as described above, and subjected to 
nanoLC/ESI
+
-HRMS-SRM analysis, a co-eluting peak was observed at similar HPLC 
retention time as EB-GI (Figure 5.4). Our efforts to separate EB-GI from this interfering 
impurity under various chromatographic conditions (a range of HPLC stationary phases, 
HPLC gradients, and HPLC buffers such as 0.05% formic acid, 5 mM ammonium acetate 
buffer (pH 6.8) and 0.1% formic acid with a gradient of methanol or acetonitrile as 
organic phase) were not successful. Although the co-elute signal was somewhat 
decreased when narrowing the precursor ion (m/z 222.1) isolation width from 3.0 amu to 
1.0 amu, this also led to a significant loss of sensitivity for the analyte (not shown). MS
2
 
experiments have revealed that the co-eluting impurity from sample matrix had a 
different MS
2
 fragmentation pattern as compared to authentic EB-GI, but unfortunately 
shared the same major fragment ion at m/z 152.0567 (Figure 5.4). Our efforts to eliminate 
the interfering peak using MS
3
 also proved unsuccessful and the co-eluting impurity 
interfered with accurate analysis of EB-GI (results not shown). We therefore focused our 
efforts on EB-GII (Scheme 5.1), which is formed upon nucleophilic attack of N7-guanine 
at an internal carbon of EB and is produced in similar amounts as its regioisomer  (75). 
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Figure 5.4 Attempts to identify the impurity co-eluting with EB-GI. EB-GI standard (2.5 
fmol) and internal standard 
15
N5-EB-GI (2.5 fmol) were spiked in synthetic 
oligodeoxynucleotide solution (150 μg) and subjected to neutral thermal hydrolysis, 
sample processing, and nano-HPLC-nanoESI
+
-HRMS
2
 analysis on an Obitrap Velos 
mass spectrometer (A). MS/MS spectrum of the co-eluting impurity from sample matrix 
(m/z 222.1681, RT 19.39) (B) and MS/MS spectrum of authentic EB-GI (m/z 222.0983, 
RT 20.00) (C). The analyte and the impurity have different fragmentation patterns, but 
share the same major fragment ion at m/z 152.0566.  
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5.3.2 NanoLC/ESI
+
-HRMS
3
 Method Validation  
 The newly developed method was validated by analyzing samples prepared by 
spiking known amounts of EB-GII (0.2 - 10 fmol) and 3 fmol of 
15
N5-EB-GII internal 
standard into 150 µg of blank human buffy coat DNA. Samples were analyzed by the 
methodology described above. An excellent correlation (R
2 
= 0.9953) was observed 
between the spiked and the observed amounts of EB-GII in the targeted sample matrix 
analysis (Figure 5.2). Method accuracy and interday/ intraday precision were determined 
by analyzing replicate samples of EB-GII (0.2 fmol) spiked into blank human DNA. The 
accuracy of the analytical method for 0.2 fmol spiked into 150 µg of blank human DNA 
was calculated as 92.9 ± 7.19 % (N = 9), while the interday and intraday precision were 
less than 8% RSD (Table 5.1). In order to evaluate the method’s sensitivity (LOD), 
aliquots of blank human DNA (150 μg each) were spiked with known amounts of EB-GII 
standard (0, 0.05, 0.1 or 0.2 fmol), followed by thermal hydrolysis and sample processing 
as described above (Scheme 5.2). The nanoLC/ESI
+
-HRMS
3
 limit of detection for EB-
GII was determined as 0.05 fmol in 150 µg of DNA (0.1 adducts /10
9
 nucleotides), which 
gave the signal-to-noise ratio ≥3. No EB-GII was detected in blank human DNA derived 
from blood leukocytes of a nonsmoker, confirming that there was no artifactual formation 
of EB-GII during the sample preparation and analysis. The method’s limit of quantitation 
was defined as the lowest amount of EB-GII spiked into blank human DNA (150 µg) that 
afforded the signal-to-noise ratios of >10 and intra/inter day precision within 15% CV. 
We found that the LOQ value of our LC-MS
3
 method for EB-guanine II was 0.2 fmol 
analyte in 150 μg of DNA, corresponding to 0.4 adducts/109 nucleosides. 
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Table 5-1 Accuracy and precision results for NanoLC/ESI
+
 HRMS
3
 analysis of EB-GII  
(0.2 fmol) spiked into 150 µg of blank human DNA. 
 
Day  Parameter value 
Day 1 Mean 0.17 
 RSD (%) 3.75 
 Accuracy (%) 86.0 
 N 3 
Day 2 Mean 0.18 
 RSD (%) 1.23 
 Accuracy (%) 91.8 
 N 3 
Day 3 Mean 0.20 
 RSD (%) 5.29 
 Accuracy (%) 100.8 
 N 3 
Interday Mean 0.18 
 RSD (%) 7.74 
 Accuracy (%) 92.9 
 N 9 
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5.3.3 EB–GII quantitation in Human Cell Culture  
The applicability of the new HPLC-MS
3
 analytical method for EB-GII was initially tested 
by quantifying these adducts in human fibrosarcoma (HT1080) cells treated with 
increasing concentrations of EB (0.5-10 µM) for 3 h. These concentrations are well 
below the EC50 of EB in HT1080 cells (13.8 mM). Following DNA extraction, EB-GII 
adducts were released by neutral thermal hydrolysis and analyzed by nanoLC/ESI
+
-
HRMS
3
 as described above. Adduct concentrations in cells treated with 0.5 μM -10 μM 
DEB increased in a concentration-dependent manner from 1.15±0.23 to 10.11±0.45 
adducts/10
8
 nucleotides (Figure 5.5).  
5.3.4 EB–GII quantitation in rat liver tissue DNA 
The new method was next used to quantify EB-GII DNA adducts in liver tissue 
DNA of F344 rats exposed to sub ppm concentrations of BD (0.5 -1.5 ppm). According 
to literature reports, laboratory rats are a better animal model of human exposure to BD 
than laboratory mice due to interspecies similarities in the metabolic pathways  (299). We 
chose low to sub-ppm exposures because this concentration range is comparable to 
occupational BD exposures in polymer or monomer industries (216). NanoLC/ESI
+
-
HRMS
3
 analyses of EB-GII in liver DNA of BD-exposed rats have revealed prominent 
analyte peaks with little to no background noise (Figure 5.6A).  
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Figure 5.5 Concentration-dependent formation of EB-GII adducts in HT1080 cells 
treated with increasing amounts of EB (0.5-10 µM).  
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Figure 5.6 A. Representative extracted ion chromatogram for nano-HPLC-nanoESI
+
- 
HRMS
3 
analysis of EB-GII adducts in liver DNA of a laboratory rat exposed to 1.0 ppm  
BD by inhalation for 2 weeks. Liver DNA (53.3 μg) was spiked with 15N5-EB-GII  
(internal standard for quantitation) and subjected to neutral thermal hydrolysis, sample  
processing, and nano-HPLC-nanoESI
+
-HRMS
3
 analysis on an Obitrap Velos mass  
spectrometer. B. Concentration-dependent formation of EB-GII adducts in liver DNA of  
laboratory rats exposed to low ppm (0.5, 1.0, 1.5 ppm) concentrations of BD.
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A dose dependent increase in adduct amounts was observed in animals treated 
with higher BD concentrations, with EB-GII numbers changing from 0.17 ± 0.05 
adducts/10
8
 nucleotides following 0.5 ppm exposure to 0.33 ± 0.08 adducts/10
8
 
nucleotides following 1.0 ppm exposure, and further to 0.50 ± 0.04 adducts/10
8
 
nucleotides following exposure to 1.5 ppm BD (Figure 5.6B). No EB-GII adducts were 
detected in control animals exposed to ambient air only. The new method was further 
applied to determine the in vivo half-lives of EB-GII adducts in liver of laboratory rats 
exposed to 1250 ppm BD. Only 7 µg of DNA was used in this case due to the high 
adduct levels in these samples. EB-GII adduct concentrations in rat tissues gradually 
decreased 1, 3 and 6 days post exposure to BD (Figure 5.7A). Data processing via first 
order kinetics analysis yielded the EB-GII half-life in rat liver DNA as 2.20 ± 0.12 days 
(Figure 5.7B), which is significantly shorter than the half-life of structurally analogous 
N7-THBG adducts in vivo (t1/2 = 3.6-4.0 days) (75).  
5.3.5 Attempted EB –GII quantitation in human blood leukocyte DNA 
To test the ability of the new method to detect BD-DNA adducts in humans, it 
was applied to blood leukocyte DNA of confirmed smokers (N = 8). Smokers are 
exposed to BD due to its relatively high concentrations in cigarette smoke (8.5-48.2 
µg/cigarette)  (289). Although we were able to successfully detect EB-GII adducts in 
human DNA (Figure 5.8), adduct amounts were below the limit of quantitation of our 
method (0.4 adducts/10
9
 nucleotides). Unfortunately, DNA amounts could not be 
increased due to the limited human sample availability. Furthermore, our in vivo 
persistence data (Figure 5.7) suggest that EB-GII adducts are rapidly released from the 
DNA backbone by spontaneous hydrolysis and/or active repair. Our current efforts are to 
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develop a nanoLC/ESI
+
-HRMS
3
 methodology for EB-GII adducts in human urine, which 
is readily available, but will require additional sample cleanup steps to remove salts and 
other polar matrix compounds prior to analysis. Our final goal is to develop analytical 
methodology that has adequate sensitivity, accuracy, and precision for quantitation of 
EB-G II adducts in human populations. 
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Figure 5.7 Persistence of EB-GII adducts in liver DNA of rats exposed to1250 ppm BD 
by inhalation (A) and first order kinetic analysis for estimation of adduct half-life in vivo 
(B). 
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Figure 5.8 Representative extracted ion chromatogram for nanoLC/ESI
+ 
HRMS
3
 analysis 
of EB-GII adducts in blood leukocyte DNA of a smoker. DNA (71 μg) was spiked with 
15
N5-EB-GII (internal standard) and subjected to neutral thermal hydrolysis, sample 
processing, and analysis on an Obitrap Velos mass spectrometer. 
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In conclusion, sensitive, accurate, and specific nanoLC/ESI
+
-HRMS
3
 isotope 
dilution methodology has been developed for accurate and precise quantitation of BD-
specific EB-GII adducts in vivo. The applicability of this method was demonstrated by 
quantitation of EB-GII adducts in human fibrosarcoma cells exposed to low micromolar 
concentrations of EB and in liver DNA of laboratory rats exposed to sub-ppm 
concentration of BD, which mimic occupational exposure in humans. The method had 
adequate sensitivity to quantify EB-GII DNA adducts in human leukocyte DNA, 
provided that that adequate DNA amounts are available for analysis. We conclude that 
nanoLC/ESI
+
-HRMS
3 
methodology holds a great promise in quantitative analyses of 
trace levels of DNA adducts in human and animal samples due to an increased 
sensitivity, specificity, and detailed structural confirmation from MS
3
 spectra. 
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6 VI. ISOTOPE DILUTION NANO LC/ESI
+
 HRMS
3
 QUANTITATION OF 
URINARY N-7-(1-HYDROXY-3-BUTEN-2-YL) GUANINE ADDUCTS AS 
BIOMARKERS OF HUMAN EXPOSURE TO 1,3-BUTADIENE 
6.1 Introduction 
1,3-Butadiene (BD) is a carcinogenic gas abundant in cigarette smoke, automobile 
emissions, and in wood smoke from forest fires (300). Human exposure to BD can also 
occur in occupational settings in styrene-butadiene polymer industries and synthetic 
rubber production facilities (216;274). BD undergoes cytochrome P450 2E1-mediated 
metabolic activation to epoxide metabolites such as 3,4-epoxy-1-butene (EB) (Scheme 
6.1) (92;93). EB is mutagenic in cultured human lymphoblasts (95) and is carcinogenic in 
laboratory animals, especially in mice (84;85;114).  
EB reacts with nucleophilic N7 positions of guanine bases of DNA to form 
regioisomeric N7-(2-hydroxy-3-buten-1-yl) guanine (EB-GI) and N7-(1-hydroxy-3-
buten-2-yl) guanine (EB-GII) adducts (Scheme 6.1) (75;103). These adducts are 
hydrolytically labile due to the positive charge generated upon alkylation of the N-7 
position of guanine, resulting in their spontananeous depurination over time (t1/2, 2.20 ± 
0.12 days) (278;282). EB-GI ad EB-GII have been previously detected in EB-treated calf 
thymus DNA (265), in EB-treated human cells in culture (104), and in tissues of 
laboratory rats and mice exposed to BD by inhalation (70;75). Liver DNA of F344 rats 
exposed to 20 - 625 ppm BD for 6 h/day, 5 days/week for 4 weeks contained 0.1-1.2 EB-
GI and 0.2-0.9 EB-GII adducts per 10
6
 guanine bases, respectively. Liver DNA of BD-
exposed B6C3F1 mice exposed to same BD concentrations contained higher adduct 
levels (0.2-3.0 EB-GI and 0.1-2.4 EB-GII adducts per 10
6
 guanine bases) due to more 
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efficient formation of EB in this species (70;75). Quantitation of EB-G adducts in 
humans exposed to BD from occupational or environmental sources is a challenging task 
due to their low levels (< 1 per 10
8
 guanine bases), requiring an ultra-sensitive 
methodologies. Recently, we reported a quantitative isotope dilution nanoLC/ESI
+ 
HRMS
3
 methodology for EB-G adducts in human blood leukocyte DNA (70). Although 
our method had excellent sensitivity (LOQ, 0.4 adducts/10
9
 nucleotides, we were unable 
to accurately quantify EB-GII in human DNA because of their low concentrations in 
humans (< 0.2 adducts/10
9
 nucleotides) and limited human blood sample availability.  
In the present study, we evaluated the possibility of quantifying EB-GII in human 
urine as biomarkers of BD exposure and metabolism to DNA-reactive epoxides. N7-
alkylguanine adducts are excreted in urine following their spontaneous hydrolysis and/or 
active repair (301). We utilized isotope dilution mass spectrometric nanoLC-high 
resolution tandem mass spectrometry (nanoLC/ESI
+
-HRMS
3
) methodology on an 
Orbitrap Velos mass spectrometer for sensitive and specific quantitation of EB-GII in 
human urine. Following full validation, the new methodology was used to quantify EB-
GII in rats exposed to BD, occupationally exposed workers, nonsmokers, and smokers of 
African American and European American ethnicity. 
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Scheme 6.1 Partial metabolic scheme of BD showing DNA adduct formation, hydrolysis 
and urinary excretion. EH, epoxide hydrolase; EB-GI, N-7-(2-hydroxy-3-buten-1-yl) 
guanine; EB-GII, N-7-(1-hydroxy-3-buten-2-yl) guanine. 
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6.2 Materials and Methods 
Note: EB is a known carcinogen and, should be handled with adequate safety 
precautions following specific material safety data sheet. 
Materials 
LC-MS grade water, methanol, and acetonitrile were purchased from Fisher 
Scientific (Pittsburgh, PA). All other chemicals and solvents were obtained from Sigma-
Aldrich (Millwaukee, WI, St. Louis, MO). Strata X polymeric reversed phase SPE 
cartridges (30 mg/ 1 mL) were obtained from Phenomenex (Torrance, CA). EB-GII and 
15
N5-EB-GII standards were prepared as previously reported (265;294). Molar 
concentrations of EB-GII and 
15
N5-EB-GII standard solutions were determined by UV 
spectrophotometry using the molar extinction coefficient (ε) of 8030 M-1 cm-1 at 284 nm 
at neutral pH (294). Isotopic purity of 
15
N5-EB-GII as determined by mass spectrometry 
was 99.93 %. Stock solutions of EB-GII and 
15
N5-EB-GII were prepared in water and 
stored at −20 °C. 
Animals and Treatment 
Male and female F344 rats (N = 3 per group) were exposed to 62.5 or 200 ppm 
for 2 weeks (6 h/day, 5 days/week) using whole-body exposure chambers at the 
Environmental Exposure and Inhalation Health Facility at the University of Texas 
Medical Branch at Galveston as reported previously (135). Control rats were exposed to 
filtered air only. Urine was collected using metabolic chambers and stored at -80 °C until 
analysis as described previously (135).  
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Human study subjects 
Spot urine samples were collected from occupationally exposed human subjects 
(N = 23) in BD production facility and control administrative workers (28 per group) 
(125;132;155). BD exposures were determined by personal monitoring for 8-h work 
shifts on 10 separate occasions over an interval of 4 months for each study subject. The 
details of the occupational exposure study have been reported previously (125;132;155). 
This work was approved by the Institutional Review Boards at Regional Institute of 
Hygiene of Central Bohemia and the University of Vermont. The archived urine samples 
were shipped to the University of Minnesota on dry ice and stored at −80 °C until 
analysis.  
Nonsmoker urine samples (N = 28) were obtained from the Tobacco Research 
Biorepository Facility at the Masonic Cancer Center, University of Minnesota. 
Nonsmoker human subjects were at least of age 19 years or older (mean age; 33 ± 12 
years) and were not pregnant or breast feeding. They consumed less than 21 alcoholic 
drinks per week and were in good physical and mental health. Nonsmokers smoked less 
than 100 cigarettes in their lifetime and were not using any tobacco products  
24 hour urine samples from male (N = 86) and female (N = 82) current smokers 
of African American (N = 86) and European American (N = 80) ancestry were collected. 
This study was approved by the University of Minnesota Institutional Review Board 
(Study # 1007M85757). Male (age: 42 ± 11) and female (age: 44 ± 11) smokers who 
smoked average of 17 cigarettes per day for at least one year were recruited. Overall 
mean CO levels in smokers were 16 ± 7 ppm for males and 20 ± 10 ppm for females. 
Subjects were asked to collect a 24 h urine sample and bring it to the Tobacco Research 
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Programs Clinic at the University of Minnesota. Urine samples were stored at -20 °C 
before analysis.  
Urine sample processing and EB-GII adduct enrichment (Scheme 6.2)  
Urine (10 µL for rat samples, 200 µL for human samples) was centrifuged at 
10,000g for 15 min to remove any particulate matter. The supernatants were spiked with 
15
N5-EB-GII (5 fmol, internal standard for mass spectrometry) and subjected to solid 
phase extraction on Strata X cartridges (30 mg/1 mL, Phenomenex, Torrance, CA). SPE 
cartridges were conditioned with 2 mL of methanol, followed by 2 mL of MilliQ water. 
Urine samples (10 – 200 µL) were loaded on to prepared cartridges, and the cartridges 
were washed with 1 mL of water, followed by 1 mL of 10% methanol in water. EB-GII 
and its internal standard were eluted with 60% methanol in water, dried under vacuum, 
and reconstituted with 200 µL of water containing dT retention time marker (0.1 mg/mL). 
Offline HPLC purification was conducted on an Agilent 1100 series HPLC system 
equipped with a UV detector and an automated fraction collector (Agilent Technologies, 
Palo Alto, CA) (70). A Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm, from 
Agilent Technologies, Palo Alto, CA) was eluted at flow rate of 1 mL/min with a 
gradient of 0.4% formic acid in Milli-Q water (A) and HPLC grade acetonitrile (B). 
Solvent composition was maintained at 0% B for 5 min and then linearly increased to 3% 
B in 10 min and further to 40% B in 5 min. The solvent composition was returned to 0% 
acetonitrile in 5 min and held at 0% for 15 min for column equilibration. UV absorbance 
was monitored at 254 nm. 2′-deoxythymidine (dT, 2.06 nmol on column) was used as a 
retention time marker, which typically eluted at 18.3 min. EB-GII eluted at ~16.6 min.  
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Scheme 6.2 Sample preparation procedure for isotope dilution nanoLC/ESI
+
 HRMS
3
 
analysis of EB-GII in urine. 
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HPLC fractions containing EB-GII and its internal standard (16.0 – 18.0 min, 1 
mL each) were collected in 1.2 mL MS total recovery vials (Thermo Fischer Scientific, 
Waltham, MA), concentrated under vacuum, and re-dissolved in LC-MS grade water (10 
μL) for nano-HPLC-nanoESI+-HRMS3 analysis. Typical injection volume was 5 µL. 
HPLC blanks containing 200 µL of water with 5 fmol of 
15
N5-EB-GII internal standard 
and dT retention time marker were periodically injected to detect any potential carryover 
during the offline HPLC clean up procedure. 
NanoLC/ESI
+
-HRMS
3
 analysis of urinary EB–GII  
All nanoLC/ESI
+
-HRMS
3
 analyses were conducted Nano2D-LC HPLC system 
(Eksigent, Dublin, CA) fitted with 5 µL injection loop and interfaced to an LTQ Orbitrap 
Velos instrument equipped with a nanospray source (Thermo Fisher Scientific Corp., 
Waltham, MA). Gradient elution was achieved using LC-MS grade water containing 
0.01% acetic acid (A) and LC-MS grade acetonitrile containing 0.02% acetic acid (B). 
Samples were loaded onto a trapping column (Symmetry C18 nanoAcquity, 0.18 × 20 
mm, Waters Corp., Millford, MA), which was connected in line with a nano-LC column 
(0.075× 200 mm) manually packed with Synergi Hydro-RP, 80Å, 4 μm chromatographic 
packing (Phenomenex, Torrance, CA). The initial HPLC flow was maintained at 2% B, 1 
µL/min, for 5.5 min to enable sample loading onto the trapping column, followed by flow 
rate decrease to 300 nL/min at 2% B for 0.5 min. The percentage of solvent B was 
linearly increased to 25% B in 19 min and further to 50% B in 10 min, returned to 2% B 
in 2 min, and equilibrated for 7 min. Under these conditions, EB-GII eluted as a sharp 
peak at 20 min. 
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The mass spectrometry analysis was performed by fragmenting [M + H]
+ 
ions of 
EB-GII (m/z 222.1) via collision induced dissociation (CID) in the linear ion trap using 
the collision energy (CE) at 25 units and the isolation width of 1.0 amu. MS/MS fragment 
ions at m/z 152.1 [Gua + H]
+
 were subjected to further fragmentation in the high collision 
dissociation (HCD) cell using nitrogen as a collision gas ( CE = 75 units, IW = 1.0 amu). 
The resulting MS
3
 fragment ions were detected in the mass range of m/z 50 to m/z 270 
using the Orbitrap mass analyzer (HRMS) at a resolution of ~ 25,000. EB-GII was 
quantified using extracted ion chromatograms from the combined signals of m/z 135.0301 
([Gua – NH3]
+
) and m/z 153.0411 ([Gua – NH3 + H2O]
+
), at a mass tolerance of 5 ppm. 
The 
15
N5 labeled internal standard ([
15
N5]-EB-GII) was quantified using an analogous 
MS
3
 scan event consisting of fragmentation of m/z 227.1 ([M + H]
+
)
 
to m/z 157.1 [
15
N5-
Gua + H]
+
 and further to m/z 139.0183 ([
15
N5-Gua – NH3]
+
). Extracted ion 
chromatograms corresponding to the sum of m/z 139.0183 ([
15
N5-Gua – NH3]
+
) and m/z 
157.0283 ([
15
N5-Gua – NH3 + H2O]
+
) at 5 ppm were generated and used for quantitation. 
A full scan event was also performed over the mass range of m/z 100-500 at a resolution 
of 15000 to monitor for any co-eluting matrix components. EB-GII amounts were 
determined by comparing the areas of the nanoLC/ESI
+
-HRMS
3
 peaks corresponding to 
the analyte and its internal standard. 
Method validation  
Standard curves were constructed by analyzing aqueous solutions containing 
fixed amounts of 
15
N5-EB-GII (5 fmol) and increasing amounts of EB-GII (0.1 - 10.0 
fmol, in triplicate), followed by regression analysis of the actual and the observed 
amounts of EB-GII. Method validation curves were constructed by spiking control 
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nonsmoker urine or artificial urine (200 µL) with 0.1 - 10 fmol of EB-GII and 5 fmol of 
15
N5-EB-GII internal standard (in triplicate), followed by sample processing and 
nanoLC/ESI
+
-HRMS
3 
analysis as described above. The observed EB-GII amounts were 
plotted against the theoretical values, followed by standard regression analysis. 
The limit of detection (LOD) of the new method was determined by spiking 
synthetic urine (200 µL) with EB-GII (0.05, 0.1, 0.2, or 0.5 fmol) and 
15
N5-EB-GII 
internal standard (5 fmol). The fortified urine samples were processed and analyzed as 
described above. The method’s limit of quantification (LOQ) was determined by spiking 
(200 µL) control nonsmoker urine described above with 0.1- 0.5 fmol of EB-GII and 5 
fmol of 
15
N5-EB-GII internal standard (in triplicate), followed by sample processing and 
nanoLC/ESI
+
-HRMS
3 
analysis by standard methods. The LOQ value was determined as 
EB-GII amount which consistently gave a signal to noise ratio (S/N) greater than 10 and 
% CV < 15% , while LOD of the method was determined as EB-GII amounts that 
resulted in S/N ratio > 3.  
Intra/inter day precision and accuracy of the analytical method was determined by 
spiking control nonsmoker urine (200 μL) with 0.2 fmol of EB-GII and 5.0 fmol of 15N5-
EB-GII internal standard, followed by sample preparation and analysis as described 
above, three times per day on three consecutive days. The relative standard deviations 
between these measurements were calculated and reported as intra-day and inter-day 
precision, while the method accuracy range was determined from the equation (Am/Aa × 
100%), where Am is the measured amount of EB-GII and Aa is the actual analyte amount 
added. 
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SPE recovery was determined by adding 
15
N5-EB-GII (5 fmol) to synthetic urine 
(200 μL) and sample processing by standard methods as described above (in triplicate). 
Unlabeled EB-GII standard (4.2 fmol) was added immediately prior to nanoLC/ESI
+
-
HRMS
3
 analysis, and the recovery was determined by comparing the theoretical and the 
observed 
15
N5-EB-GII:EB-GII peak area ratios. Analyte signal suppression in urine 
matrix was evaluated from the ratio of peak area of EB-GII (4.2 fmol) spiked into 
artificial urine matrix post sample processing, and the corresponding peak area of the EB-
GII obtained by nanoLC/ESI
+
-HRMS
3
 analysis of a pure standard in water (N = 3). 
The stability of EB-GII in human urine matrix was determined using a smoker 
urine sample. The urine was frozen for 24 hours at -20 °C and thawed for 2 hour at room 
temperature (freeze-thaw cycle 1), after which it was processed and analyzed in 
duplicates. This procedure was repeated for two additional freeze-thaw cycles, followed 
by sample processing and analysis. Freeze-thaw cycle variability was determined using 
%CV within and between cycles. 
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6.3 Results 
6.3.1 NanoLC/ESI
+
-HRMS
3 
method development for EB-GII in human urine 
Human urine it is a highly complex and variable biological matrix containing 
many polar metabolites, bile salts, and other small molecules which can adversely affect 
urinary DNA adduct analysis due to ESI signal suppression (302;303). Therefore, 
analyte-selective enrichment strategies such as solid phase extraction (SPE) and/or offline 
HPLC fractionation are typically required for trace level analyses of DNA adducts in 
urine (304;305). Our experimental approach for quantitation of EB-GII in human urine is 
summarized in Scheme 6.2. Our methodology employs 200 µL of human urine. 
Following centrifugation to remove any particulate matter, the supernatant is spiked with 
15
N5-EB-GII internal standard (5 fmol). The use of isotopically labeled internal standard 
accounts for any analyte loss during sample enrichment and allows for absolute 
quantitation. The spiked samples are subjected to solid phase extraction on Strata X 
cartridges (30 mg/ 1mL) to eliminate the bulk of impurities, followed by further sample 
enrichment by offline HPLC and quantitative analysis via nanoLC/ESI
+
-HRMS
3 
(Scheme 
6.2). 
During initial stages of method development, several SPE solid phases were 
tested for EB-GII isolation form urine matrix, including Strata X (Phenomenex), Oasis 
HLB (Waters Corp.), and Isolute ENV+ (Biotage). Among these, Strata X was the most 
effective in respect to elimination of co-eluting impurities and analyte recovery. Strata X 
SPE method was further optimized, resulting in SPE recovery of 56.6 ± 1.72 % in spiked 
urine samples. 
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Our initial experiments established that SPE alone did not afford sufficient sample 
purity for nanoLC-MS analysis of EB-GII because of the presence of co-eluting 
impurities (results not shown). Therefore, SPE enriched fractions were subjected to 
additional enrichment by offline HPLC (70). HPLC fractions containing EB-GII and its 
internal standard (retention time, 16-17 min) were collected, concentrated under vacuum, 
and reconstituted with 10 µL of water for nanoLC/ESI
+
-HRMS
3 
analysis. HPLC blanks 
were periodically injected to determine analyte carryover during offline HPLC clean up 
procedure.  
NanoLC/ESI
+
-HRMS
3 
analysis was performed using an Orbitrap Velos mass 
spectrometer (70). We took advantage of accurate mass capabilities of the instrument in 
order to maximize the specificity and sensitivity of EB-GII detection in human samples. 
The use of MS
3
 mode provided an increased specificity and a reduced background noise, 
leading to excellent signal to noise ratios. Analysis of standard solutions containing 0.1-
10.0 fmol of EB-GII and 5.0 fmol of 
15
N5-EB-GII each in 25 µL of water (5 µL on 
column) resulted in linear standard curves (y = 1.0044x, R
2 
= 0.9984). 
The nanoLC/ESI
+
-HRMS
3 
method was further validated by analyzing EB-GII 
(0.1-10 fmol) and 
15
N5-EB-GII (5 fmol) standards spiked either into artificial urine or 
nonsmoker urine (200 µL), followed by sample processing and analysis by standard 
methodologies. A linear correlation was observed between the spiked and the observed 
amounts of EB-GII in urine matrix (y = 1.0042x, R
2
 = 0.992 for nonsmoker urine and y = 
0.9649x, R
2
 = 0.994 for artificial urine) (Figures 6.1). No EB-GII was detected in this 
particular non-smoker (data not shown).  
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Figure 6.1 NanoLC/ESI
+
-HRMS
3
 method validation: correlation between the spiked and 
the observed amounts of EB-GII spiked into 200 µL of nonsmoker urine. Spiked amounts 
were 0, 0.1, 0.2, 0.5, 1, 5, or 10 fmol of EB-GII and 5 fmol of 
15
N5- EB-GII (internal 
standard), followed by sample processing and MS analysis. 
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Method LOD and LOQ values determined from analysis of spiked samples were 0.25 
fmol/mL and 0.5 fmol/mL artificial urine and nonsmoker urine, respectively. Intraday 
and interday assay precision (% coefficient of variance) determined by repeated analysis 
of EB-GII (0.2 fmol) spiked into either nonsmoker urine (200 µL) was 13.1 % (Table 
6.1). Minimal signal suppression (<25 %) was observed upon comparison of 
nanoLC/ESI
+
-HRMS
3
 peak areas in the presence and in the absence of urine matrix 
(post-SPE). Method accuracy was determined to be 109.9 ± 10.4% when 0.2 fmol of EB-
GII was spiked into 200 µL of nonsmoker urine, along with 5 fmol of 
15
N5-EB-GII (N = 
5) . Freeze-thaw stability studies of a smoker urine sample (200 µL, 2.45 ± 0.34 fmol) 
showed low variability (< 15% RSD). 
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Table 6-1 Accuracy and precision results for NanoLC/ESI
+
 HRMS
3
 analysis of EB-GII 
(0.2 fmol) spiked into 200 µL of nonsmoker urine. 
Day  Parameter value 
Day 1 Mean 0.19 
 RSD (%) 13.1 
 Accuracy (%) 96.4 
 N 3 
Day 2 Mean 0.19 
 RSD (%) 11.7 
 Accuracy (%) 97.5 
 N 3 
Day 3 Mean 0.21 
 RSD (%) 9.9 
 Accuracy (%) 103.5 
 N 3 
Interday Mean 0.19 
 RSD (%) 10.6 
 Accuracy (%) 99.2 
 N 9 
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6.3.2 Quantitation of EB-GII in urine of F344 rats exposed to BD by inhalation 
The validated nanoLC/ESI
+
-HRMS
3 
method was initially used to quantify EB-GII 
in urine of F344 rats (n = 3 each) treated with 0, 62.5 or 200 ppm BD by inhalation for 2 
weeks (6 h/day, 5 days/week). Urinary EB-GII amounts increased in a concentration-
dependent manner (Figure 6.2). Low but detectable amounts of EB-GII (14.5 – 87.0 
pg/mL) were found in urine of control rats exposed to filtered air only (Figure 6.2). This 
is consistent with previous studies that detected EB-specific urinary metabolites of BD, 
2-(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene and 1-(N-acetyl-L-cystein-S-yl)-2-
hydroxy-but-3-ene (MHBMA), in unexposed animals and in non-smoker human subjects 
(135). Mean concentrations of EB-GII in urine of male F344 rats urine exposed to 62.5 or 
200 p.p.m. BD were 679.3 ± 86.3 pg/mL and 1567.4 ± 401.5 pg/mL urine, respectively (p 
= 0.06, unpaired two sample t-test, Figure 6.2). Interestingly, urinary EB-GII 
concentrations were 1.5 times higher in female rats (p = 0.15, unpaired two sample t-test) 
as compared to males, with 1311.7 ± 413.9 pg/mL and 2672.4 ± 1005.69 pg/mL (p = 
0.12, unpaired two sample t-test) present following exposure to 62.5 and 200 ppm BD, 
respectively (Figure 6.2), suggesting possible gender differences in BD, 
metabolism/urinary DNA adduct formation.  
 
6.3.3 Quantification of EB-GII in urine of smokers, nonsmokers, and occupationally 
exposed workers 
We next employed nanoLC/ESI
+
-HRMS
3 
to
 
determine urinary EB-GII concentrations in 
confirmed nonsmokers (N = 28), smokers (N = 29), administrative control workers (N = 
29), and occupationally BD exposed workers from a BD production facility (N = 24). 
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Figure 6.2 Concentration-dependent formation of EB-GII adducts in F344 male and 
female rats treated with increasing amounts of EB (0, 62.5, 200 ppm). 
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Smokers included in this study were between the ages of 19-44 and smoked at least 20 ± 
7 cigarettes/day, with mean CO concentration levels of 20 ± 7 ppm. Nonsmokers smoked 
less than 10 cigarettes in their life time with age range between 19 and 44. NanoLC/ESI
+
-
HRMS
3
 analyses have revealed clear EB-GII signals in most human urine samples 
analyzed (see examples in Figure 6.3A, B) with good S/N ratios and excellent 
chromatographic peak shapes. In contrast, we were unable to quantify the EB-GI 
regioisomer due to a co-eluting peak which interfered with its analysis (70). The co-
eluting impurity peak with m/z of 222.1681 has different MS/MS fragmentation pattern 
than EB-G adducts of interest, but shared the same major fragment ion at m/z 152.0566, 
which interfered with accurate quantitation of EB-GI in human sample. Since our efforts 
to separate EB-GI from this contaminant by modifying HPLC conditions were 
unsuccessful, we focused on the EB-GII isomer only. Mean concentrations of EB-GII in 
urine of nonsmokers and smokers were 1.24 ± 2.31 and 1.78 ± 2.81 pg/mg creatinine, 
respectively. These differences were not statistically significant, probably because of the 
limited group size (p = 0.08, group t-test) (Figure 6.4A). In contrast, urinary 
concentrations of EB-GII in urine of occupationally exposed workers (N = 23, exposed to 
0.1–2.2 ppm BD) were significantly higher than in urine of administrative controls ( N = 
28) exposed to <0.01 ppm BD (2.94 ± 3.54 pg/mg creatinine and 0.93 ± 1.85 and pg/mg 
creatinine, , respectively, see Figure 6.4B) (p = 0.0051, Group t-test).  
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Figure 6.3 Representative extracted ion chromatogram for nanoLC/ESI
+
-HRMS
3
 
analysis of EB-GII adducts in smoker (A, C), occupationally exposed BD worker urine 
(B, D) (200 µL each) spiked with 
15
N5-EB-GII (internal standard for quantitation) and 
subjected to sample processing, and nanoLC/ESI
+
-HRMS
3
 analysis on an Obitrap Velos 
mass spectrometer. 
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Figure 6.4 Box plots showing urinary EB-GII adducts levels showing statistically 
significant differences between administrative worker controls and occupationally 
exposed BD workers (A) and no significant differences between smokers and 
nonsmokers (B). 
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We next investigated urinary BD-DNA adducts in smokers belonging to two 
different ethnic groups. Urinary EB-GII concentrations in African American and 
European American smokers (male and female, total number = 166) were quantified 
(Table 6.2). No statistically differences in urinary EB-GII adduct levels were observed 
between male and female smokers in the multi ethnic study. We also did not observe any 
correlation between EB-GII levels and smokers’ age, exhaled carbon monoxide, and 
cigarettes pet day. However, highly significant ethnic differences were observed between 
EB-GII excretion by African American and European American smokers, with European 
American smokers excreting 4-fold more EB-G II than African Americans (Table 6.2). 
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Table 6.2: Urinary EB-GII levels in African American (N = 86) and European American 
smokers (N = 80). 
 
EB-GII (pg/mg Creatinine) 
Smokers 
Ethnicity  N  
Unadjusted Mean ± 
SD  
Geometric Mean 
± SD *  
Adjusted  
P-value 
*  
Afr.Am. 86 0.32 ± 0.31 0.14 ± 0.02 
<0.0001 
Eur.Am. 80 1.31 ± 2.33 0.52 ± 0.09 
*The geometric means on the log transformed variables and the p-values are adjusted 
for age and sex  
  
Smokers (N = 168)  Males (N = 86)  Females (N = 82)  
Age (years)  42 ± 11 44 ± 11 
CO levels (ppm)  16 ± 7 20 ± 10 
Cigarettes smoked per day (CPD)  17 ± 7 17 ± 7 
pg EB-GII/mg creatinine, Average ± SD  0.81 ± 1.97 0.76 ± 1.34 
pg EB-GII/mg creatinine, Range, 
(Median)  
0.005 – 13.64 
(0.31) 
0.005 – 9.82 
(0.36) 
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6.4 Discussion 
Urinary DNA adducts represent useful biomarkers of carcinogen exposure and 
metabolic activation to electrophilic species. DNA adducts can be released from the DNA 
backbone and excreted in urine as free nucleobases as a result of their spontaneous 
depurination (278;306) or their active repair via base excision repair pathways (307). 
Previous studies have detected urinary nucleobase adducts induced by estrogens (308), 
lipid peroxidation products (309), N-ethyl-N-nitrosourea (306), and reactive metabolites 
of environmental chemicals such as polyaromatic hydrocarbons (310) and styrene (311). 
In contrast, urinary DNA adducts of the important environmental, industrial, and cigarette 
smoke carcinogen 1,3-butadiene have not been previously investigated. Covalent BD-
nucleobase adducts within genomic DNA have been widely utilized as biologically 
relevant biomarkers of BD exposure and metabolic activation to reactive epoxides 
(69;74;114;115;295). However, human DNA is not always available from large 
epidemiological studies due to the invasive nature of blood and tissue collection.  
In our earlier study, we have reported mass-spectrometry based quantitation of N-
7-(1-hydroxy-3-buten-2-yl) guanine (EB-GII) adducts induced by 3,4-epoxy-1-butene 
(EB) in DNA isolated from peripheral blood leukocytes of smokers, nonsmokers and 
occupationally exposed BD workers (70). Athough EB-GII was detectable in blood DNA 
of most human subjects, its concentrations were below the LOQ of the method (0.4 
adducts/10
9
 nucleotides or 0.2 fmol/ 150 µg of DNA) due to relatively low levels of 
human exposure to BD, limited amounts of blood sample available, and spontaneous 
hydrolysis of EB-GII adducts. N7-guanine adducts such as those induced by BD-derived 
epoxides are hydrolytically unstable due to the presence of positive charge on N-7 
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position of the alkylated base and are spontaneously released from the DNA backbone 
over time (75;115;295).  
We therefore decided to develop a qantitative method for EB-GII adducts in 
human urine, which is readily available in quantity and is easier to collect. Since urine is 
a highly complex and variable biological matrix as compared to DNA, advanced sample 
enrichment procedures (SPE, offline HPLC) were used to isolate urinary adducts of 
interest, followed by sensitive and specific analysis by nanoLC/ESI
+
-HRMS.
3
 EB-GII 
adducts were first quantified in urine of male and female F344 rats exposed to BD by 
inhalation (Figure 6.2). We found that BD adduct numbers correlated with BD exposure 
concentrations, with higher numbers of adducts formed in female rats as compared to 
males. However, these gender differences were not statistically significant (p = 0.15) 
(213;277). This is consistent with the previous reports where no differences in EB levels 
were found between male and female Sprague-Dawley rats exposed to BD (150;312). 
Background of levels EB-GII (14.5 – 87.0 pg/mL) were detected in urine of 
control rats which had not been exposed to BD (Figure 6.2), suggesting that there might 
be an endogenous source for this adduct (129). This finding in accord with a previous 
report where EB specific urinary mercapturic acid metabolite 2-(N-acetyl-L-cystein-S-
yl)-1-hydroxybut-3-ene/1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-3-ene(MHBMA) was 
detected in the urine of control F344 rats (142). Furthermore, significant quantities of the 
corresponding EB specific-hemoglobin adduct N-(2-hydroxy-3-butenyl)–valine (HB-Val) 
were found in unexposed F344 rats (118). It has been hypothesized that MHBMA and 
other four carbon chain metabolites can originate from lipid peroxidation pathways or 
catabolism of carbohydrates (133;134;142).  
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EB-GII adducts were readily detectable in human urine (Figure 6.3), with adduct 
concentrations ranging between 1.1 to 4.0 pg/mg creatinine. The use of accurate mass 
MS
3
 methodology on an Orbitrap mass spectrometer has allowed us to obtain MS
3
 
spectra of urinary EB-GII from human samples, which matched that of an authentic 
standard (Figures 6.3). Accurate quantitation was achieved by using isotope dilution with 
the corresponding 
15
N-labeled standard. The validated NanoLC/ESI
+
-HRMS
3
 method has 
an accuracy of 109.9 ± 10.4% and intra/inter day precision (%CV) less than 13% for 0.2 
fmol spiked in 200 µL of nonsmoker urine. A comparison of EB-GII adducts levels in 
urine of occupationally exposed workers and control administrative workers (Figure 
6.4B) provides evidence for an increased adduct numbers in exposed individuals (Group 
t-test, p = 0.0051), consistent with differences in BD exposure. This finding indicates that 
urinary EB-GII adduct levels can be used as mechanism-based biomarkers of BD 
exposure in humans. In contrast, EB-GII adduct levels were not statistically different 
between confirmed smokers and nonsmokers (group t-test, p = 0.08 Figure 6.4A). BD is 
produced in cigarette smoke by thermal cracking process due to the combustion of 
complex molecules such as carbohydrates, amino acids, phytosterols, paraffins, and other 
tobacco components, which is known to vary according to the type of tobacco, its curing 
process, and its carbohydratecontent (160;313;314). Although smokers are generally 
exposed to higher concentrations of BD than nonsmokers, these differences were not 
reflected in our study that was limited to a small number of subjects N = 28/group). 
Determination of true amounts of BD exposure in smokers is difficult due to the 
variability factors such as puff volume, duration, interpuff interval, number of puffs per 
cigarette which is again based on the extent of nicotine addiction (315;316). Lya G et al. 
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estimated that smokers consuming on an average of 20 cigarettes/day are exposed to 0.01 
mg BD/kg/day, considering BD amounts per cigarette (76.4–259.6 µg/cigarette), the 
amount that reaches alveoli (70%), and the extent of alveolar absorption (50%). For a 70 
kg individual, the total amount of BD consumption would be 0.7 mg BD/day (161). In the 
case of occupational BD exposure ( 1.0 ppm or 2.21 mg/m
3
 OHSA exposure limit, 1 ppm 
BD = 2.21 mg/m
3
) (216) and considering average human inhalation volume of 20 m
3
/day, 
BD occupational human exposure is around 44.2 mg/day, which is on average 60 fold 
higher than the amount inhaled by smoker (161). Average BD urinary metabolite 
concentrations of monohydroxybutenyl-mercapturic acid (MHBMA), N-acetyl-S-(3,4-
dihydroxybutyl)-L-cysteine (DHBMA), and 4-(N-acetyl-L-cystein-S-yl)-1,2,3-
trihydroxybutane (THBMA) in occupationally exposed workers were 82 ± 138, 3094 ± 
4162 and 157 ± 158 ng/mg creatinine, respectively (135). In smokers, the corresponding 
concentrations were 11 ± 12, 631 ± 452 and 31 ± 20 ng/mg creatinine respectively (135). 
It is possible that our inability to detect differences in urinary EB-GII levels between 
smokers and nonsmokers (Figure 6.4A) is due to relatively low BD exposures in case of 
smoking as compared to occupational exposure, environmental sources of BD, and 
endogenous formation of BD metabolites. Nonsmokers included in our study might have 
been exposed to low levels of environmental BD exposure from automobile exhaust (0.1-
10 ppb) (284), second hand smoke (5.0-8.6 ppb) (161) and wood burning (290).  
In contrast, workers employed at BD monomer and polymer industries can be exposed to 
much greater (up to 60 fold) amounts of BD and thus excrete significantly higher EB-GII 
concentrations in their urine. Although smoking is a major risk factor for lung cancer, 
only 1 out of 10 smokers develop lung cancer. Smokers belonging to various ethnic 
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groups have different risk of lung cancer development, with the relative risk highest 
among African American and Native Hawaiian smokers followed by European 
American, Japanese American and Latino smokers (167). According to another 
independent five year study by National Cancer Institute, lung cancer incidence rates 
were highest in African Americans, followed by European Americans and others ethnic 
groups (157;158).We hypothesized that the differences in the lung cancer risk was 
attributed to varied metabolic enzymes/pathways involved in the metabolism of 
carcinogens present in cigarette smoke. As BD is one of the carcinogens present in 
cigarette smoke we intended to use urinary BD-DNA adducts to provide a sensitive, non-
invasive biomarkers of carcinogen exposure, metabolic activation, human cancer risk and 
explain the differences in lung cancer risk among African American (N = 86) and 
European American smokers (N = 80). We found that there are significant inter ethnic 
differences in BD metabolism and urinary EB-GII levels between African American 
(0.32 ± 0.31 pg/mg creatinine, N = 86) and European American smokers (1.31 ± 2.33 
pg/mg creatinine, N = 80) (P-value = <0.0001 adjusted for age and sex). Urinary EB-GII 
levels represent the concentration of BD DNA adducts released from DNA due to 
hydrolysis or DNA adduct repair. Increased concentration of urinary EB-GII adducts in 
European American Smokers then African American Smokers might represent efficient 
removal of EB-GII adducts in DNA hence explaining the relatively decreased risk of BD 
induced DNA damage and cancer in European American Smokers as compared to 
African American Smokers. But further studies involving smokers from other ethnic 
groups such as Latino, Japanese and Native Hawaiians along with European American 
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and African American Smokers with increased population size should be used for this 
study to confirm this result.  
In summary, we have developed and validated an isotope dilution nanoLC/ESI
+
-
HRMS
3
 method for urinary EB-GII adducts of BD in humans. This method has excellent 
sensitivity, accuracy and selectivity. Although nucleobase adducts found in urine may 
have sources other than DNA (for example, they can be formed from RNA or cellular 
nucleoside pools), urinary EB-GII can serve as biomarkers of BD exposure and metabolic 
activation in future epidemiological studies.  
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7 VII. SUMMARY AND CONCLUSIONS 
Human exposure to 1,3-butadiene (BD) is widespread because of its widespread 
presence in automobile exhaust (284), cigarette smoke (90), forest and wood fires (290), 
and occupational settings such as synthetic rubber and plastic polymer production 
industries (274). Among various carcinogens present in cigarette smoke, 1,3-butadiene 
(BD) has a very high cancer risk index (159) and is likely to contribute to the induction of 
smoking-mediated lung cancer in smokers (157). Hence, it is important to determine the 
extent of BD exposure in humans. One of the best ways to monitor human exposure to a 
carcinogen is to quantify carcinogen specific biomarkers such as urinary metabolites, 
protein adducts, and DNA adducts (279). Among various biomarkers of carcinogen 
exposure, DNA adducts directly correlate to cancer risk because of their ability to cause 
cancer causing mutations (Scheme 1.1) (293).  
BD is metabolically activated by cytochrome P450 monooxygenases CYP2E1 
and CYP2A6 to form electrophilic epoxide metabolites (EB, EBD, and DEB), which 
react with nucleophilic bases in DNA to form covalent adducts (Scheme 1.8) (92;152). 
Apart from reacting with DNA, BD metabolites also alkylate cellular proteins such as 
hemoglobin to form protein adducts (Scheme 1.9) (125;128) or are detoxified by 
hydrolysis and conjugation with glutathione to form BD-mercapturic acids, which are 
excreted in urine (Scheme 1.10) (120;125). BD-protein adducts and BD-mercapturic 
acids have been previously used as biomarkers of human exposure to BD (125). In 
contrast, to our knowledge, BD-DNA adducts had not been previously detected in 
humans.  
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Several BD-specific DNA adducts had been identified from studies in laboratory 
rats and mice exposed to relatively high concentrations of BD by inhalation (6.25-625 
ppm) (116) (Schemes 1.7 and 1.8). By comparison, BD exposures in humans range 
between 1 to 3 ppm BD in an occupational exposure settings (274) and low ppb levels in 
cigarette smoke and environmental sources (161), giving rise to very low amounts of BD 
DNA adducts (< 1-3 adducts/10
8
 nucleotides). In this Thesis, ultra-sensitive mass 
spectrometric methods have been developed for the quantitation of BD-DNA adducts in 
humans exposed to BD from smoking and occupational sources.  
In Chapter 2 of this Thesis, isotope dilution nanoLC/ESI
+
-SRM methods were 
developed for quantitation of diepoxybutane specific DNA-DNA crosslinks (bis-N7G-
BD) in liver DNA of laboratory mice exposed to sub-ppm levels of BD (0.5-1.5 ppm) 
(Scheme 2.1) (69). We employed an offline HPLC analyte enrichment procedure coupled 
with nanospray HPLC-ESI
+
- MS/MS to achieve excellent sensitivity for bis-N7G-BD in 
genomic DNA (LOQ, 1.0 fmol in 100 µg DNA, corresponding to 0.03 adducts per 10
7
 
nucleotides) (Scheme 2.2). Using this bioanalytical methodology, we successfully 
quantified bis-N7G-BD adducts in liver DNA of B6C3F1 mice exposed to 0, 0.5, 1.0, 1.5 
ppm BD for 2 weeks (6 h/day, 5 days/week). We observed an increase in bis-N7G-BD 
numbers with BD exposure, giving rise to 5.7 ± 3.3, 9.2 ± 1.5, and 18.6 ± 6.9 adducts per 
10
9
 nucleotides in animals exposed to 0.5, 1.0 and 1.5 ppm BD, respectively (Figure 2.5). 
Higher efficiency of adduct formation (bis-N7G-BD adducts/10
7
 nucleotides/ppm of BD) 
was observed at concentrations of BD less than 6.25 ppm, which are close to human 
occupational exposure concentrations (Figure 2.6) (216). We concluded that it important 
to quantify BD specific DNA adducts at sub ppm concentrations which are more relevant 
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to human occupational exposures, environmental exposure, and cigarette smoking. 
However, we have been not able to detect bis-N7G-BD adducts in human blood DNA 
samples using this method. This is likely because bis-N7G-BD adduct levels in humans 
are below the limit of quantitation of our method as a result of an inefficient formation 
and/or rapid detoxification of DEB in humans (135). This is consistent with our recent 
observation that DEB specific urinary mercapturic acid (bis-BDMA) was not detected in 
urine of humans occupationally exposed to BD (135). It has been proposed that DEB 
concentrations in BD-exposed humans are low because of the efficient activity of epoxide 
hydrolase in human cells (Scheme 1.10) (135). 
In Chapter 3 of this Thesis, the mechanisms of repair of intestrand bis-N7G-BD 
cross-links in mammalian cells were investigated. Isogenic Chinese hamster lung 
fibroblasts cell lines deficient in Fanconi Anemia (FA) and nucleotide excision repair 
pathways (V-H4 and V-H1) were used in order to test the involvement of these pathways 
in removal of bis-N7G-BD adducts. Cytotoxicity studies in wild type V79 fibroblasts, FA 
repair deficient V-H4 cells, and NER deficient V-H1 cells have revealed that the repair 
deficient clones were much more sensitive to DEB-mediated toxicity as compared to the 
wild type cells (Figure 3.1A, B). Furthermore, bis-N7G-BD adduct numbers increased 
linearly with time upon DEB treatment (10 -100 µM). Importantly higher levels of bis-
N7G-BD cross-links were observed in V-H1 and V-H4 cells deficient in NER and FA 
repair pathways as compared to V79 wild type cells (Figure 3.3A, B). The involvement 
of NER repair in bis-N7G-BD removal was further confirmed using NER inhibitor UCN-
01 (Figure 3.4). Furthermore, γH2AX immunocytochemistry and alkaline comet assays 
(Figure 3.5, 3.6) have revealed an exaggerated formation of DNA double strand breaks 
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(DSBs) during the repair of DNA-DNA crosslinks (245;270). In summary, we have 
shown that DEB exposure leads to increased cytotoxicity and accumulation of bis-N7G-
BD crosslinks and DSBs in NER- and FA repair deficient cells, suggesting the 
involvement of these pathways in the repair of BD induced bis-N7G-BD adducts. FA 
repair pathway appears to be more important for protecting human cells against DEB-
mediated toxicity as compared to NER.  
The third goal of this thesis was the development of ultra-sensitive isotope 
dilution HPLC-ESI
+
-HRMS/MS methodologies for quantification of BD-DNA adducts in 
humans. We initially focused on N7-THBG because it is formed from the most abundant 
BD epoxide (EBD) (Scheme 4.1). We took advantage of the high mass resolution 
capabilities of the Orbitrap Velos mass spectrometer, affording excellent LOD values for 
N7-THBG (0.3 adducts/10
9
 nucleotides). Using this methodology, N7-THBG adducts 
were quantified in blood leukocyte DNA of smokers and non-smokers. Unexpectedly, 
N7-THBG concentrations were similar in DNA of smokers and non-smokers (8.21 ± 5.12 
vs 7.08 ± 5.29 adducts /10
9
 nucleotides, respectively; P = 0.60) (Table 4.2) and remained 
unchanged upon smoking cessation, suggesting that N7-THBG adduct levels in human 
leukocytes might not be related to smoking (Figure 4.6). Our observation of N7-THBG 
adducts in nonsmokers may be a result of environmental exposure to BD and/or 
endogenous sources of N7-THBG. In contrast, N7-THBG levels were significantly 
increased in leukocyte DNA of occupationally exposed individuals (9.73 ± 3.80 adducts/ 
10
9
 nucleotides, 1.51 ± 1.12 ppm BD) as compared to matched administrative controls 
(3.07 ± 2.15 adducts/ 10
9
 nucleotides, 0.009 ± 0.012 ppm) (Table 4.3). Our validated 
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mass spectrometry method for N7-THBG has adequate accuracy and sensitivity for future 
human biomonitoring studies.  
In an attempt to identify a biomarker of BD exposure that is related to smoking,  
we developed a nanoLC/ESI
+
-HRMS
3
 method for quantification of N-7-(1-hydroxy-3-
buten-2-yl) guanine (EB-GII) adducts in human blood leukocyte DNA (Chapter 4, 
Scheme 5.1). Since EB-GII are induced by less abundant BD epoxide, 3,4-epoxy-1-
butene (EB), the added sensitivity of nanospray HPLC and high resolution HRMS
3
 on an 
Orbitrap Velos mass spectrometer was necessary (Scheme 5.2). The EB-GII adducts were 
released by thermal hydrolysis and enriched by offline HPLC purification. Following 
method validation, EB-GII were quantified in liver DNA of laboratory rats exposed to 
sub-ppm concentrations of BD (0, 0.5, 1.0, 1.5 ppm) by inhalation. A linear increase in 
EB-GII concentrations were observed, with 0.17 ± 0.05, 0.33 ± 0.08, and 0.50 ± 0.04 
adducts per 10
8
 nucleotides in liver DNA of F344 rats exposed to 0.5, 1.0 and 1.5 ppm 
BD, respectively (Figure 5.6B). We also determined the in vivo half-life of EB-GII 
adducts (2.20 ± 0.12 days) in rat liver DNA (Figure 5.7B). Finally the new methodology 
was applied to analyze EB-GII in blood leukocyte DNA of smokers and nonsmokers. 
Although EB-GII adducts were detected in human DNA of BD exposed individuals, their 
amounts were below the limit of quantitation of our method (0.4 adducts/10
9
 nucleotides, 
0.2 fmol in 150 µg of DNA). Unfortunately, DNA amounts could not be increased due to 
limited blood sample volumes available. In vivo persistence data suggested that EB-GII 
adducts were rapidly released from the DNA backbone by spontaneous hydrolysis and/or 
active repair. Therefore, we focused our efforts on developing a sensitive mass 
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spectrometric methodology for EB-GII adducts in human urine, which is more readily 
available than blood.  
 Sensitive nanoLC/ESI
+
-HRMS
3
 method was developed for quantitation of EB-
GII in urine of human subjects exposed to BD (Chapter 5). As urine is a more complex 
biological matrix as compared to DNA hydrolysates, an additional solid phase extraction 
step for EB-GII analyte enrichment was incorporated prior to offline HPLC cleanup, 
followed by nanoLC/ESI
+
-HRMS
3
 analysis (Scheme 6.2). Our quantitative method for 
urinary EB-GII adducts was extensively validated for accuracy, intra/interday precision, 
LOD (0.25 fmol/mL urine), LOQ (1 fmol/mL urine) and freeze-thaw stability. Following 
validation, the method was applied to quantify EB-GII in urine of male and female F344 
rats exposed to BD (0, 62.5 and 200 ppm). A concentration-dependent increase in urinary 
EB-GII adduct excretion was observed (Figure 6.2). Although female animals excreted 
1.5 times higher levels of EB-GII than males, the difference was not statistically 
significant (p > 0.15 , unpaired two sample t-test). This method was then applied to 
quantify EB-GII levels in urine samples of smokers, nonsmokers, and occupationally 
exposed workers (Figure 6.4). Although urinary levels of EB-GII were higher in smokers 
as compared to nonsmokers (1.78 ± 2.81 pg/mg vs 1.24 ± 2.31 creatinine, respectively) 
this difference was not statistically significant ( p = 0.08, group t-test). In contrast, 
average urinary concentrations of EB-GII adducts in occupationally exposed workers 
(2.94 ± 3.54 pg/mg creatinine following 0.1–2.2 ppm BD exposure) were significantly 
higher than in urine of matched administrative controls (0.93 ± 1.85 pg/mg creatinine , < 
0.01 ppm BD exposure). This can be explained by lower BD concentrations in 
mainstream cigarette smoke (76.4-259.6 µg/cigarette, low ppb levels of BD exposure) 
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(161) as compared to occupational exposure to BD (0.5-1.0 ppm BD) (216). Furthermore, 
statistically significant differences were observed in urinary EB-GII excretion between 
European American and African American smokers (Eur. Am. 1.31 ± 2.33 pg/mg 
creatinine Afr. Am. 0.32 ± 0.31 pg/mg creatinine, p = <0.0001).  
In summary, the research described in this Thesis has led to the development of 
novel isotope dilution mass spectrometric methods for sensitive quantitation of BD-
induced bis-N7G-BD, N7-THBG, EB-GII adducts in vivo. All three adducts were 
quantified in tissues of BD-exposed laboratory animals, while N7-THBG, EB-GII 
adducts were also measured in humans exposed to BD from cigarette smoke and 
occupationally exposed workers. The new methodology has adequate sensitivity, 
accuracy, and precision to be used for future human BD exposure biomonitoring studies.  
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8 VIII. FUTURE DIRECTIONS 
8.1 BD DNA adductomics strategies to quantify genome wide DNA damage upon 
BD exposure  
As described in the Introduction (Chapter 1), DNA adductomics is a top down 
approach to detect and quantify global DNA damage  (199). BD-DNA adducts studied so 
far were investigated by a bottom up approach, where the structure of the target 
quantified nucleobase adduct is pre-determined. Hence, some important BD induced 
DNA adducts might have been missed in these targeted studies. By using triple 
quadrupole mass spectrometry, multistage ion trap scanning (LC–MSn), or accurate mass 
spectrometry HR-MS
n
 type scanning, it is possible to detect novel BD-DNA adducts by 
monitoring a neutral loss of sugar (116 amu) from structurally modified nucleosides. To 
facilitate the identification of novel BD-DNA adducts, laboratory animals can be exposed 
to a mixture of BD isotopomers, 
13
C2-BD, and  
2
H6-BD by inhalation. Any BD-DNA 
adducts formed will display a characteristic isotope pattern with 2 and 6 mass units apart, 
thus providing a unique way to identify novel BD-DNA adducts and global DNA damage 
induced by BD (Figure 8.1 A). We hypothesize that these studies will discover novel BD-
DNA adducts arising from other DNA bases such as cytosine, thymine, adenine, and 
guanine which might be useful as novel BD specific biomarkers. Furthermore, they may 
explain the mutational spectra of BD which is dominated by A→T transversions, 
although the majority of adducts identified so far are formed at guanine (96).  
In a separate study, we propose to investigate global BD-DNA damage in workers 
occupationally exposed to BD (BD polymer industries) known to be at an increased risk 
for leukemia. The results can be compared to controls using comprehensive DNA 
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adductomics methodology (figure 8.1B) (199;205). A differential analysis between BD 
exposed and control workers using results from DNA adductomics methodology can 
identify global BD adducts likely responsible for the observed increase in cancer risk. 
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Figure 8.1(A) Stable isotope labeling-facilitated DNA adductomics that can be used to 
identify novel BD-DNA adducts.  
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(B) Constant neutral loss of deoxyribose sugar (116 amu) can be used for data dependent 
scanning to identify unknown adducts in DNA of individuals occupationally exposed to 
BD  (199;205). 
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8.2 Investigation of Fanconi Anemia (FA) pathway in the repair DNA-DNA 
crosslinks induced by DEB. 
 Fanconi Anemia (FA) pathway is important for repair of DNA-DNA crosslinks 
induced by various carcinogens and drugs (189;195). In Chapter 2 of this Thesis, we 
investigated the involvement of the FA pathway in repair of DEB-induced bis-N7G-BD 
crosslinks. An increased accumulation of bis-N7G-BD adducts was observed in FA repair 
pathway deficient V-H4 Chinese hamster cells. V-H4 cells are known to be ultra- 
sensitive to DNA damage induced by DNA cross-linking agents such as mitomycinC 
(MMC), cisplatin (cis-DDP), and DEB (251). In fact, DEB is commonly used to diagnose 
FA (317). V-H4 clones show phenotypic features similar to human patients with Fanconi 
Anemia (251). However, V-H4 cells are not genetically very well characterized for FA 
repair pathway (251). Furthermore, Chinese hamster lung fibroblasts are genetically 
different from human cells, so it would be beneficial to study FA repair pathway in 
human cell culture.  
The FA pathway is a complex DNA repair pathway with at least 8 
complementation group proteins FANCA, B, C, D1, D2, E, F and G. It is important to 
understand the role of particular proteins in the repair of bis-N7G-BD adducts induced by 
BD. We also wish to identify the minimal core FA complex essential for the repair of bis-
N7G-BD. This information can provide insights into tolerable genetic deficiencies in 
human FA genes corresponding to certain proteins in the FA core complex. Several 
human lymphocyte and fibroblast cell lines deficient in specific FA proteins are available 
from the Coriell Institute Cell Repositories. Some of them are listed in the Table 8.1 
below. bis-N7G-BD repair studies will be conducted in these cell lines to study the 
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cytotoxicity, double strand break formation, and the rate of bis-N7G-BD adduct 
formation and removal as compared to wild type cells treated with DEB. DEB induced 
DNA damage studies in specific FA protein repair deficient cells can provide insights 
into tolerable genetic deficiencies in human FA genes corresponding to certain proteins in 
the FA core complex. 
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Table 8-1 Human cell lines deficient in FA repair pathway 
Catalog ID Decription  Human Cell 
type 
GM16756 
GM16633 
Fanconi Anemia Complementation Group, (FANC) 
FANCD2 
B-Lymphocyte 
Fibroblast 
GM13020 
GM00449 
FANCC B-Lymphocyte 
Fibroblast 
GM16632 
GM13022 
FANCA Fibroblast 
B-Lymphocyte 
GM13023 FANCD1 B-Lymphocyte 
GM16757 FANCF B-Lymphocyte 
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8.3 Improved analytical methods for N7-(2, 3, 4-trihydroxybut-1-yl) guanine (N7-
THBG) 
 N7-THBG is a DNA adduct formed from the most abundant BD epoxide, 3,4-
epoxy-1,2-butanediol (EBD) (Scheme 4.1). Owing to its three hydroxyl groups, N7-
THBG is a very polar molecule and does not retain well on standard reverse phase HPLC 
columns. Commercially available 3-(dansylamino)phenylboronic acid (DPBA) can be 
used for derivatization of diol functionality of N7-THBG (Scheme 8.1). Since limited 
stability in water is a common problem with boronic acid esters derivatives, organic 
mobile phases can be employed for HPLC retention and elution of DPBA-N7-THBMA 
derivatives  (318). The resulting boronic acid ester will be analyzed by isotope dilution 
reverse phase nanospray HPLC-ESI-MS/MS.      
 Alternatively, nanospray liquid chromatography coupled to inductively coupled 
plasma tandem mass spectrometry (nanoLC-ICP-MS/MS) technique can also be used to 
detect and quantify element boron in derivatizated N7-THBG boronic acid ester to 
quantify trace levels in parts per trillion range (319). Although isotope dilution is not 
possible in ICP-MS, another boron containing compound with similar structure can be 
used as an internal standard (320).  
 Alternatively, underivatized N7-THBG can be retained using boronate affinity 
chromatography using specific columns packed with boronic acid stationary phases 
which is known as online derivatization to retain diols (321).  
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Scheme 8.1 Proposed derivatization of N7-THBG with 3-(dansylamino) phenylboronic 
acid (DPBA) 
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8.4 Quantification of BD-DNA adducts in smokers belonging to different ethnic 
groups. 
In studies described in Chapter 6, we quantified urinary BD DNA adducts (EB-
guanine II (EB-GII)) in samples from smokers belonging to two ethnic groups (European 
American and African Americans, 80 samples per group) and observed 3-fold greater 
urinary levels of EB-GII in European Americans (Table 6.2). Ethnic differences in BD-
DNA adduct formation and urinary excretion may be caused by genetic polymorphisms 
in drug metabolism genes such as CYP2E1, glutathione-S-transferases GSTM1, GSTT1, 
and epoxide hydrolase (EH), or in DNA repair genes involved in adduct removal. To 
further explore ethnic/racial differences in BD metabolism, we propose to expand this 
study to a large multi-ethnic cohort involving Native Hawaiian, Japanese American, 
European American, Latino, and African American smokers (450 per group). This will 
enable us to correlate the observed differences in BD-DNA adducts with specific genetic 
polymorphisms (Figure 8.2). In the same study, it would be useful to include smokers 
that develop lung cancer, so that the relationship with lung cancer risk can be evaluated. 
We hypothesize that genetic polymorphisms in BD metabolizing enzyme CYP2E1 may 
lead to low enzyme activity, reduced concentrations of BD epoxides, decreased levels of 
BD-DNA adducts, and reduced lung cancer risk. In contrast, genetic polymorphisms in 
BD epoxides detoxifying enzymes such as epoxide hydrolase (EH) and glutathione -S-
transferase (GSTT1, M1) may lead to lower detoxification activity than normal, resulting 
in accumulation of BD epoxides and the corresponding adducts and an increased lung 
cancer risk. The levels of BD-DNA adducts can also be mediated by polymorphisms in 
DNA repair proteins such as those involved in FA and NER pathways. 
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Figure 8.2 Multi ethnic cohort study design for the correlation of BD metabolic enzyme 
genetic polymorphisms with urinary BD-DNA adducts.  
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8.5 Measurement of BD induced DNA adducts in a mouse model of cigarette smoke 
exposure.  
In our studies described in Chapters 4-6, we did not observe statistical differences 
between the concentrations of BD-DNA adducts in smokers and nonsmokers. It is 
important to determine whether smoking increases the levels of BD-DNA adducts above 
endogenous levels. We propose to use an animal model of cigarette smoke exposure. In 
the literature, there are several mouse models of smoking induced chronic obstructive 
pulmonary disease (COPD) including whole body exposure and nose only exposure 
models (322-325). Although these models differ in type of mice strains used and 
commercial brands of cigarette smoke (323), they can be used to evaluate the extent of 
1,3-butadiene exposure from cigarette smoke and levels of BD DNA adducts formed 
upon smoking. The dose of cigarette smoke can be standardized based on nicotine and 
CO levels simulating human exposure to mainstream and side stream smoke (326). 
Although many previous studies have investigated BD-DNA adducts in 
laboratory animals exposed to BD gas (137), we hypothesize that other carcinogens and 
co-carcinogens present in cigarette smoke may influence its metabolism. Metabolic 
differences are expected to be observed between direct exposure to BD by inhalation and 
BD exposure along with cigarette smoke constituents due to metabolic enzyme induction 
and inhibition (327;328). For example, CYP2E1 monooxygenase has been reported to be 
induced by cigarette smoke, which should lead to increased metabolic activation of BD to 
its DNA-reactive epoxides (328).  
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8.6 Development of a high throughput mass spectrometric method for simultaneous 
quantitation of bis-N7G-BD, N7-THBG and EB-Gua II.  
In our current methodology, bis-N7G-BD, N7-THBG, and EB-guanine II are 
analyzed separately using adduct-specific enrichment and detection strategies. It is our 
long term goal to develop a single method for simultaneous quantitation of all three BD 
DNA adducts in biological matrices such as DNA or urine. Since all three adducts are to 
the N7 position of guanine and are structurally related, it should be possible to develop 
MS methodology for simultaneous quantitation of all three adducts in a single analysis. 
As indicated by calculated partition coefficients (miLogP, Scheme 8.2) (329;330) the 
three analytes have variable hydrophobic properties and are expected to behave 
differently on reverse phase HPLC. However, all three are N7-guanine adducts leading to 
reduced stability of N-glycosidic bond. Hence, all three adducts can be selectively 
released from DNA using neutral thermal hydrolysis. Following their release from DNA, 
ultrafiltration will be used to remove partially hydrolyzed DNA. Final enrichment can be 
performed by offline HPLC clean up using fraction collection of adduct specific 
fractions. Urinary adduct analysis may require additional solid phase extraction 
enrichment. For isotope dilution mass spectrometric quantitation, use of optimized 
nanospray reverse phase LC is preferred over other methods due to increased ionization 
leading to improved sensitivity. Accurate mass and high resolution MS is preferred over 
conventional triple quadrupole MS because of improved signal to noise ratio leading to 
increased sensitivity. This simplified procedure will save time and resources as all three 
lesions can be quantified in a single analysis. 
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Scheme 8.2 BD-DNA adducts induced by epoxide metabolites of BD. miLogP values 
were calculated using molinspiration cheminformatics tool (329).  
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8.7 Quantitation of BD DNA adducts induced by wood burning, second hand smoke, 
and endogenous sources.  
In addition to cigarette smoking, BD is known to be produced from incomplete 
combustion of wood burning such as in forest fires (276;331). It is important to quantify 
BD exposure specific biomarkers such as DNA adducts, hemoglobin adducts and urinary 
metabolites in human populations exposed to BD from various sources such as forest and 
house fires. Specific human populations of interest are fire workers and people living in 
areas affected by forest fires. Other human populations of interest for quantitation of BD 
exposure biomarkers would be people exposed to second hand smoke from various 
sources such as cigarette smoke filled bars (0.81 to 8.6 ppb) and casinos (90;332).     
In our studies described in Chapter 5 and 6, BD-DNA adducts were detected in 
nonsmokers with no known exposure to BD. These adducts may be formed as a result of 
environmental BD exposure or may originate from an endogenous source (134;141). 
Similarly, urinary mercapturic acids formed from HMVK and EBD have been detected in 
control rats (135). Very low levels of BD epoxide, 3,4-epoxy-1-butene (EB) specific 
DNA adduct EB-GII was detected in the urine of control rats exposed to filtered air (14.5 
– 87.0 pg/mL, Chapter 6). It has been proposed that EB-diol, the common precursor to 
HMVK and EBD, can be formed during the carbohydrate catabolism (129). To 
differentiate the endogenous and exogenous BD exposure specific BD-DNA adduct 
formation, animals can be exposed with 
13
C2-1,3-butadiene or 
2
H6-1,3-butadiene (2 
weeks, 6 h/day, 5 days/week). At the end of the exposure period, urinary BD DNA EB-
GII adducts (
13
C2-EB-GII or 
2
H6-EB-GII versus unlabeled EB-GII formed endogenously) 
can be quantified by the methods described in Chapters 4, 5 and 6. Comparison of 
13
C2-
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EB-GII or 
2
H6-EB-GII with unlabeled EB-GII would provide information on the relative 
contributions of exogenous and exogenous BD-DNA adducts.  
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